CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
[ADDRESS_559290]
Cambridge, MA  [ZIP_CODE]
[LOCATION_002]
PROTOCOL NUMBER: 230LE201 Biogen Idec Research Limited
Innovation House
[ADDRESS_559291]
Maidenhead, Berkshire
SL6 4AY
[LOCATION_008]
PHASE OF DEVELOPMENT: 2
PROTOCOL TITLE: A 2-Part Phase [ADDRESS_559292] NO: 2015- 004359 -32  
DATE: 15 March 2019
Version 5.0
Final
Supersedes previous Version 4.0 dated 08 February 2018./ [STUDY_ID_REMOVED]
Protocol 230LE201 Version 5.[ADDRESS_559293] OF ABBREVIATION S
.....................................................................................11
3. SYNOPSI S
.................................................................................................................13
4. STUDY SCHEMATI C AND 
SCHEDULE OF ACTI VITIES FOR STUDY 
230L E201 ...................................................................................................................18
4.1. Study  Schematic .........................................................................................................18
4.2. Schedule of Activities .................................................................................................20
4.3. Additional I nformation ...............................................................................................32
4.3.1. Site Personnel .............................................................................................................32
4.3.2. Skin RNA Tape Harvesting (Parts A and B) ..............................................................32
4.3.3. Joint Count Assessment (Part A Only )
.......................................................................32
4.3.4. Skin Photograph y (Parts A and B) ..............................................................................33
4.3.5. Skin Biopsy  (Part B Only )
..........................................................................................33
[IP_ADDRESS]. Skin Biopsy  for Confirming CLE Diagnosis
..............................................................33
[IP_ADDRESS]. Optional Skin Biopsy ..................................................................................................33
4.3.6. CLASI Adjudication (Part B Onl y)............................................................................33
4.3.7. Blood RNA Paxgene and Skin Biopsy  Immunohistochemistry  Assessments ............ 34
5. INTRODUCTION ......................................................................................................35
5.1. Overview of Lupus Ery thematosus ............................................................................35
5.2. Current Therapi[INVESTIGATOR_441062] ..............................................................35
5.3. Profile of Previous Experience with BIIB059 ............................................................36
5.3.1. Nonclinical Experience ...............................................................................................36
5.3.2.
Clinical Experience.....................................................................................................36
5.4. Study  Rationale ................................ ................................ ................................ ........... 38
5.5. Rationale for Dosing Regimen ...................................................................................39
5.5.1. Part A ..........................................................................................................................39
5.5.2. Part B ................................ ................................ ................................ .......................... 39
5.5.3. Rationale for Placebo ................................ ................................ ................................ ..40
6. STUDY OBJECTIVES AND ENDPOINTS................................ .............................. 41
7. STUDY DESIGN ................................ ................................ ................................ .......45
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
47.1. Study  Overview ..........................................................................................................45
7.2. Overall Study  Duration and Follow -Up (Part A) .......................................................46
7.2.1. Screening ....................................................................................................................46
7.2.2. Treatment ....................................................................................................................46
7.2.3. Follow -Up...................................................................................................................46
7.3. Overall Study  Duration and Follow -Up (Part B) ........................................................[ADDRESS_559294]
S ....................................................................................49
8.1. Inclusion Criteria ........................................................................................................49
8.1.1. Inclusion Criteria (Parts A and B)
..............................................................................49
8.1.2. Inclusion 
Criteria (Part A Specific) ............................................................................49
8.1.3. Inclusion Criteria (Part B Specific)
............................................................................49
8.2. Exclusion Criteria .......................................................................................................50
8.2.1.
Exclusion Criteria (Parts A and B) .............................................................................50
9. ENROLLMENT, REGISTRA TION, AND RANDOMIZAT ION
............................54
9.1.
Screening and Registration.........................................................................................54
9.2. Randomization of Subjects .........................................................................................54
9.3. Blinding P rocedures ....................................................................................................54
10. DISCONTINUATION OF S TUDY TREATMENT AND/O R 
WITHDRAWAL OF SUBJEC TS FROM THE STUDY ...........................................56
10.1. Discontinuation of Study Treatment ...........................................................................56
10.2.
Withdrawal of Subjects From Study ................................ ................................ ........... 56
11. STUDY TREATMENT USE .....................................................................................57
11.1. Study  Treatment Regimen ..........................................................................................57
11.1.1. Part A ................................ ................................ ................................ .......................... 57
11.1.2. Part B ................................ ................................ ................................ .......................... 57
11.1.3. BIIB059 ................................ ................................ ................................ ...................... 57
11.1.4. Placebo ................................ ................................ ................................ ........................ 57
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
511.2. Study  Treatment Precautions ......................................................................................57
11.3. Study  Treatment Compliance .....................................................................................58
11.4. Concomitant Therap y and Procedures ........................................................................58
11.4.1. Concomitant Therap y
.................................................................................................58
[IP_ADDRESS]. Allowed Concomitant Therap y...................................................................................58
[IP_ADDRESS].
Disallowed Concomitant Therap y ..............................................................................65
[IP_ADDRESS]. Rescue Medication Usage Guidelines During the Treatment Period .........................66
[IP_ADDRESS]. Rescue Medication Usage Guidelines During the Safety  Follow -Up Period .............66
11.4.2. Concomitant Procedures .............................................................................................66
11.5. Continuation of Treatment ..........................................................................................66
12. STUDY TREATMENT MANA GEMENT ................................................................67
12.1. BIIB059 ......................................................................................................................67
12.1.1. BIIB059 Preparation ...................................................................................................67
12.1.2.
BIIB059 Storage .........................................................................................................67
12.1.3.
BIIB059 Handling and Disposal.................................................................................68
12.1.4. BIIB059 Accountability
..............................................................................................68
12.2. Placebo ........................................................................................................................68
13. EFFI CACY ASSESSMENTS ....................................................................................69
13.1. Clinical Efficacy  Assessments ....................................................................................69
13.2. Pharmacokinetic Assessments ....................................................................................69
69
70
70
14.
SAFETY ASSESSMENTS ................................ ................................ ........................ 71
14.1. Clinical Safety  Assessments .......................................................................................71
14.2. Laboratory  Safet y Assessments ..................................................................................71
14.3. BIIB059 Specific Safet y Assessments ................................ ................................ ........ 71
15. SAFETY DEFINITIONS, RECORDI NG, REPORTI NG, AND 
RESPONSIBILIT IES.................................................................................................72
15.1.
Definitions ................................ ................................ ................................ .................. 72
15.1.1. Adverse Event ................................ ................................ ................................ ............. 72
15.1.2. Serious Adverse Event ................................ ................................ ................................ 72

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
615.1.3. Prescheduled or Elective Procedures or Routinely  Scheduled Treatments ................73
15.2. Safety  Classifications ..................................................................................................73
15.2.1. Investiga tor Assessment of Events
.............................................................................73
15.2.2. Relationship of Events to Study  Treatment ................................................................73
15.2.3. Severity  of Events .......................................................................................................74
15.2.4. Expectedness of Events ..............................................................................................74
15.3. Monitoring and Recording Events ..............................................................................74
15.3.1. Adverse Events ...........................................................................................................74
15.3.2. Serious Adverse Events ..............................................................................................74
15.3.3. Immediate Reporting of Se rious Adverse Events .......................................................75
[IP_ADDRESS]. Deaths .........................................................................................................................75
15.3.4.
Suspected Unexpected Serious Adverse Reactions....................................................75
15.4. Procedures for Handling Special Situations ...............................................................76
15.4.1. Pregnancy ...................................................................................................................76
15.4.2. Overdose .....................................................................................................................76
15.4.3. Medical Emergency ....................................................................................................76
[IP_ADDRESS]. Unblinding for Medical Emergency ...........................................................................[ADDRESS_559295] E SIZE ...........79
16.1. Efficacy .......................................................................................................................79
16.1.1. Analy sis Population ................................ ................................ ................................ ....79
16.1.2. Methods of Anal ysis................................ ................................ ................................ ...79
[IP_ADDRESS]. Analy sis of the Primary  Endpoint ................................ ................................ ............... 80
[IP_ADDRESS]. Analy sis of the Secondary  Endpoints ................................ ................................ ......... 81
[IP_ADDRESS]. Exploratory  Endpoints Analy sis.................................................................................82
16.2. Pharmacokinetics ................................ ................................ ................................ ........ 82
16.2.1. Analy sis Population ................................ ................................ ................................ ....82
16.2.2. Methods of Anal ysis................................ ................................ ................................ ...82
82

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
782
82
82
82
16.5. Safety ..........................................................................................................................83
16.5.1. Analy sis Population ....................................................................................................83
16.5.2. Methods of Anal ysis...................................................................................................83
[IP_ADDRESS]. Adverse Events ...........................................................................................................83
[IP_ADDRESS]. Clinical L aborat ory Evaluations and Vital Signs
.......................................................83
16.6. Immunogenicit y Data .................................................................................................84
16.6.1. Analy sis Population ....................................................................................................84
16.6.2. Methods of Anal ysis...................................................................................................84
16.7. Interim Anal yses.........................................................................................................84
16.7.1. Interim Anal ysis 1:  Futility ........................................................................................84
16.7.2. Interim Anal ysis 2:  End of Treatment Periods
..........................................................[ADDRESS_559296] OF TABLES
Table 1:
Schedule of Activities Part A ................................ ................................ ..................... 20
Table 2: Schedule of Activities Part B......................................................................................26
Table 3: Pharmacokinetic Assessments ....................................................................................31
Table 4: Study  Objectives and Endpoints .................................................................................41
Table 5:
Prednisone Equivalence Values for Common Alternatives................................ ........ 59
Table 6: Topi[INVESTIGATOR_441063] ...................................................60
Table 7:
Oral Corticosteroid Tapering Schedule ......................................................................63
Table 8: Disallowed Concomitant Therap y and Required Washout Periods Prior to 
Randomization ............................................................................................................[ADDRESS_559297] OF FIGURES
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
9Figure 1: Study  Design Part A ...................................................................................................18
Figure 2: Study  Design Part B ....................................................................................................[ADDRESS_559298]
Maidenhead, Berkshire 
SL64AY
[LOCATION_008]
For urgent medical issues in which the study ’s Medical Director should be contact[INVESTIGATOR_530], please 
refer to the Study  Reference Guide’s Official Study  Contact [CONTACT_71330].
Biogen may  transfer any  or all of its study -related responsibili ties to a contract research 
organization (CRO) and other third parties; however, Biogen retains overall accountability for 
these activities.
Protocol 230LE201 Version 5.[ADDRESS_559299] OF ABBREVIATION S
ACL E acute cutaneous lupus erythematosus
ACR American College of Rheumatology
AE adverse event
ANCOVA analysis of covariance
AUC area under the concentration -time curve
BDCA2 blood dendritic cell antigen-2
BILAG British Isles Lupus Activity  Group
CCLE chronic cutaneous lupus ery thematosus
CL clearance
CLASI Cutaneous L upus Ery thematosus Disease Area and Severity  Index
CLASI-A CLASI–Activity
CLASI-D CLASI–Damage
CLE cutaneous lupus ery thematosus
Cmax maximum observed concentration
Cmin minimum observed concentration 
CPK creatine phosphokinase
CRO contract research organization
DHA Directions for Handling and Administration 
DLE discoid lupus ery thematosus
ECG electrocardiogram
eCRF electronic case report form
ET early termination
GCP Good Clinical Practice
HBV hepatitis B virus
HCV hepatitis C virus
HRQoL health-related quality  of life
IA interim analy sis
IC90 concentration resulting in 90% inhibition of response
ICF informed consent form
ICH International Council for Harmonisation
IDMC independent data monitoring committee
IFN interferon
IFN-α interferon -alpha
IgG1 immunogloblulin, class G, ty pe [ADDRESS_559300] Model Repeat Measurement 
MPS mycophenolate sodium
mRNA messenger RNA
 
NSAID nonsteroidal anti- inflammatory  drug
PCS Physical Component Summary
PD pharmacod ynamic
pDC plasmacy toid dendritic cell
PGA Physician’s Global Assessment 
PGI Physician’s Global I mpression
PIP proximal interphalangeal
PK pharmacokinetics
PP per-protocol
Q2W every  2 weeks 
Q4W every  4 weeks
RNA ribonucleic acid
SAD single ascending dose
SAE serious adverse event
SAP statistical analy sis plan
SC subcutaneous
SCLE subacute cutaneous lupus ery thematosus
SELENA Safety  of Estrogen in Lupus: National Assessment
 
SLE systemic lupus ery thematosus
SLEDAI -2K Systemic Lupus Ery thematosus  Disease Activity  Index [ADDRESS_559301] of care
SRI Systemic Lupus Ery thematosus Responder Index
SRI-4 Systemic Lupus Ery thematosus Responder Index Response of ≥4
S[LOCATION_003]R suspected unexpected serious adverse reaction 
t1/[ADDRESS_559302]

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
133. SYNOPSIS 
Protocol Number: 230L E201
Protocol Title:A 2-Part Phase 2 Randomized, Double -Blind, Placebo- Controlled 
Study Evaluating the Efficacy and Safety of BIIB059 in Subjects 
with Systemic Lupus Erythematosus and Active Skin 
Manifestations andinSubjects with Active Cutaneous Lupus 
Erythematosus with or without Systemic Manifestations
Version Number 5
Name [CONTACT_204922] y Treatment:BIIB059
Study  Indication:Part A: S ystemic lupus erythematosus with active joint and active 
skin manifestations
Part B: Active cutaneous lupus erythematosus (subacute or 
chronic cutaneous lupus erythematosus including discoid lupus 
erythematosus) with or without systemic manifestations
Study RationaleMost therapi[INVESTIGATOR_441064] (SLE) 
are only partially effective and are associated with considerable 
toxicity.  Furthermore, no medicines are specifically approved for 
the treatment of cutaneous lupus erythematosus (CLE).  
Blood dendritic cell antigen -2 (BDCA2) is a type II, C -type lectin 
receptor that is uniquely expressed on the cell surface of 
plasmacytoid dendritic cells (pDC) and was the first receptor 
described to negatively down -regulate the type I interfero n (IFN) 
response in these cells.  In both CLE and SLE, type I IFN 
expression correlates with disease activity and severity.  By 
[CONTACT_441106]2, BIIB059 treatment is expected to target pDC 
in affected tissues leading to decreased IFN production, as well a s 
the reduction of other pDC -derived factors that contribute to SLE 
and CLE pathogenesis.
Phase of Development: 2
Study  Objectives and 
Endpoints:The primary objective of the study is to evaluate the efficacy of 
BIIB059 in reducing disease activity in subjects with SLE with 
active skin manifestations and joint involvement (Part A), and in 
subjects with active CLE (subacute CLE [SCLE] or chronic CLE 
[CCLE], including discoid lupus erythematosus [DLE]) with or 
without systemic manifestations (Part B).
Part A: The primary endpoint that relates to this 
objective is the change in active joint count (28 -joint 
assessment) from Baseline to Week 24. The active 
joint count is defined as the sum of the tender joint 
count and the swollen joint count.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
14Part B: The primary endpoint that relates to this 
objective is the percent change in Cutaneous Lupus 
Erythematosus Disease Area and Severity Index --
Activity (CLASI -A) score from Baseline to Week 16.
Secondary Objectives and Endpoints
To evaluate additional efficacy param eters of BIIB059 in 
reducing SLE/CLE disease activity.
The endpoints that relate to this objective are:  
Skin related
CLASI -50, defined as a 50% improvement from 
baseline in CLASI -A score, at Week 24 (Part A) and 
at Weeks 12 and 16 (Part B).
Percent change in CLASI -A score from Baseline to 
Week 12, Week 16, and Week 24 (Part A) and Week 
12 (Part B).
A ≥4-point reduction in CLASI -A score at Week 24 
(Part A) and at Weeks 12 and 16 (Part B) compared 
with baseline.
SLE disease activity related (Part A Onl y)
Proportion of subjects with a composite response, defined as: 
SLE Responder Index (SRI) of ≥4 (SRI -4) at 
Week 24, where SRI -4 is defined as:
oA reduction from baseline of ≥4 points  in 
Systemic Lupus Erythematosus  Disease 
Activity Index 2000 (SLEDAI -2K), and
oNo new organ system affected, as defined by 
[CONTACT_441107] 
(BILAG) -[ADDRESS_559303]’s 
lupus disease activity defined by < 0.3 point  
increase in the Physician’s Global 
Assessment (PGA) [visual analog scale 
(VAS)] 
No protocol -prohibited medication or treatment.
Concomitant corticosteroid dosage at Week 24 to 
be ≤10mg/day.
Concomitant corticosteroid dosage at Week 24 to 
be ≤Day 1 corticosteroid dosage.
No increase in corticosteroid dose between 
Weeks 17 and 24.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
15 Change from baseline to Week 24 in SLEDAI -2K score
 Proportion of subjects with no new organ system affected, 
as defined by [CONTACT_441108] -2004 A and no more than 
one new BILAG -2004 B from baseline to Week 24
 Change from baseline to Week 24 in PGA (VAS) score
Pharmacokinetics Objectives and Endpoints (Parts A and B): 
To evaluate the pharmacokinetic parameters of BIIB059, 
including:
BIIB059 clearance, volume of distribution, and absorption 
rate.
Safety and Tolerability Objectives and Endpoints (Parts A and B)
To evaluate the safety and tolerability of BIIB059.
The endpoints that relate to this objective are as follows: 
Nature, severity, relationship to study treatment, and 
incidence of adverse events (AEs) and serious 
adverse events (SAEs)
Change from baseline in standard laboratory 
parameters, vital signs and electrocardiogram (ECG) 
results  
Immunogenicity (antibodies to BIIB059)
Absolute and percent change fro m baseline over time 
in immunoglobulin levels and vaccine- related 
immunoglobulin titers
Additional study objectives are listed in Section 6.
Study  Design: 2-part, randomized, double- blind, parallel group, placebo -
controlled study 
Study  Location:The study will be conducted at approximately 130 centers in the 
[LOCATION_002], Europe, Latin America, and Asia.
Number of Planned Subjects:Part A:   
The maximum number of subjects in Part A is approximately 
190 subjects.  Of these 190 subjects, approximately 100 subjects 
will be enrolled under protocol version 2 or subsequent versions.  
If the study is not stopped for futility at the interim analysis 
(IA1), then up to 70 additional subjects may be added (up to a 
total of approximately 170 subjects under protocol version 2 or 
subsequent versions).  Subjects enrolled under protocol version 
1 will remain on their original treatment assignment (up to a 
total of approximately 20 subjects).
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
16Part B:
The maximum number of subjects in Part B is approximately 
130 subje cts.  Of these 130 subjects, approximately 100 subjects 
will be enrolled under protocol version 2 or subsequent versions.  
Subjects enrolled under protocol version 1 will remain on their 
original treatment assignment (up to a total of approximately 30 
subjects).
An interim analys is (IA 1) for futility of Part B and possible 
expansion of Part A will be performed.  IA 1 will be performed  
after approximately 45% of Part B subjects under protocol 
version [ADDRESS_559304] completed their Week 12 
Treatment Period visit.  At the time of this IA, it is estimated 
that over 50% of subjects in Part A will have completed their 
Week 12 Treatment Period visit.   Following the IA, up to an 
additional 70 subjects may be enrolled in Part A and the 
BIIB059 dose m ay be adjusted .  Details are provided in 
Section 16.7.1 .
A second IA (IA 2) of efficacy and safety data will occur after 
the last subjects complete the Double -Blind Treatment Periods 
for Part A (at Week 24) and Part B (at Week 16).  Details are 
provided i n Section 16.7.2 .
For both IAs (1 and 2), all Investigators, study site personnel, 
and subjects will remain blinded to treatment assignments until 
after the final database lock.  
Study  Population:The study (Parts A and B) will be conducted in subjects 18 to 75 
years of age, inclusive. 
Part A:
All subjects must have a diagnosis of SLE according to the 1997 
revised American College of Rheumatology (ACR) 
classification for SLE along with active skin manifestations and 
joint involvement ( Appendix C) .
At Screening and randomization, all subjects must have at least 
4tender joints 
andat least [ADDRESS_559305] 4 of the 
swollen joints in the proximal interphalangeal (PIP) joints, 
metacarp ophalangeal (MCP) joints and/or wrist.  A joint that is 
both tender and swollen will be included in both categories 
(counts as 1 tender and 1 swollen).   
Subjects must also demonstrate at least one sign of active lupus 
skin disease, including ACLE, SCLE, and/or CCLE (e.g., DLE), 
with skin activity defined by [CONTACT_257441] -2K at the time of 
Screening and randomization .  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The informatio n contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
17Part B:
All subjects must have active skin manifestations (CLASI -A ≥8) 
and a diagnosis of CLE that has been histologically confirmed 
(in the p ast or at Screening), with or without SLE 
manifestations.  Active CLE is defined as follows: 
SCLE with a CLASI -A erythema score ≥2
and/or
CCLE, including DLE, with at least 1 active DLE 
lesion with a minimum CLASI -A erythema score 
≥2, and a CLASI -D scarring score ≥1.
Detailed criteria are described in Section 8.
Treatment Groups: Part A:  
Subjects will be randomized in a 1:1 ratio to 1 of  2 treatment 
groups to receive subcutaneous BIIB059 (450 mg) or placebo 
every 4 weeks, with an additional dose at Week 2, for a total of 
7doses (Weeks 0, 2, 4, 8, 12, 16, and 20).  This randomization 
scheme will apply to the approximately 100 subjects randomized 
under protocol version 2 or subsequent versions and to any 
additional subjects if a decision to expand is made following the 
IA. 
Part B:  
Subjects will be randomized in a 1:1:1:1 ratio to 1 of 4 treatment 
groups to receive subcutaneous BIIB059 (50 mg, 150 mg, or 
450mg) or placebo every 4 weeks, with an additional dose at 
Week 2, for a total of 5 doses (W eeks 0, 2, 4, 8, and 12).  This 
randomization scheme will apply to the approximately 100 
subjects randomized under protocol version 2 or subsequent 
versions. 
Duration of Treatment and 
Follow -
up:Part A:
Study duration for each subject may be up to 40 weeks:
Screening Period:  up to 4 weeks
Treatment Period:  24 weeks
Follow -up Period:  12 weeks 
Part B:
Study duration for each subject may be up to 32 weeks:
Screening Period:  up to 4 weeks
Treatment Period:  16 weeks
Follow -up Period:  12 weeks
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
184. STUDY SCHEMATIC AND SCHEDULE OF ACTIVITI ES FOR STUDY 230LE20 1
4.1. Study Schematic  
Figure 1: Study Design Part A
Abbrev iations: ANA=antinuclear antigen; dsDNA= double -stranded DNA; IA=interim analysis;  FU=follow -up visit; MCP=metacarpophalangeal joints; 
OCS=oral corticosteroid; PIP=proximal interphalangeal joints;  Q4W=every 4 w eeks; SoC=standard of care; TD1=Treatment Da y 1.
** At least [ADDRESS_559306] be PIP, MCP, and/or w rist joints.  A joint that is both tender and sw ollen will be included in both categories (counts a s  
1tender and 1 sw ollen).
Black triangles represent dosing visits.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
19Figure 2: Study Design Part B
Abbreviations: CLASI -A=Cutaneous Lupus Erythematosus Disease Area and Severity Index -Activity Scale; CLE=cutaneous lupus erythematosus; FU=follow -
up visit; IA=interim analysis; OCS=oral corticosteroid; Q4W=every 4 w eeks; SoC=standard of care; TD1=Treatment Day [ADDRESS_559307] or at Screening.
Black triangles represent dosing visits.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
204.2. Schedule of Activities 
Table 1: Schedule of Activities Part A
Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
            Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D)Tests and 
Assessments2,3
Informed Consent 
Form (s)X
Inclusion/ 
Exclusion CriteriaX X
Randomization X
Dem ographic data X
SLE and other 
medical historyX
Documentation of 
SLE by [CONTACT_441109]
12-lead ECG4X X
Chest x -ray5(if 
required by [CONTACT_21482])X
Tuberculosis test6X
Serum virology 
RNA (HIV,  
hepatitis B and C)X
Urine drug screen X
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
21Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
            Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D)Tests and 
Assessments2,3
Serum pregnancy 
testX
Urine pregnancy 
test7 X X X X X X X X X X X
Physical 
examination,  
weight, height8X X X X X X X X X X X
Vital signs9X X X X X X X X X X X X X
BILAG- 2004 X X X X X X X X
CLASI X X X X X X X X X X
Physicians Global 
Assessment of SLE 
(VAS)10X X X X X X X X X X
Skin photography 
of target lesion11 X X X12
Joint Count (28 
joint assessment)X X X X X X X X X X

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
22Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
            Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D)Tests and 
Assessments2,3
Study treatment 
administration13 X X X X X X X
Corticosteroid 
diary14 X X X X X X X X X X X X
Laboratory Assessment
Hem atology X X X X X X X X X X X
Blood chemistry X X X X X X X X X X X
Urinalysis 
(including 
microscopic 
examination)X X X X X X X X X X X
Urine protein -
creatinine Ratio 
(spot urine)X X X X X X X X X X X
Direct Coombs 
AnalysisX X X X X X X X
Coagulation X X X X X X X X
CD19+ B Cell 
count15 X
Pharm acokinetics
Serum BIIB05916X X X X X X X X

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
23Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
            Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D)Tests and 
Assessments2,[ADDRESS_559308] -Reported Questionnaires20

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
24Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
            Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D)Tests and 
Assessments2,3
Safety
Serum for vaccine -
related 
immunoglobulin 
titers21X X
Antibodies to 
BIIB059X X X X X
Immunoglobulin 
(total, IgG, IgA, 
IgM)X X X
Concomitant 
medication/ 
proceduresMonitor and record from signing of informed consent through the end of the study
Serious adverse 
eventsMonitor and record from signing of informed consent through the end of the study
Adverse events Monitor and record from time of first dose through the end of the study
Abbreviations:   ACR=American College of Rheumatology; BILAG=British Isles Lupus Activity Group; CLASI=Cutaneous Lupus Disease Area and Severi ty 
Index; CLE=cutaneous lupus erythematosus; C=complement; CPK=creatine phosphokinase; CRP=C -reactive protein; D=day; DNA=deoxyri bonucleic acid; 
dsDNA=double -stranded DNA; ECG=electrocardiogram; ESR=erythrocyte sedimentation rate; ET=early termination; FU=follow -up; h=hour(s); HIV=human 
immunodeficiency virus; Ig=immunoglobulin; ; ; 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
25RNA=ribonucleic acid; ; SLE=systemic lupus erythematosus; SLEDAI -
2K=Systemic Lupus Erythematosus Disease Activity Index 2000; TB=tuberculosis; VAS =visual analog scale.
1Follow -up visit will be conducted 4, 8, and [ADDRESS_559309] Treatment Period Visit (Week 24 or ET). 
2Assessments (e.g., CPK, ECG, etc.) may be performed as required to confirm SLEDAI -2K and BILAG findings.  
3On each dosing day (Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, and Day 141) all assessments should be performed prior to dosing.
4To be performed locally.
5Where mandated by [CONTACT_1295], a chest x -ray will be obtained locally during the screening perio d, unless a previous chest x -ray or the documented results 
from a chest x -ray obtained within [ADDRESS_559310] x -ray or x -ray results will be review ed by  [CONTACT_737] (or designee) 
in order to exclude patients with active TB infection from entering the study.
6Testing to be performed locally.  Indeterminate Quantiferon or T -SPOT tests may be repeated once and w ill be considered positive if retest results are positive 
or indeterminate. Subjects with documented BCG vaccination must perform a TB test at Screening and will be excluded if they exhibit skin induration  ≥5 mm 
or a positive Quantiferon or positive or borderline T -SPOT (Elispot) test. 
7To be performed locally.
8Height should be measured only once; i.e., at the Day 1/baseline visit.
9Vital signs include seated arterial blood pressure, heart rate, and oral body temperature.   
 
11One lesion is to be selected at baseline as the target lesion (the most se vere active CLE lesion is recommended).  The  target lesion must be the same lesion 
used for tape  harvesting and the same lesion over time.
[ADDRESS_559311] paper diaries for recording corticosteroid use will be distributed on Day 1, r eviewed w ith site staff at each study visit, and collected by [CONTACT_441110]. 
15 Only for subjects with prior B cell directed therapi[INVESTIGATOR_014] w ithin 52 w eeks of Screening; this test should be performed at a centr al laboratory.
16 Pharmacokinetic evaluations will be conducted as follows: Study Day 1 (predose –[ADDRESS_559312] -dose 4 h ±1 h), Day 8 (any time during visit), Day 29 (predose 
–1 h and postdose 4 h ±1 h), Day 85 (predose –1 h and postdose 4 h±1 h), Day 113 (predose –1 h), an d Day 169 (any time during visit). During the Follow -up 
Period, 1 sample will be collected on Days 197 and 253 (any time during the visit) [ Table 3].  The time and date of PK sample collection and BIIB059 dose 
should be recorded in the eCRF.
  
21Vaccine- related immu noglobulin titers for tetanus, diphtheria, and Pneumococcus will be collected. 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the writte n consent of Biogen MA Inc.
26Table 2: Schedule of Activities Part B
Screening 
PeriodTreatm ent Period Follow -up Period1
Study WeekWithin 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16/ ET FU4 FU8 FU12
                                          Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)113
(±3D) 141
(±5D)169
(±5D)197
(±5D) Tests and Assessments2,3
Informed Consent Form(s) X
Inclusion/Exclusion Criteria X X
Randomization X
Dem ographic Data X
CLE, SLE and Other Medical History X
Documentation of SLE by [CONTACT_441111] X
12-lead ECG4X X
Chest x -ray5(if required by [CONTACT_21482])X
Tuberculosis Test6X
Serum Virology (HIV, Hepatitis B and 
C) RNAX
Urine Drug Screen X
Serum Pregnancy Test X
Urine Pregnancy Test7X X                                                                                                                            X X X X X X X
Physical Examination, Weight, Height8X X X X X X X X X
Vital Signs9X X X X X X X X X X X
CLASI10X X X X X X X X

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
27Screening 
PeriodTreatm ent Period Follow -up Period1
Study WeekWithin 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16/ ET FU4 FU8 FU12
                                          Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)113
(±3D) 141
(±5D)169
(±5D)197
(±5D) Tests and Assessments2,3
Physicians Global Assessment of SLE 
(VAS)11,12 X X X X X X X
Skin photography of target lesion13X X X X
Study treatment administration14X X X X X
Corticosteroid Diary15X X X X X X X X X X
Laboratory Assessment
Hem atology X X X X X X X X X
Blood Chemistry X X X X X X X X X
Urinalysis (including microscopic 
examination)X X X X X X X X X
Urine Protein -Creatinine Ratio (spot 
urine)X X X X X X X X X
CD19+ B Cell Counts16X
Pharm acokinetics
Serum BIIB05917X X X X X X X X

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
28Screening 
PeriodTreatm ent Period Follow -up Period1
Study WeekWithin 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16/ ET FU4 FU8 FU12
                                          Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)113
(±3D) 141
(±5D)169
(±5D)197
(±5D) Tests and Assessments2,3
Safety
Antibodies to BIIB059 X X X X
Immunoglobulin (total, IgG, IgA, IgM) X X X

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or publishe d without the written consent of Biogen MA Inc.
29Screening 
PeriodTreatm ent Period Follow -up Period1
Study WeekWithin 4 
Weeks Prior to 
Randomization0 1 2 4 8 12 16/ ET FU4 FU8 FU12
                                          Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)113
(±3D) 141
(±5D)169
(±5D)197
(±5D) Tests and Assessments2,3
Concomitant Medication/Procedures Monitor and record from signing of informed consent through the end of the study
Serious Adverse Events Monitor and record from signing of informed consent through the end of the study
Adverse Events Monitor and record from time of first dose through the end of the study
Abbreviations:   ACR=American College of Rheumatology; C = complement; CLASI = Cutaneous Lupus Disease Area and Severity Index; CLE = cutaneou s lupus 
erythematosus; CRP = C-reactive protein; D = day; DNA = deoxyribonucleic acid; dsDNA = double -stranded DNA; ECG = electro cardiogram; ESR = erythrocyte 
sedimentation rate; ET = early termination; FU = follow -up; HIV = human immunodeficiency virus; Ig=immunoglobulin; ; RNA = 
ribonucleic acid; ; SLE = systemic lupus erythematosus; SLEDAI -2K = Systemic 
Lupus Erythematosus Disease Activity Index; TB = tuberculosis; VAS = visual analog scale.
  
1Follow -up visits will be conducted 4, 8, and [ADDRESS_559313] Treatment Period Vis it (Week 16 or ET). 
2Assessments (e.g., CPK, ECG, etc.) may be performed as required to confirm SLEDAI -2K findings.
3On each dosing day (Day 1, Day 15, Day 29, Day 57, and Day 85) all assessments should be performed prior to dosing.
4To be performed locally.
5Where mandated by [CONTACT_1295], a chest x -ray will be obtained locally during the screening period, unless a previous chest x -ray or the documented results 
from a chest x -ray obtained within [ADDRESS_559314] x-ray or x -ray results will be review ed by  [CONTACT_737] (or designee) 
in order to exclude patients with active TB infection from entering the study.
6Testing to be performed locally.  Indeterminate Quantiferon or T -SPOT tests may be repeated once, and w ill be considered positive if retest results are positive 
or indeterminate. Subjects with documented BCG vaccination must perform a tuberculosis test at Screening and w ill be excluded if they exhibit skin induration 
≥5 mm or a positive Quantiferon or positive or borderline T -SPOT (Elispot) test.
7To be performed locally.
8Height should be measured only once; i.e., at the Day 1/baseline Visit.
9Vital signs include seated arterial blood pressure, heart rate, and oral body temperature.
10CLASI will b e assessed by [CONTACT_29517] a trained designee at all  assessments (Section 19.2.2 ).  CLASI scores at Screening will be verified by [CONTACT_441112].
14Follow ing administration of study treatment, subjects should remain at the study center for [ADDRESS_559315] paper diaries for recording corticosteroid use will be distributed on Day 1, reviewed with site staff at each study visit, and collected by [CONTACT_441110].
16Only for subjects with prior B cell directed therapi[INVESTIGATOR_014] w ithin 52 w eeks of Screening; this test should be performed at a centr allaboratory.
17Pharmacokinetic evaluations will be conducted as follows:  Day 1 (pre- dose –[ADDRESS_559316] -dose 4 h ±1 h), Day 8 (any time during the visit), Day 29 (predose –
1 h and postdose 4 h ±1 h), Day 85 (predose –1 h and postdose 4 h ±1 h), and Day 11 3 (any time during the visit).  During the Follow -up Period, 1 sample w ill 
be collected on Days 141, 169, and 197 (any time during the visit) [Table 3].
  

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the writte n consent of Biogen MA Inc.
31Table 3: Pharmacokinetic Assessments
Study Week 0 1 2 4 8 12
16 20 24Follow -Up 
Period
Study Day 18
(±2 d)15
(±2 d)29
(±3 d)57
(±3 d)85
(±3 d)113
(±3 d)141
(±3 d)169
(±3 d)Part A
Day 197 and 
253 (±5 d)
Part B
Day 141, 
169, and 197 
(±5 d)
Part A
PK Sam pling 
Timepoint(s)Predose 
(–1 h)
Postdose 
(4 h ±1 h)Any 
time 
during 
visitPredose 
(–1 h)
Postdose 
(4 h ±1 h)Predose 
(–1 h)
Postdose 
(4 h ±1 h)Predose   
(–1 h)Any time 
during 
visitAny time 
during 
visit
Part B
PK Sam pling 
Timepoint(s)Predose 
(–1 h)
Postdose 
(4 h ±1 h)Any 
time 
during 
visitPredose 
(–1 h)
Postdose 
(4 h ±1 h)Predose 
(–1 h)
Postdose 
(4 h ±1 h)Any time 
during 
visit Any time 
during 
visit
Abbreviations:   d=days; h=hour(s); PK=pharmacokinetic
Protocol 230LE201 Version 5.[ADDRESS_559317], the Principal Investigator (or a qualified designee)  will be responsible for 
administering the following instruments throughout the study .  Eve ry effort will be made to 
ensure that assessments are performed b y the same evaluator for a given subject over time. 
Cutaneous L upus Ery thematosus Disease Area and Severity  Index (CL ASI)
British Isles Lupus Activity Group 2004 (BILAG) [Part A only ] 
Systemic Lupus Ery thematosus Disease Activity  Index –2000 (SLEDAI -2K) [all 
subjects in Part A and subjects in Part B with SL E by [CONTACT_441113]] 
  
  
  
 
An unblinded pharmacist (or authorized designee) will be responsible for the storage, 
distribution, preparation and accountability  of study  treatment.  The unblinded pharmacist will 
also be responsible for maintaining th e unblinded pharmacy  record separate from the main study  
file in order to support the study  blind .
4.3.2. Skin RNA Tape Harvesting (Parts A and B)
Skin tape harvesting (tapi[INVESTIGATOR_441065] ; the most severe active CLE lesion is 
recommended) will be collected at Week 0 (baseline), Week 4, and Week 16 for Part A and 
PartB.  Onl y 1 affected target lesion of active CLE should be tested. The same target lesion 
sampled at baseline should be sampled at subsequent timepoints to study  the evolution of th e 
same lesion over time.  
Refer to the Study  Reference Guide for instructions on collection and processing of samples.
4.3.3. Joint Count Assessment (Part A Only)
Joint counts will be evaluated at all visits by  a trained independent joint assessor.  The joint 
counts for an individual subject must be performed by  [CONTACT_441114].
For this study , the joint assessment will be carried out on 28 joints. The joints to be assessed 
bilaterally  include the shoulders, elbows, wrists (radiocarpa l, carpal, and carpometacarpal bones 
are considered as a single unit), metacarpophalangeal (MCP) joints (MCP 1, 2, 3, 4, and 5), 
proximal interphalangeal (PI P) joints (PI P 1, 2, 3, 4 and 5), and the knees.  Artificial and 
anky losed or fused joints will be excluded from tenderness and swelling assessments.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
334.3.4. Skin Photography (Parts A and B)
Part A
In Part A, close -up clinical photographs of the target skin lesion (most severe active CLE lesion) 
will be obtained at Week 0 (baseline), Week 4, and Week 16 (or at early termination, if 
applicable).  The target skin lesion is the same lesion that will be used for tape harvesting. 
Part B
In Part B, for skin lesions with CL ASI-A score greater than 0, photographs of each lesion and of 
the corresponding region with lesi on(s) will be obtained at Screening, Week 0 (baseline), 
Week 4, and Week 16 (or at early  termination, if applicable).  Photographs taken at Screening 
will be evaluated b y a central adjudicator to verify  the CLASI -A score assignment b y the 
Investigator and confirm eligibility .  
One lesion is to be selected at baseline as the target lesion (the most severe active CLE lesion is 
recommended).  The same target lesion must be photographed and used for tape harvesting and 
optional biopsy  at each applicable timepo int.
Identical technical settings should be maintained.  Biogen will provide cameras and devices for 
standardized photography .  These photographs will be sent electronically  to the central database.  
On the day  of photography , subjects are requested to avoid apply ing ointments, creams, or make -
up onto their skin prior to the visit.
For further details please see the Study  Reference Guide.
4.3.5. Skin Biopsy (Part B Only) 
[IP_ADDRESS]. Skin Biopsy for Confirming CLE Diagnosis 
For subjects without historical biopsy  data, diagn osis will be confirmed during Screening b y skin 
biopsy  that can be read at a local laboratory  or the central laboratory , at the  discretion of the 
Investigator. A punch biopsy  will be performed for diagnostic purposes. Subjects with an 
available historical biopsy  do not need a screening biopsy  for diagnosis. 
[IP_ADDRESS]. Optional Skin Biopsy
 
 A punch biopsy  should be performed. 
Biopsies should be taken from the same lesion at both timepoints, and a biopsy  from the edge of 
the active lesion is preferred.  For further details on skin biopsy , see the Study  Reference Guide.
4.3.6. CLASI Adjudication (Part B Only)
CLASI will be assessed by  [CONTACT_29517] a tra ined designee and entered by  [CONTACT_441115] (Section 19.2.2). CL ASI scores at Screening will be verified by  [CONTACT_441112] .

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
344.3.7. Blood RNA Paxgene and Skin Biopsy Immunohistochemistry Assessments 
Blood samples will be collected from all subjects to evaluate  biomarkers that may  be related to 
BIIB059 activity  or indicative of subjects who may  respond to BIIB059.  Biomarkers may  
include but are not limited to baseline levels of interferon (IFN)- induc ible messenger RNA 
(mRNA) [i.e., ty pe I IFN signature].  Effects of BIIB059 on these or other markers of disease 
may also be evaluated.
Classical immunohistochemistry in CLE skin biopsies (Part B) will be performed to study  
changes in PD  biomarkers that m ay be related to BIIB059 activity  in the skin, including but not 
limited to IFN-related proteins.  In situ hybridization may  also be performed to study  changes in 
IFN-regulated or cy tokine and chemokine mRNA levels after BIIB059 treatment. 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
355. INTRODUCTION 
BIIB059 is a humanized immunoglobulin class G, ty pe 1 (IgG1) monoclonal antibody  that 
specificall y recognizes blood dendritic cell antigen 2 (BDCA2), a t ype II, C -type lectin receptor 
expressed exclusively on the surface of human plasmacy toid dendritic cell s (pDCs).  BDCA2 
receptor engagement in pDC prevents or diminishes toll -like receptor 
(TLR)7- andTLR9 -induced production of IFN-α, and pDC- derived cy tokines and chemokines 
[Cao 2007; Dzionek 2001; Fanning 2006; Röck 2007 ].  In non-clinical studies, BIIB059 has been 
shown to potently  inhibit all TL R9-induced t ype I IFNs, as well as other pDC -derived cy tokines 
and chemokines.  BIIB059 ligation leads to rapid internalization of BDCA2 from t he cell surface 
of human pDC and its co -localization with TL R9 in the late endol ysosomal compartment, which 
appears to be necessary  f or inhibition of TL R9 signaling.  In vitro, BIIB059 also triggers 
internalization of CD32a which may  prevent immune comple x stimulation of pDC 
[Pellerin 
2015] .  By [CONTACT_441106]2, BIIB059 treatment should target pDC in affected tissues in 
patients with SL E and CLE and decrease production of IFN -α, as well as other IFN subt ypes and 
pDC -derived cy tokines and chemokines that contribute to SLE and CLE pathogenesis.
5.1. Overview of Lupus Erythematosus
Systemic lupus ery thematosus (SL E)is an autoimmune disease that affects multiple organ 
systems and is unpredictable in disease severit y, with periods of illness or flares alternating with 
periods of remission.  The diverse presentation of lupus can range from rash and arthritis, anemia 
and thrombocy topenia, serositis, nephritis, seizures and psy chosis.  At its onset, SL E may  
involve one or more organ sy stems, including the musculoskeletal, cutaneous, vascular, renal, 
pulmonary , hematologic, and nervous s ystems.  Disease prevalence is approximately  1 in 1000 
individuals overall, but varies with race and ethnicity .  SL E is more common in women than in 
men (up to 10times more common).  Subjects with moderate to -severe SLE consider their 
health- related quality  of life (HRQoL) to be poor [Fauci and Longo 2008; Jiménez 2003].
Cutaneous lupus ery thematosus is a chronic autoimmune disease that may  present with or 
without SLE. Up to 80% of subjects with SL E will have cutaneous manifestations.  Based on 
histopathological findings, the cutaneous manifestations of lupus ery thematosu s (LE) may  be 
classified into L E-specific and LE -nonspecific skin lesions (e.g., urticarial vasculitis, livedo 
reticularis), which may  be observed in other autoimmune diseases.  LE- specific skin lesions may  
be further subdivided based on clinical and histo pathological characteristics into acute cutaneous 
LE, subacute cutaneous LE (SCLE), and chronic cutaneous LE (CCLE), representing, 
respectivel y, 15%, 8%, and 73% of all CL E [Gilliam and Sontheimer 1981 ; Grönhagen and 
Nyberg 2014] .  In CCL E, the most common for m (80%) is DLE, which is rarely  associated with 
systemic LE manifestation.  L ess than 10% of patients with DL E fulfill 4 of the SL E American 
College of Rheumatology (ACR) criteria, and between 5% and 10% of individuals with DL E 
will develop full SL E[Biazar 2013; Koskenmies 2008 ; Okon and Werth 2013; Vasquez 2013].
5.2. Current Therapi[INVESTIGATOR_441066] E are onl y partially effective and have considerable toxicity.  
Nonsteroidal anti -inflammatory  drugs (NSAIDs) and antimalarials are commonly  used a s 
Protocol 230LE201 Version 5.[ADDRESS_559318]-line therapi[INVESTIGATOR_441067].  Corticosteroids and immunosuppressive drugs continue to 
be the mainstay  for treating flares of moderate- to-severe SLE disease.  Although 
immunosuppressive drugs can partiall y improve the outcome of severe SLE, very often the 
disease is incompletel y controlled.  I n addition, immunosuppressive and corticosteroid drugs are 
associated with serious side effects [Doria 2014; Petri 2013; Ruiz -Arruza 2014] .  Belimumab 
(Benl ysta®) is the only targeted therapy  approved to treat SL E.  Subjects treated with belimumab 
and standard of care (SoC) had an increased rate of treatment response compar ed with those 
receiving placebo and SoC; however, the treatment effect was small, with 9% to 13% of patients 
achieving an SL E Responder Index (SRI) response of 4 i n the registration studies [ Furie 2011 ; 
Navarra 2011; van Vollenhoven 2012] .
To date, no medications have been specifically  approved for t he treatment of CL E.  Current 
therapi[INVESTIGATOR_441068], topi[INVESTIGATOR_22726], and intralesional 
corticosteroids (for scalp lesions).  For subjects who are refractory to topi[INVESTIGATOR_52201] y or who have 
widespread or scarring skin d
isease, s ystemic therapy , including the antimalarial agents 
hydroxychloroquine, chloroquine, or quinacrine, is used.  Other s ystemic medications that can be 
useful in moderate and/or severe CLE subject subsets include dapsone, retinoids, azathioprine, 
methotrexate, thalidomide, and occasionall y systemic corticosteroids [Okon and Werth 2013; 
Schultz 2015 ; Winkelmann 2013 ].  Unsatisfactory effectiveness and/or associated toxicities limit 
the use of antimalarial therapi[INVESTIGATOR_441069] -to-severe CLE and/or DLE.  In a prospective study  
including 300 subjects with CL E (86 SCL E, 160 DL E, 54 others), in subjects who were treated 
with hy droxychloroquine, only  21% (men) to 41% (women) reported clinical remission after at 
least 12 weeks of therap y.  Complete remission was negatively correlated with DL E diagnosis 
and male sex [Francès 2012] .  Use of antimalarial agents is also associated with toxicities, 
including retinal toxicity , gastrointestinal disorders, skin hy perpi[INVESTIGATOR_371], my opath y, and 
white discoloration of lighter skin [Chang 2011 ].  
5.3. Profile of Previous Experience with BIIB059
5.3.1. Nonclin ical Experience
Nonclinical toxicology  studies in cy nomolgus monkey s showed that BIIB059 administered every  
2 weeks (Q2W), with up to 26 -weeks of exposure at doses up to 125 mg/kg, was well tolerated, 
with no mortalities and no general or organ toxicity  observed.  No effect on the central nervous, 
respi[INVESTIGATOR_696], or cardiovascular sy stems, no alteration in the immune cell population, and no 
clinical or histopathological evidence of injection- site reactions were associated with intravenous 
(IV) or subcutaneous (SC) administration of BIIB059.  
See the Investigator’s Brochure for detailed information on nonclinical studies.
5.3.2. Clinical Experience
BIIB059 is under development as a first -in-class therap y for the treatment of SL E.  It has been 
evaluated in a Phase 1 single -ascending -dose (SAD) and multiple -ascending -dose (MAD) study  
(230L E101).  Briefl y, this first -in-human study  was a randomized, blinded, placebo -controlled 
study  designed to evaluate the safety , tolerability  and pharmacokinetics (PK) of single and 
multiple ascending doses of BIIB059.  The study  consisted of 3 parts and included healthy  
volunteers and subjects with SL E who fulfilled the 1997 ACR classification criteria.  In Part 1, 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
37healthy  volunteers received a single IV dose of BIIB059 that ranged from 0.05 to 20 mg/kg, in 
order to assess the safet y and tolerability  of BIIB059 and determine its PK and 
pharmacod ynamic (PD) activity .  The bioavailability  of a single BIIB059 50 mg (fixed) dose 
administered SC to healthy  volunteers was also determined in Par t 1.  In Part 2, subjects with 
SLE and skin manifestations received a single BIIB059 IV dose of 20 mg/kg.  In Part 3, health y 
volunteers received up to 3 doses of BIIB059 that ranged from 20 mg to 300 mg every  2 weeks 
(Q2W) or every  4 weeks (Q4W); SL E subj ects received 2 doses of BIIB059 50 mg SC Q4W or 
3doses of BIIB059 ≤300 mg SC Q2W, for a total of 3 doses.
The PK data from Study  230L E101 demonstrate that maximum observed concentration (C max) 
and area under the concentration-time curve (AUC) for BIIB059 increased with dose following 
single IV administration (0.05 mg/kg to20 mg/kg).  Target -mediated clearance (CL) for 
BIIB059 was observed at lower doses e.g., <1 mg/kg and became saturated at doses ≥1 mg/kg.  
Following SC administration to healthy  volunte ers, BIIB059 C maxwas reached in approximately  
6 day s, with a bioavailability  of approximately  50%.  The AUC ∞in SL E subjects was 39% lower 
when compared to healthy volunteers at IV doses of 20 mg/kg. Following multiple SC 
administrations (20 mg to 300 mg) the AUC 0
-28din SL E subjects was 40% lower as compared 
with healthy  volunteers at SC doses of 50 mg.  The accumulation ratio for AUC was lower in 
SLE subjects (2.58) compared to healthy  volunteers (2.66), after BIIB059 SC administration. 
Overall, the targ eted mechanism of action of BIIB059, the absence of toxicological findings up 
to the highest dose tested, and the available clinical safet y data support the ongoing evaluation of 
BIIB059 in subjects with SL E and CLE.  The safety  data obtained to date in he althy  volunteers 
and subjects with SL E supports the evaluation of BIIB059 in this Phase 2 clinical Study  
230L E201.
Study  230LE101 results indicated that complete BDCA2 internalization (i.e., target engagement 
and PD activity ) was achieved at all dose level s, the duration of which was dose dependent.  
Reappearance of BDCA2 on circulating pDCs occurred when serum concentrations of BIIB059 
decreased to approximately  1g/mL.  BDCA2 internalization was similar for healthy  volunteers 
and subjects with SL E.  In a ddition, Study  230LE101 demonstrated proof of biological activity  
in SLE, whereb y the IFN signature [CONTACT_441157] E subjects, 
consistent with the mechanism of action of BIIB059.   
Skin biopsies in [ADDRESS_559319] a 4 -point 
reduction in CL ASI score at Week 4 and/or Week 12, indicating that the PD signal was 
associated with a clinica l reduction in skin involvement in this exploratory  anal ysis [Furie 2016] .
Data from Part [ADDRESS_559320]- in-human study, which included 54 healthy  volunteers (38 received 
BIIB059), indicated that BIIB059 treatment was well tolerated at single doses up to 20 mg/kg in 
these SAD cohorts, with no severe AEs.  Data from Part 2 (SAD), which included 12 SL E 
subjects (8 received BIIB059), indicated that BIIB059 treatment was well tolerated at single 
doses of 20 mg/kg [ Furie 2016 ].  Data from Part 3 (MAD), which included 33 healthy  volunteers 
(25 received BIIB059) and 10 SL E subjects (8 received BIIB059), indicated that BIIB059 
treatment was well tolerated at multiple doses up to 300 mg in this study .  Three SLE subjects 
experienced SAEs: [ADDRESS_559321] enrolled in Part 2 of the study  (BIIB059 20 mg/kg IV) and 2 
subjects enrolled in P art 3b of the study  (BIIB059 50 mg SC and BIIB059 300 mg SC).  None of 
Protocol 230LE201 Version 5.[ADDRESS_559322] discontinue d 
study  treatment due to an AE not related to BIIB059; however, none withdrew from the study  
due to an AE.
See the Investigator’s Brochure for detailed information on BIIB059 clinical studies. 
5.4. Study Rationale
A hallmark of SLE and CLE is the production of autoantibodies to a variety  of nuclear antigens 
that account for some of the pathological manifestations [Achtman and Werth 2015 ; Fauci and 
Longo 2008 ; Rahman and I senberg 2008 ].  Although the pathogenesis of SL E and CLE is not 
fully  understood, there is increasing evidence that th
e cytokine famil y of t ype I IFNs, most 
notably  IFN-α, play s a central role in the pathogenesis of SL E, including the cutaneous 
manifestations seen in CLE.  In both CL E and SLE, ty pe I IFN expression correlates with both 
disease activity  and severity  [Braunstein 2012 ; Dall 'era 2005 ; Hellquist 2009 ; Järvinen 2010; 
Niewold 2012] .  Furthermore, the “IFN signature” that represents a messenger RNA expression 
pattern of IFN -inducible genes has been observed in more than half of SLE patients and in 70% 
to 75% of patients with active disease [Furie 2015 ; Kalunian 2016 ].  Although not predictive of 
flares or changes in disease activity , a high IFN signature [CONTACT_441158]  [Baechler 2003 ; Petri 2009 ].  
In CLE, t ype I IFNs are thought to be involved in amplify ing intralesional inflammation by  
[CONTACT_441116] -inducible chemokines and recruitment of T cells into the skin.  As pDC have been 
identified as the main IFN -producing cells in CLE [Farkas 2001 ; Ghoreishi 2012; Vallin 1999]
blocking pDC and the IFN pathway  may  provide clinical benefit.  Recent data from  Phase 2 
studies with IFN -
α-blocking agents (sifalimumab and anifrolumab) demonstrated improvement 
in sy stemic lupus disease activity  and, more specifically , cutaneous manifestations, further 
supporting the rationale for blocking the IFN pathway  in patients with SL E and CL E with or 
without sy stemic manifestations [Furie 2015; Khamashta 2014] .  
BDCA2 is a t ype II, C -type lectin receptor that is uniquely  expressed on the cell surface of pDC 
and was the first receptor described to negativel y down -regulate the t ypeI IFN response in these 
cells [ Cao 2007; Dzionek 2001; Fanning 2006; Röck 2007] .  In SLE, pDC are found to be 
decreased in the blood and to be present in target organs such as the skin or the kidney [Farkas 
2001; Vermi 2009 ].  By  [CONTACT_441106]2, BIIB059 treatment should target pDC in affected 
tissues in patients with SLE and CL E and decrease product ion of IFN- α, as well as other IFN 
subty pes and pDC -derived cy tokines and chemokines that contribute to SLE and CL E 
pathogenesis.  In addition, BIIB059 may  decrease localization of pDC in SLE -or CLE -affected 
organs such as the skin and restore the number of circulating pDC in the blood.
Altogether, given the lack of highl y efficacious and safe treatments for active SL E and CL E, and 
the large impact of this disease on health- related quality  of life (HRQoL) in SL E and CLE 
patients, there is currently  a large unmet need for new targeted therapi[INVESTIGATOR_014].  Based on its 
mechanism of action, BIIB059 has the potential to decrease skin disease activity .  In addition, 
based on data currently  available, BIIB059 presents an acceptable safet y profile, and hence it is 
therefor e justified to evaluate its potential efficacy in subjects with active SLE or CLE.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
395.5. Rationale for Dosing Regimen
5.5.1. Part A
Single IV as well as multiple SC doses of BIIB059 up to and including 20 mg/kg and [ADDRESS_559323] demonstrated acceptable tolerability in the Phase 1 
Study  (230LE101).  In general,  BIIB059 serum concentrations were slight ly lower in subjects 
with SL E than in health y volunteers following dosing with BIIB059 50 mg SC (single and 
multiple dose administration).  Additionally , the median percent change from baseline in 
BDCA2 on pDC surfaces was equivalent between SL E and health y subjects following SC doses 
of 50 mg.  
Single doses of 450 mg administered SC Q4W, with an additional dose at Week 2, will be used 
in Part A.  The dosing regimen was selected based on Phase 1 safet y, PK, PK -BDCA2 
internalization relationship and extrapo lated inhibitory  potency  (concentration resulting in 90% 
inhibition of response [IC 90]) of pDC I FN-α production [Pellerin 2015].  The BIIB059 fixed dose 
of 450 mg SC Q4W, with an additional dose at Week 2, was selected to achieve C minlevels 
similar to 3 -fold of the calculated IC 90for IFN- α inhibition. Furthermore, this dose regimen with 
an additional dose of 450 mg at Week 2 and a bioavailability  (F) of 0.45 is expected to result in 
cumulative exposure comparable to or lower than that achieved b y the single dose of 20 mg/kg 
IV for a 65- kg person, the highest dose tested in healthy  volunteers. 
5.5.2. Part B
The dosing regimen was selected based on the Phase 1 safet y, PK, PK- BDCA2 internalization 
relationship, and extrapolated inhibitory  potency  (concentration resulting in 90% inhibition of 
response [I C90]) of pDC IFN -α production [
Pellerin 2015 ]. BIIB059 fixed doses of 50, 150 and 
450 mg SC Q4W, with an additional dose at Week 2, were selected for the Phase 2 study  because 
simulations conducted, based upon the population PK model developed using the phase 1 data, 
predicted that:
At the low dose of 50 mg SC Q4W, BIIB059 is expected to achieve plasma 
concentrations sufficient to maintain 90% BDCA2 internalization for the majority  of the 
dosing interval.
At the middle dose of 150 mg SC Q4W, BIIB059 is expected to achieve plasma 
concentrations similar to or in excess of the calculated IC 90for IFN- α for the majority  of 
the dosing interval.
At the top dose of 450 mg SC Q4W, BIIB059 is expected to achieve C minlevels similar to 
3-fold of the calculated IC90for IFN -α inhibition. 
The selected doses are considered safe and tolerable, based upon the results of the Phase 1 
study .The dosing regi men of 450 mg SC Q4W, with an additional dose of 450 mg at Week 2 
and a bioavailability  (F) of 0.45, is expected to result in cumulative exposure over 12 weeks that 
is comparable to or lower than that achieved b y the single dose of 20 mg/kg IV for a [ADDRESS_559324] dose tested in health y volunteers.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
405.5.3. Rationale for Placebo 
The use of placebo is justified because subjects assigned to placebo may  also be receiving 
background lupus SoC.  Any  prior lupus background medication allowed in this study  that has 
been initiated prior to Screening will be authorized according to the protocol specifications 
(Section [IP_ADDRESS].1).  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
416. STUDY OBJECTIVES AND ENDPOINTS
Table 4: Study Objectives and Endpoints
Primary Objective Primary Endpoint
To evaluate the efficacy of 
BIIB059 in reducing disease 
activity in subjects with SLE with 
active cutaneous manifestations 
and joint involvement (Part A), 
and in subjects with active CLE 
(SCLE or chronic CLE, including 
DLE) with or without systemic 
manifestations (Part B).Part A:  
Change in active joint count (28 -joint assessment) from Baseline 
to Week 24; the active joint count is defined as the sum of tender 
and swollen joint counts.
Part B:  
Percent change in CLASI -A score from Basel ine to Week 16.
Secondary Objectives Secondary Endpoints
To evaluate additional efficacy 
parameters of BIIB059 in 
reducing SLE/CLE disease 
activity.
Skin related (Part A and 
Part B):
SLE disease activity related   
(Part A only):CLASI -50, defined as a 50% improvement from baseline in 
CLASI -A score at Week 24 (Part A) and Weeks 12 and 16 
(Part B)
Percent change in CLASI -A score from baseline to Weeks 12, 
16, and 24 (Part A) and Week 12 (Part B)
A ≥4-point reduction in CLASI -A score relative to baseline at 
Week 24 (Part A) and at Weeks 12 and 16 (Part B)
Proportion of subjects with a composite response, defined as: 
SLE Responder Index (SRI) of ≥4 (SRI -4) at 
Week 24, where SRI -4 is defined as:
oA reduction from baseline of ≥4 point s  in 
Systemic Lupus Erythematosus  Disease 
Activity Index 2000 (SLEDAI -2K)  and
oNo new organ system affected, as defined by 
[CONTACT_441108] -[ADDRESS_559325]’s lupus 
disease activity defined by <0.3 point  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
42increase in PGA (VAS) 
No protocol -prohibited medication or treatment.
Concomitant corticosteroid dosage at Week 24 to 
be ≤10mg/day
Concomitant corticosteroid dosage at Week 24 to 
be ≤Day 1 corticosteroid dosage
No increase in corticosteroid dose between Weeks 
17 and 24
Change from baseline to Week 24 in SLEDAI -2K score
Proportion of subjects with no new organ system affected, as 
defined by [CONTACT_441108] -2004 A and no mor e than one new 
BILAG -2004 B from baseline to Week 24
Change from baseline to Week 24 in PGA VAS score
To evaluate pharmacokinetic 
parameters of BIIB059 (Parts A 
and B)BIIB059 clearance, volume of distribution, and absorption rate
To evaluate the safety and 
tolerability of BIIB059 (Parts A 
and B)Nature, severity, relationship to study treatment and incidence 
of AEs and SAEs
Change from baseline in standard laboratory parameters, vital 
signs and ECGs 
Immunogenicity (antibodies to BIIB059)
Absolute and percent change from baseline over time in 
immunoglobulin levels and vaccine -related immunoglobulin 
titers
 
  
 
  
  
  


Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
43  
 
   
  
  
 
  
  
  
 
  
  
 
 
   
  
  

 
  
 
   
  
 
 
   
 
 


Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
44
 
 

 
 
 

 
 
 
Abbreviations:  A CR = American College of Rheumatology; AE = adverse event; BILAG = British Isles Lupus Activity Group; 
CLASI -A = Cutaneous Lupus Erythematosus Disease Area and Severity Index –Activity;  
; CLE = cutaneous lupus erythematosus; ECG = electrocardiogram; 
; ; ; PGA = 
Physician’s Global Assessment; ; SAE = serious adverse event;  
; SLE = systemic lupus erythematosus; SLEDAI -2K = Systemic Lupus 
Erythematosus Disease Activity Index – 2000; SRI -4 = SLE Responder Index of ≥4; V AS = visual analog scale.
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
457. STUDY DESIGN
7.1. Study Overview
This is a 2- part randomized, double -blind, parallel -group, placebo -controlled, multicenter 
Phase 2 trial designed to evaluate the efficacy  and safet y of BIIB059 in subjects with SL E with 
active skin manifestations and joint involvement (Part A) or active CLE, defined as SCL E  or 
CCLE, including DLE, with or without SL E (Part B). The stud y will be co nducted at 
approximately  130 centers in the [LOCATION_002], Europe, Latin America, and Asia.
Study  treatment will begin following a 28 -day Screening period.
In Part A, subjects will be randoml y assigned to 1 of 2 treatment groups in a 1:1 ratio and will 
receive either BIIB059 (450 mg) or placebo subcutaneously  every  4 weeks (Q4W) for 24 weeks, 
with an additional dose at Week 2, for a total of 7 doses ( Figure 1). The maximum number of 
subjects in Part A is approximately  190 subjects.  Of these 190 subjects, approximately  100 
subjects will be enrolled under protocol version 2 or subsequent versions.  If the study  is not 
stopped for futility  at the interim analy sis (IA), then up to 70 additional subjects may  be added 
(up to a total of approximately  170 subjects under protocol version 2 or subsequent versions).  
Subjects enrolled under protocol version 1 will remain on their original treatment assignment (up 
to a total of approximately
 20 subjects) and will not be reconsented under protocol version 2.  
Randomizat ion will be stratified by [CONTACT_441117] ( ≤10mg vs. >10 mg) and by  
[CONTACT_1617] (
[LOCATION_002] vs. Asia vs. Latin America and Europe ).
In Part B, approximately  130 subjects will be randomized; of these, approximately  [ADDRESS_559326] completed the Week 12 / Earl y Terminati on Visit.  
Subjects enrolled in protocol version 2 or subsequent versions will be randomly  assigned to 1 of 
4 treatment groups in a 1:1:1:1 ratio, with approximately  25 subjects per treatment arm to receive 
either a fixed dose of BIIB059 (50 mg, 150 mg, or 450 mg) or placebo SC every  4 weeks (Q4W) 
for 16 weeks, with an additional dose at Week 2, for a total of 5 doses ( Figure 2).  
Randomization will be stratified by [CONTACT_441118]-A score ( ≤10 vs. >10) and DLE (presence, absence).
An IA (IA 1) for futility  of Part B and possible expansion of Part A will be performed.  IA 1 will 
be performed  after approximately  45% of Part B subjects under protocol version [ADDRESS_559327] completed their Week 12 Treatment Visit.  At th e time of this IA, it is estimated 
that over 50% of subjects in Part A will have completed their Week 12 treatment visit.  
Following the IA, up to an additional 70 subjects maybe enrolled in Part A and BIIB059 dose 
may by [CONTACT_441119].   The additional subjects in Part A may  be enrolled based on a more inclusive 
criteria to include an expanded SLE population.  Details are provided in Section 16.7.1.
An interim database lock and IA (IA 2) of efficacy  and safet y data will occur after the last 
subjects complete th e Double -Blind Treatment Periods for Part A (at Week 24) and Part B (at 
Week 16). Details are provided in Section 16.7.2. 
For both IAs (1 and 2), all I nvestigators, study  site personnel, and subjects will remain blinded to 
treatment assignments until aft er the final database lock. 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
467.2. Overall Study Duration and Follow -Up (Part A) 
The total duration of study  participation for each subject who completes Part A of the study  will 
be approximately  40 weeks (a 4- week Screening Period, a 24 -week double -blind Treat ment 
Period, and a 12 -week Follow -up Period).  Details on the timing of assessments during the stud y 
are presented in Table 1.  
7.2.1. Screening
Subject eligibility  for the study  will be determined within [ADDRESS_559328] eligibility  will be recon firmed prior to randomization on Day  1.  Eligible subjects will 
receive study  treatment on Day  1 and return to the study  site for additional dosing every  4 weeks 
through Week 20, with an additional dose at Week 2.  Following each administration of study  
treatment, subjects should remain at the study  center for 1 hour to be monitored for the 
development of potential allergic or anaph ylactic reactions.  Subjects will receive stud y 
treatment at baseline (Day 1), Week 2 (Day  15),  Week 4 (Day  29), Week 8 (Day  57), Week 12 
(Day  85), Week 16 (Day  113), and Week 20 (Day  141) for a total of 7 doses.    
Subjects will undergo study  assessments (see 
Table 1) at each of the dosing visits and will also 
undergo assessments at Week 1 (Day  8) and Week 24 (Day  169), though study  treatment is not 
administered at these visits.  The last dose of study treatment will be administered at Week 20 
(Day  141). 
7.2.3. Follow -Up
Subjects are to return to the study  site for follow -up (FU) visits at 4, 8, and [ADDRESS_559329] Treatment P eriod visit (Week 24 or Earl y Termination [ET] Visit).  Follow
-up visits will be 
conducted at Week FU4 (Day  197), Week FU8 (Day  225) and Week FU12 (Day  253).  The final 
study  visit will be Week FU12.    
Subjects who prematurely discontinue study treatment during the Double -blind Treatment 
Period should complete all study  assessments for the Week 24/ET Visit as soon as possible, but 
within 4 weeks.  Subjects who discontinue study  treatment should also complete the study  
assessments for the Safety  FU Visits at Week FU4, Week FU8, and Week FU12 after their ET 
Visit. 
Subjects who are prematurely  withdrawn from the study during the Double -blind Treatment 
Period should complete all study  assessments for the Week 24/ET Visit as soon as possible, but 
within [ADDRESS_559330] is unwilling or unable to attend the study  FU Visits, or at 
minimum the ET Visit, and decides to withdraw consent, the reason for withdrawal will be 
documented and no further assessments will be obtained.  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
477.3. Overall Study Duration and Follow -Up (Part B)
The total duration of study  participation for each subject who completes Part B of the stud y will 
be approximately  32 weeks (a 4- week Screening Period, a 16 -week double -blind Treatment 
Period, and a 12 -week Follow -up Period).  Details on the timing of assessments during the stud y 
are presented in Table 2.  
7.3.1. Screening
Subject eligibility  for the study  will be determined within 4 weeks prior to randomization.  
Laboratory  assessments for eligibility  may  be repeated once if the results are out of eligibility  
range but considered not clinically  significant b y the Investigator.
For subjects without a historical biopsy -proven diagnosis of CLE, eligibility  will be confirmed 
during Screening b y a skin biopsy  that can be read at a local laboratory (if a pathologist is 
present) or at a central laboratory .  Subjects with a documented historical biopsy  do not need a 
Screening biops y for diagnosis. 
See Section 9for details on screening and registration of subjects.
7.3.2. Treatment
Subject eligibility will be reconfirmed prior to randomization on Day  1.  Eligible subjects will 
receive study  treatment on Day  1 and return to the study  site for additional dosing every  4 weeks 
through Week 12, with an additional dose at Week 2.  Following each administration of study  
treatment, subjects should remain at the stud y center for 1 hour to be monitored for the 
development of potential allergic or anaph ylactic reactions.  Subjects will receive stud y 
treatment at baseline (Day 1), Week 2 (Day  15),  Week 4 (Day  29), Week 8 (Day  57), and 
Week 12 (Day  85), for a total of 5 doses.    
Subjects will undergo stu dy assessments (see Table 2) at each of the dosing visits and will also 
undergo assessments at  Week 1 (Day  8) and Week 16 (Day 113), though study  treatment is not 
administered at these visits.  The last dose of study treatment will be administered at Wee k 12 
(Day  85).
7.3.3. Follow -Up
Subjects are to return to the study  site for follow -up visits on Week FU4 (Day  141), Week FU8 
(Day  169), and Week FU12 (Day  197) after the last Treatment Period visit (Week 16 or ET 
Visit).  The final study  visit will be Week FU12.   
Subjects who prematurely discontinue study treatment during the Double -blind Treatment 
Period should complete all study  assessments for the Week 16/ET Visit as soon as possible, but 
within 4 weeks.  Subjects who discontinue study  treatment should also c omplete the study  
assessments for the Safety  FU Visits at Week FU4, Week FU8, and Week FU12 after their ET 
Visit. 
Subjects who are prematurely  withdrawn from the study during the Double -blind Treatment 
Period should complete all study  assessments for the 
Week 16/ET Visit as soon as possible, but 
within [ADDRESS_559331] is unwilling o r unable to attend the study  FU Visits, or at minimum the 
ET Visit, and decides to withdraw consent, the reason for withdrawal will be documented and no 
further assessments will be obtained.
7.4. Study Stoppi[INVESTIGATOR_441070], ethics committees and any  applicable regulatory  agencies when 
the study  is to be placed on hold, completed, or terminated.  
Conditions that may  warrant termination of the study include, but are not limited to the 
following: 
The discovery  of an unexpected, serious, or unacceptable risk to the subjects enrolled 
in the study
A decision on the part of Biogen to suspend or discontinue testing, evaluation, or 
development of the product
7.5. End of Study
The end of stud y is last subj ect’s last visit.
Protocol 230LE201 Version 5.[ADDRESS_559332] S
8.1. Inclusion Criteria 
8.1.1. Inclusion Criteria (Parts A and B) 
To be eligible to participate in this study , candidates must meet the following eligibility  criteria 
at Screening or at the time point specified in the individu al eligibility  criterion listed:  
1.Ability  of the subject to understand the purpose and risks of the study  and provide signed 
and dated informed consent and authorization to use confidential health information in 
accordance with national and local subject privacy regulations.  
2.Age [ADDRESS_559333] dose of study treatment.  For further 
details of contraceptive requirements for this study , please refer to Section 15.5.
8.1.2.
Inclusion Criteria (Part A Specific) 
1. Diagnosis of SLE fulfilling at least 4 out of 11 of the 1997 revised ACR classification 
criteria for SLE ( Appendix C), wit h a diagnosis made ≥24 weeks prior to signing the 
informed consent form (ICF).
2.Positive antinuclear antibody  test at Screening (central laboratory  titer ≥1:80) and/or 
elevated anti- double -stranded DNA ( ≥30 IU/mL).
3. At least one sign of active skin disease, including acute, subacute, and/or chronic 
cutaneous lupus (e.g., discoid lupus ery thematosus), with skin activity defined by  
[CONTACT_257441] -2K.   
4. Must have at least [ADDRESS_559334] joints.  Note:  A joint 
that is both tender and swollen will be included in bot
h categories (counts as 1 tender and 
1 swollen). 
6.To allow for accurate assessment of joint tenderness and swelling, subjects who may be 
taking NSAIDs or other analgesics, including narcotics or medical marijuana, must agree 
not to take a dose of these med ications within 24 hours prior to the joint assessment 
visits.
8.1.3. Inclusion Criteria (Part B Specific)  
1.Must have diagnosis of CLE that has been histologically  confirmed (in the past or at 
Screening), with or without systemic LE manifestations.  The histolog ical diagnosis 
confirmation should be documented at Screening. For subjects without historical biopsy  
Protocol 230LE201 Version 5.[ADDRESS_559335] active skin manifestations that fulfill the 
following:  
Subacute CL E with a CLASI -A ery thema score of ≥2
and/or
Chronic CL E, including DL E, with at least 1 active DLE lesion with a minimum 
CLASI-A ery thema score ≥2 and in addition, CLASI -D scarring score ≥1
2.CLASI-A ≥[ADDRESS_559336] active CLE despi[INVESTIGATOR_441071] (defined as 
either topi[INVESTIGATOR_441072] 12 weeks prior to 
Screening) OR previously documented failure to respond to t hese agents when used for at 
least 12 weeks OR the requirement to discontinue these agents due to side effects or poor 
tolerability .
8.2. Exclusion Criteria 
8.2.1. Exclusion Criteria (Parts A and B) 
Candidates will be excluded from stud y entr y if any of the followin g exclusion criteria exist at 
Screening, or at the timepoint specified in the individual criterion listed:
1. Current enrollment or a plan to enroll in any  interventional clinical study  in which an 
investigational treatment or approved therap y for investigati onal use is administered.  A 
washout period of at least 12 weeks or 5 half- lives (whichever is longer) is required prior 
to randomization.  Participation in observational registries is allowed.
2.For subjects who previously  received an investigational or approved treatment that blocks 
IFN-α, a washout  period of [ADDRESS_559337] result at Screening for human immunodeficiency  virus.  
7.Current active hepatitis C virus (HCV) infection, determined as HCV RNA above the 
limit of detection, in subjects with positive HCV antibody  titer.
8.Positive test result at Screening for hepatitis B virus (HBV; defined as positive for either 
hepatitis B surface antigen or hepatitis B core antibody ).
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
519. Active lupus nephritis or moderate- to-severe or chronic kidney  disease (urine protein to 
creatinine ratio >2.0 or estimated glomerular filtration rate <30 mL/min/1.73 m2 
calculated using the abbreviated Modification of Diet in Renal Disease equation) 
[Stevens 2007].
10.Subjects with a history  of suicide attempt or suicidal ideation within 1 y ear prior to 
Screening.
11.Active neurops ychiatric SL E including but not limited to the following: seizure, new or 
worsening impaired level of consciousness, ps ychosis, deli rium or confused state, aseptic 
meningitis, ascending or transverse m yelitis, chorea, cerebellar ataxia, mononeuritis 
multiplex, or demy elinating s yndromes.
12.Any active skin conditions other than CL E that may  interfere with skin assessments (e.g., 
psoriasis , non- LE skin lesions, non -LE alopecia areata, drug- induced lupus).  
13.History  of severe herpes infection, such as herpes encephalitis, ophthalmic herpes, or 
disseminated herpes.
14.History  of chronic, recurrent (3 or more of the same ty pe of infection in a 52 -week 
period), or recent serious infection (e.g., pneumonia, septicemia, herpes zoster) as 
determined b y the Investigator and requiring anti -infective treatment within 12 weeks 
prior to Screening.
15. Signs of herpes or varicella zoster viral infection (specif ically chicken pox, shingles, or 
herpes zoster) within 12 weeks prior to Screening.
16.History  of or current diagnosis of active tuberculosis (TB), or untreated latent TB 
infection (LTBI), determined by a TB skin test with purified protein derivative as 
evide nced b y induration ≥5 mm or a positive Quantiferon, positive or borderline T -SPOT 
(Elispot) test performed locally , either at Screening or documented with results within [ADDRESS_559338] 
received complete LTBI treatment prior to Screening without evidence of re -exposure 
prior to entering the study .
Subject with current household contacts with active TB will also be excluded unless 
the subject is being treated and there is evidence that household contacts are being 
treated.
Indeterminate Quantiferon or T -SPOT tests may  be repeated once, and will be 
considered positive if retest results are positive or indeterm inate. Subjects with 
documented BCG vaccination must perform a TB test at Screening and will be 
excluded if skin induration ≥5 mm or a positive Quantiferon or positive or borderline 
T-SPOT (Elispot) test. 
17.Presence of [LOCATION_001] Heart Association class III or IV congestive heart failure.
18.Known hy persensitivity  to BIIB059 or any  of the components of the formulated BIIB059 
or matching placebo.  
Protocol 230LE201 Version 5.[ADDRESS_559339] been completely  excised and considered 
cured >2 years prior to Screening. 
20.History  of any  clinicall y significant cardiac, endocrinologic, hematologic, hepatic, 
immunologic, metabolic, urologic, pulmonary , neurologic, dermatologic, psy chiatric and 
renal, or other major disease, as determined b y the Investigator.  Specifically , a diagnosis 
of an y other s ystemic autoimmune disease other than secondary  Sjögren’s sy ndrome, 
such as rheumatoid arthritis, psoriatic arthritis, dermatopoly miositis, sy stemic sclerosis 
(scleroderma), etc, which may  confound the evaluation of the effect of investigational 
product. 
21.History  of substance abuse (except for cannabinoid) within 24 weeks prior to Screening, 
based on the Investigator’s opi[INVESTIGATOR_1649].
22.Female subjects who are pregnant, currentl y lactating, have stopped lactating in the past 
[ADDRESS_559340] dose of study  treatment.
Previous Therapi[INVESTIGATOR_014]
23.Use of IV or intramuscular (IM), or intra -articular (Part A only ) corticosteroids within 12 
weeks prior to randomization.
24.Use of high- potency  topi[INVESTIGATOR_441073]/or topi[INVESTIGATOR_12450] (immunosuppressant) for 
skin lesions within 7 days prior to randomization.
25.Use of high- potency  intralesional corticosteroid within 4 weeks prior to randomization.  
26.Part A subjects who are receiving s ystemic corticosteroid treatment at a dose exceeding 
20mg/day  prednisone (or its equivalent), or if an y dose of prednisone (or its equivalent) 
has not been stable for ≥4 weeks prior to randomization.  
27.Part B subjects who are r eceiving s ystemic corticosteroid treatment at a dose exceeding 
15mg/day  of prednisone (or its equivalent), or if any dose of prednisone (or its 
equivalent) has not been stable for ≥4 weeks prior to randomization.  
28.Use of thalidomide or lenalidomide, I V or SC immunoglobulin, or plasmapheresis within 
12 weeks of randomization.  
29.Use of tacrolimus, pi[INVESTIGATOR_031], or sirolimus within 4 weeks prior to randomization.
30. Use of oral or parenteral rituximab, ocrelizumab, or other B cell-directed biologic 
therapi[INVESTIGATOR_441074] 24 weeks prior to randomization.  Subjects with prior B cell-directed 
therapi[INVESTIGATOR_6523] 52 weeks of Screening will be excluded if total CD19 B cell level is <25 
cells/µL  as measured at Screening at the central laboratory .  
31.Use of cy clophosphamide, cy closporine, mixoribine, atacicept, abatacept, belimumab, 
tocilizumab, or tumor necrosis factor (TNF) inhibitors within 12 weeks or 5 half -lives 
(whichever is longer) prior to randomization. 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5332.Use of immunosuppressive or disease -modify ing treatments for SLE or CLE (via an oral, 
IV, or SC route) that were initiated less than [ADDRESS_559341] 12 weeks at doses above the prescribed maximu m listed here (medication 
list includes, but is not limited to the following):  antimalarial medications 
(hydroxy chloroquine up to 400 mg/day , quinacrine 100 mg/day  maximum, chloroquine 
250 mg/day ), dapsone 150 mg/day , methotrexate 25 mg/week, azathioprine 200 mg/day , 
6-mercaptopurine 100 mg/day, and mycophenolate mofetil (MMF) 3 g/day or 
mycophenolate sodium (MPS) 2160 mg/day . 
33.Immunizations with live or live -attenuated vaccines within [ADDRESS_559342] dose of study  treatment.
Laboratory  abnormalities
34. Aspartate aminotransferase or alanine aminotransferase >2.0 times the upper limit of 
normal at Screening.  
35.Hemoglobin <5.5 mmol/L [9 g/dL], neutrophils <1.5 x 103/µL, platelets <75 x 109/L at 
Screening.
36.Any abnormal laboratory test result at Screening that is considered clinically  significant 
and unrelated to the underly ing disease (SLE/CL E), as determined b y the Investigator, 
and would preclude the subject from participating in the study .  Clinical laboratory  tests 
may be repeated one time, at the discretion of the Investigator, if there are questionable 
results, or if abnormalities are felt to be due to inherent variability  of the test procedure.  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
549. ENROLLMENT, REGISTRA TION, AND RANDOMIZAT ION
9.1. Screening and Registration
Subjects (or their legall y authorized representative [e.g., parent or legal guardian], where 
applicable) must provide informed consent before any screening tests are performed (see 
Section 17.3).  When a subject signs the ICF, tha t subject is considered to be enrolled in the 
study .  Participating study  sites are required to document all screened candidates initially  
considered for inclusion in this study .  If a subject is excluded from the study , the reasons for 
exclusion will be d ocumented in the subject’s source documents and on the screening log.
For subjects entering Part A, screening tender and swollen joint counts will be performed b y an 
independent joint assessor at each site prior to study entry .    
For subjects entering Pa rt B, screening CLASI scores will be verified by  [CONTACT_441120] (Section 19.2.2 ) prior to study  entry
.  
Subjects will be registered at the Screening Visit; as part of stud y screening, potential subjects 
will have the study  risks and bene fits explained to them, the associated ICF reviewed with them, 
and all their questions answered.
If a subject initially  fails any  of the screening criteria and is deemed as a screen failure by  [CONTACT_441121] [ADDRESS_559343] infection, histological 
confirmation of CLE diagnosis (Part B) and receipt of the approval from the Medical Monitor.  
Randomization will be stratified by [CONTACT_441122] (Section 7.1).
No subject may  begin treatment prior to assignment of a unique identification number 
(registration) and randomization through the interactive response technology  (IRT) sy stem. An y 
subject identification numbers or r andomization schedule assignments that have been assigned 
will not be reused even if the subject does not receive treatment.  Rescreened subjects will be 
assigned a new number.
Subjects who withdraw from the study  after randomization may  not be replaced.
Refer to the Study  Reference Guide for details on registration and randomization.
9.3. Blinding Procedures
This is a randomized, double -blind, placebo -controlled study .
Protocol 230LE201 Version 5.[ADDRESS_559344] (or designee) and the unblinded Pharmacy  Mo
nitor.  
 
  Efforts will be made to ensure that no members of the team involved in study  conduct 
will be unblinded.  Unblinding is permitted onl y in the case of a medical emergency  or serious 
medical condition, when knowledge of the stud y treatment is essential for the immediate clinical 
management or welfare of the study  subject, as judged by  [CONTACT_737].  
Refer to the Study  Reference Guide for details about unblinding.
There will be two IAs in the study . 
For IA [ADDRESS_559345] with study  sites until after the final database lock.
All Investigators, study  site personnel, and subjects will remain blinded to treatment assignments 
until after the final database lock.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5610. DISCONTINUATION OF S TUDY TREATMENT AND/O R 
WITHDRAWAL OF SUBJEC TS FROM THE STUDY
10.1. Discontinuation of Study Treatment
A subject must permanently  discontinue study  treatment for an y of the following reasons:
The subject becomes pregnant.  Stud y treatment must be discontinued immediately.  
Report the pregnancy  according to the instructions in Section 15.4.1.
The subject withdraws consent to continue study
 treatment.  
The subject exp eriences a medical emergency  that necessitates permanent 
discontinuation of study  treatment.
The subject experiences a medical emergency  that necessitates unblinding of the 
subject’s treatment assignment.
The subject is unwilling or unable to compl y with t he protocol.
At the discretion of the Investigator for medical reasons.
The reason for discontinuation of study  treatment must be recorded in the subject’s electronic 
case report form (eCRF).   
Subjects who prematurely discontinue study treatment during t he Double -blind Treatment 
Period should complete all study  assessments for the ET Visit as soon as possible, but within [ADDRESS_559346] be withdrawn from the stud y for any one of the following reasons:
The subject withdraws consent.
The subject enrolls into another interventional clinical study  in which an 
investigational treatment or approved therap y for investigational use is administered.
The subject is unwilling or unable to compl y with the protocol.
Subjects who are prematurely  withdrawn from the study during the Double -blind Treatment 
Period should complete all study  assessments for the ET Visit as soon as possible, but within [ADDRESS_559347]’s withdrawal from the study  must be recorded in the subject’s eCRF. 
The level of consent withdrawal (e.g., whether samples collected but not yet anal yzed can still be 
used/anal yzed, and so on) should also be recorded in the eCRF.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5711. STUDY TREATMENT USE
11.1. Study Treatment Regimen
11.1.1. Part A
Subjects will be randomized in a 1:1 ratio to 1 of the following 2 treatment groups:
BIIB059 450 mg 
Placebo 
Dose regimen:  every  4 weeks (Q4W) SC, with an additional dose at Week 2, for a total of 7 
doses.  
11.1.2. Part B 
Subjects will be randomized in a 1:1:1:1 ratio to 1 of the following 4 treatment groups:
BIIB059 50 mg
BIIB059 150 mg  
BIIB059 450 mg 
Placebo 
Dose regimen:  every  4 weeks SC 
(Q4W) , with an additional dose at Week 2, for a total of 5 
doses.
11.1.3. BIIB059
Biogen will provide BIIB059 to sites.
11.1.4. Placebo
Placebo (0.9% sodium chloride) will be commercially  available saline supplied by  [CONTACT_441123].
11.2. Study Treatment Precautions
Following administration of study  treatment, subjects should remain at the study  center for 
1hour to monitor for the development of potential allergic or anaphy lactic reactions.  
Epi[INVESTIGATOR_441075], diphenhy dramine (or equivalent) for IV injection, and any  other 
medications and resuscitation equipment for the emergency  management of anaph ylactic 
reactions must be available in the room where the infusion is being performed.
BIIB059 or placebo should be administered within the stated window of the scheduled visit (±2 
or 3 day s; see Table 1andTable 2).  If a subject misses a planned dose (i.e., outside of the 2- or 
3-day window), the missed dose should be administered as soon as possible, and no later than 
5days after the last day  of the planned window.  If the Week 2 dose (the second dose to be 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
58administered in the study) can't be g iven within the planned window, the missed dose should be 
skipped and the subject should receive the next scheduled dose as per protocol.
11.3. Study Treatment Compliance
Compliance with treatment dosing is to be monitored and recorded b y site staff.
11.4. Concomitant Therapy and Procedures
11.4.1. Concomitant Therapy
A concomitant therap y is any drug or substance administered between Screening and the final 
study  visit.
[IP_ADDRESS]. Allowed Concomitant Therapy
All permitted therapi[INVESTIGATOR_014], unless indicated otherwise, should be taken at a stable dose starting from 
the Screening Visit until the end of the Treatment Period.  A stable dose is defined as no increase 
or decrease during a specified time period.  Dose decrease is allowed where specified by  
[CONTACT_990].
Any medications, other than tho se excluded per Section 8.2, that are considered necessary  for the 
subject’s welfare and that do not interfere with the trial conduct or assessments, may  be given at 
the Investigator’s discretion and should be recorded in the eCRF dedicated page.
[IP_ADDRESS].1. Backgroun d Therapi[INVESTIGATOR_441076] 
[IP_ADDRESS].1.1. Systemic Lupus Erythematosus 
Standard of care therap y that may  be continued during the study  for SL E includes 1 of the 
following single immunosuppressants or immunomodulators, delivered via IV, SC, or oral 
administration: azathiopri ne (up to 200 mg/day ), 6-mercaptopurine (up to 100 mg/day ), 
mycophenolate (either as MMF at up to 3 g/day  or MPS up to 2160 mg/day), and methotrexate 
(up to 25 mg/week).  Other permitted SoC therapi[INVESTIGATOR_441077] 
(hydroxy chloro
quine (up to 400 mg/day ), quinacrine (100 mg/day), chloroquine (up to 250 
mg/day ), and dapsone (up to 150 mg/day )as well as corticosteroids (see Section [IP_ADDRESS].2) and 
NSAIDs (see Section [IP_ADDRESS].3.1 ).
All background therap y for SL E given prior to Scre ening or randomization must have been kept 
stable or discontinued as specified in the inclusion/exclusion criteria for a subject to be eligible 
for the stud y.  These medications must remain stable during Screening or randomization as well 
as the 24-week (P art A) or 16-week (Part B) Treatment Period, with the exception of the 2 
corticosteroid rescue attempts allowed during corticosteroid tapering in Part A of the study  
(Section [IP_ADDRESS].2 ).  No initiation of new immunosuppressant therapy  or increase in dose of 
current immunosuppressant is allowed.  Subjects who initiate SL E SoC therap y during the stud y 
will be considered treatment failures.  They  are encourage to continue receiving study  treatment 
and complete the stud y at the I nvestigator’s discretion.
Standard of care medications that are part of the subject’s previous SLE treatment will not be 
provided b y Biogen.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
5911.[IP_ADDRESS].2. Cutaneous Lupus Erythematosus 
All background therap y for CL E given prior to Screening must have been kept stable or 
discontinued as specified in the inclusion/exclusion criteria ( Section 8) for a subject to be 
eligible for the study.  These medications must remain stable during the Screening Period as well 
as the Treatment Period.
[IP_ADDRESS].2. Corticosteroid Usage During the Study 
In Part A, corticosteroid u se at doses above 20 mg/day  of prednisone or prednisone equivalent is 
not allowed (with the exception of Rescue 1 during corticosteroid tapering; see Table 7).  In 
PartB, corticosteroid use at doses above 15 mg/day of prednisone or prednisone equivalent i s not 
allowed.  Doses stated are for a total daily  dose of prednisone or prednisolone; other 
corticosteroids may  be used instead at the equivalent doses listed.  See Table 5for prednisone 
equivalence values of commonly  used corticosteroids. 
Systemic (IM or IV) or intra -articular (Part A) administration of corticosteroids is not allowed 
for the duration of the study ; a washout period of [ADDRESS_559348] be observed prior to 
randomization.
Nonsy stemic corticosteroids (defined as otic, intranasal, inhaled, or o phthalmic) are permitted 
without restriction.  See Section [IP_ADDRESS].2.1 for guidance on the use of topi[INVESTIGATOR_8826].  
Table 5: Prednisone Equivalence Values for Common Alternatives
Medication Equivalent (mg) to 1 mg 
of Prednisone
Betamethasone 0.15
Cortisone 5
Dexamethasone 0.15
Hydrocortisone 4
Prednisolone 1
Methylprednisolone 0.8
Triamcinolone 0.8
[IP_ADDRESS].2.1. Topi[INVESTIGATOR_441078].  The use 
of low or lower mid -potency  topi[INVESTIGATOR_441079] .  Table 6provides 
guidance for topi[INVESTIGATOR_121464].  Subjects are requested to avoid use of topi[INVESTIGATOR_441080] y, and for 24 hours prior to 
the primary  endpoint CLASI  assessment at the Week 16 Visit.
High -potency  steroids and/or topi[INVESTIGATOR_12450] (immunosuppressant) for skin les ions, including 
intralesional corticosteroids, are prohibited.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
60Table 6: Topi[INVESTIGATOR_441081] -Potency or Lower Mid -Potency Topi[INVESTIGATOR_441082]-Potency
Hydrocortisone acetate 0.1 to 0.25% 
Desonide 0.05% cream
Methylprednisolone 0.25% 
Fluocinolone acetonide 0.01%Lower Mid- Potency
Fluocinolone acetonide 0.025%  cream
Triamcinolone acetonide 0.1%
Fluticasone propi[INVESTIGATOR_16847] 0.05% cream
Hydrocortisone butyrate 0.1% cream
Betam ethasone valerate 0.05% 
Clobetasone butyrate 0.05%.
For a list of commonl y used topi[INVESTIGATOR_441083] y, see 
Appendix B. The Investigator is invited to contact [CONTACT_1034]’s Medical Monitor with 
questions about topi[INVESTIGATOR_441084] .
[IP_ADDRESS].2.2. Part A Specific Instructions
Intra-articular Corticosteroids 
Intra -articular administration of corticosteroids is not a llowed for the duration of the study ;  a 
washout period of [ADDRESS_559349] active SLE with joint and skin manifestations at Screening and 
randomization.  Subjects may  be tre ated with SL E background SoC therapi[INVESTIGATOR_441085] #[ADDRESS_559350] dose of study treatment (i.e., until Day 28).  The tapering schedule should begin 4 weeks 
(Week 5; Day s 29 to 35) after the first dose of study  treatment. The tapering regimen is intended 
to reduce the daily  dose of prednisone (or equivalent) to 10 mg/day  or lower by  [CONTACT_10585] 12 (Day  
85) of the stud y, as outlined in Table 7.
If a subject deviates from the planned taper ing schedule, they  might be considered a treatment 
failure ( see Section [IP_ADDRESS] )
.  Subjects are allowed to continue to receive the investigational 
product and to complete the study  at the discretion of the Investigator.  
Subjects who achieve the Week 12 dose of 10 mg of prednisone (or equivalent) or lower may  
remain on this dose or continue to taper between Week 13 and Week 16 at the discretion of the 
Investigator.  The dose of prednisone (or equivalent) will remain stable (at the Week 16 dose) 
between We ek 17 and Week 24.
Screening: 
Subjects who are receiving corticosteroids must receive a stable dose throughout the Screening 
period; no initiation, increase, or decrease of corticosteroid dose is permitted.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
61The maximum daily  dose of corticosteroid allowed is 20 mg of prednisone (or equivalent).
Treatment period:
Oral corticosteroid dose tapering (as described in Table 7) is mandatory  within the rules for dose 
changes outlined below. 
Briefl y, oral corticosteroids dosing guidelines are as follow: 
Stable corticosteroid dose from Day  1 to Week 4 (Day  1 to Day  28) 
Decrease in corticosteroid dose from baseline between Week 5 and Week 11 
(Day s29 to 78)
Stable corticosteroid dose at Week 12 (Day s 79 to 85)
Stable Week 12 corticosteroid dose, or decrease by  2.5 mg between Week 13 and 
Week 16 (Day  86 to 113) 
Stable corticosteroid dose (at Week 12 dose) between Week 17 and Week 24 (Day s 
114 to 169)
Between Day  1 to Week 4, the corticosteroid dose can be increased to a maximum of 10 mg/day  
above Day  [ADDRESS_559351] return to Day 1 level within 7 day s (Rescue 1).  Between Week 5 
and Week 7 (Rescue 2), ORbetween Week 9 and Week 11 (Rescue 3), the corticosteroid dose 
can be increased to the previous dosage level for up to 1 week before resuming the tapering 
schedule.  Onl y two rescues out of the three described above are allowed, at the discretion of the 
Investigator.
Overall, TWO corticosteroid res cues are allowed:  
Rescue 1 and Rescue 2; OR
Rescue 1 and Rescue 3; OR 
Rescue 2 and Rescue 3.
Any other increase in corticosteroid dose may  be considered a treatment failure and/or a protocol 
deviation (depending on the timing or severity  of the deviati on) for the analy sis (see Section 
[IP_ADDRESS] ).  Subjects who cannot fulfill the corticosteroid tapering schedule should still complete 
the study  and remain on the investigational product.  Corticosteroid dose should be recorded in 
the subject diary  (Section [IP_ADDRESS].2.4).
Day 1 to Week 4:
Stable dosage at Day  1 dose level, 1 oral corticosteroid rescue (Rescue 1) for SL E activity  is 
allowed up to a dose no higher than 10 mg above the baseline level (maximum of 30 mg/day ), 
but the dose must return to baseline (Day 1) level within 7 day s. A dose increase is strongl y 
recommended to be avoided within 1 week of a planned stud y visit.
Week 5 to Week 7:
Decrease as per the tapering schedule .  One oral corticosteroid rescue (Rescue 2) for SLE 
activity  is allowed up to a dose no higher than the previous dosage level, but the dose must be 
Protocol 230LE201 Version 5.[ADDRESS_559352] oral corticosteroid dosage prior to rescue level within 7 day s.  A dose increase 
is not permitted within 1 week of a planned stud y visit.
Week 8:
Decrease as per tapering schedule.  No increases are allowed.
Week 9 to Week 11:
Decrease as per tapering schedule. One oral corticosteroid rescue (Rescue 3) for SLE activit y is 
allowed up to a dose no higher than the previous dosage level, but the dose must be returned t o 
last oral corticosteroid dosage prior to rescue level within 7 day s.  A dose increase is not 
permitted within 1 week of a planned stud y visit.
Week 12:
No increase or decrease allowed.
Week 13 to Week 16:
Stable dosage or decrease as per the tapering schedule (no increase is allowed).  The 
corticosteroid dose must alway s be ≤Week 12 dose.
Week 17 to Week 24:
Stable dosage at Week 16 dosage, no increases or decreases are allowed.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONF IDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
63Table 7: Oral Corticosteroid Tapering Schedule 
Allowable 
OCS Rescue 
Dosing1Timing 
by [CONTACT_41585] 
(Days)OCS Starting Dose Prior to Tapering (m g/day)
20 m g 17.5 m g 15mg 12.5 mg 10 m g 7.5 m g 5 mg 2.5 to <5 m g
Rescue 1 Week 1-42  
(Day 1 to 
28)Stable
1 OCS rescue for SLE activity allowed up to maximum 10 mg/day above Day [ADDRESS_559353] return to Day 1 level within 7 days
Rescue 2 Week 53
(Day 29 to 
35)17.5 15 12.5 10 7.5 5 5 or 2.5 2.5 to <5
Week 63
(Day 36 to 
43)17.5 15 12.5 10 7.5 5 5 or 2.5 2.5 to <5
Week 73
(Day 44 to 
50)15 12.5 12.5 10 7.5 5 5 or 2.5 2.5
Week 8
(Days 51 to 
57)15 12.5 10 7.5 7.5 5 5 or 2.5 2.5
Rescue 3 Week 93
(Days 58 to 
64)12.5 10 10 7.5 5 2.5 2.5 0 to 2.5
Week 103
(Days 65 to 
71)12.5 10 10 7.5 5 2.5 2.5 0 to 2.5
Week 113
(Days 72 to 
78)10 7.5 7.5 52.5 to 
<52.5 2.5 0 to 2.5
Week 12
(Days 79 to 
85)10 7.5 7.5 52.5 to 
<52.5 2.5 0 to 2.5
Week 13 -
16
(Days 86 to 
113)Stable at Week 12 dose or decrease
Week 17 -
24
(Days 114 
to 169)Stable at Week 16 dose
Abbreviations:  OCS = oral corticosteroids; SLE = systemic lupus erythematosus.
1 Two rescues are allowed out of the three described. 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
642Between Weeks 1 and 4 (Rescue 1).  Once a dose is reduced  it must not be re-increased, with the exception of the 1 time 
rescue.
3 Between Weeks 5 and 7 (Rescue 2) and between Weeks 9 and 11 (Rescue 3), the dose can be increased to the previous dose 
level for up to 1 week before restarting the tapering schedule.
[IP_ADDRESS].2.3. Part B Specific Instructions
Oral Corticosteroid
No corticosteroid tapering schedule is planned for subjects in Part B.  The dose of corticosteroids 
given at Screening should not exceed 15 mg/day  and should remain stable (no increase 
throughout the Screening, Treatment, and Follow- up Periods) .  
An incr ease of corticosteroid dose will be considered a treatment failure (see Section [IP_ADDRESS]).  
Subjects are allowed to remain in study
 and receive the investigational product.   
[IP_ADDRESS].2.4. Subject Diaries
Subjects will be issued a paper diary  to record daily  corticoste roid use (topi[INVESTIGATOR_160788]) between 
study  visits.  Subjects will be instructed to bring the diary  to the clinic at each visit, where it will 
be collected and reviewed by  [CONTACT_8786].  
[IP_ADDRESS].3. Pain Medication
[IP_ADDRESS].3.1. Nonsteroidal Anti -inflammatory Treatments
Subjects taking stable doses of NSAIDs (e.g., ibuprofen, naproxen, aspi[INVESTIGATOR_248]) for SLE s ymptoms at 
Screening should continue to do so throughout the trial; however, subjects should refrain from 
using NSAIDs within 24 hours before each stud y visit.  Subjects taking sta ble doses of NSAIDs 
for reasons other than SLE are encouraged to titrate down as tolerated.
Low-dose aspi[INVESTIGATOR_248] (<350 mg/day ) at stable doses for cardiovascular prophylaxis is permitted 
during the stud y.  
[IP_ADDRESS].3.2. Acetaminophen
Acetaminophen (paracetamol) may  be init iated for pain control of SLE s ymptoms during the 
study .  The medication should be titrated down as tolerated. The maximum dose of 
acetaminophen or pain medications that contain acetaminophen is 3 g/day .
[IP_ADDRESS].3.3. Other Pain Medications
Other pain medications, inclu ding opi[INVESTIGATOR_858], other narcotics, and medical marijuana, may  be used 
to treat sy mptoms of arthritis and other extra -articular conditions in SL E as needed; however, 
these medications may  not be used within 24 hours of a study  visit if they  are used as needed. If 
opi[INVESTIGATOR_441086], a stable dose should be maintained from 
Screening until the end of the Treatment Period.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6511.[IP_ADDRESS]. Vitamin D and Calcium Supplements 
Use of vitamin D 3(≥400 IU/day ) and calcium supplements (≥800 mg/day ) is recom mended for 
prevention of glucocorticoid -or postmenopausal -induced bone loss.  Subjects should continue 
these medications per SoC with no change in dose during the stud y.  
[IP_ADDRESS].5. Vaccines
Live and live -attenuated vaccines are not permitted within [ADDRESS_559354] dose of study treatment.
[IP_ADDRESS]. Disallowed Concomitant Therapy
Table 8provides a list of medications prohibited during stud y participation (and during the 
prescribed washout period prior to rand omization).  
Table 8: Disallowed Concomitant Therapy and Required Washout Periods Prior to 
Randomization
Generic Name [CONTACT_441159] (monoclonal antibodies and and fusion proteins) 
Rituximab, ocrelizumab, other B -cell directed 
therapi[INVESTIGATOR_014]124 weeks
Abatacept, belimumab, tocilizumab, TNF inhibitors 12 weeks or 5 half -lives (whichever is longer)
Immunosuppressants
Tacrolimus, pi[INVESTIGATOR_031], sirolimus 4 weeks
High -potency topi[INVESTIGATOR_441073]/or topi[INVESTIGATOR_113899] (immunosuppressive) for skin lesions7 days 
High -potency intralesional corticosteroids 4 weeks
IV or IM corticosteroids (Parts A and B) 12 weeks
Intra -articular corticosteroids (Part A) 12 weeks
Cyclophosphamide, cyclosporine, mixoribine 12 weeks or 5 half -lives (whichever is longer)
Other
IV and SC immunoglobulin 12 weeks
Plasmapheresis 12 weeks 
Thalidomide or lenalinomide 12 weeks
Investigational or approved agent that blocks IFN -α24 weeks 
Any investigational therapy, including BIIB059, 
and any not mentioned above24 weeks
IFN = interferon; IM=intramuscular; IV = intravenous; SC=subcutaneous; TNF = tumor necrosis factor
1Subjects with history of B -cell directed therapi[INVESTIGATOR_25365] 24 w eeks but less than 52 w eeks prior to Screening will 
be excluded if the total CD19 B -cell level is <25 cells/μL as measured at Screening.
Protocol 230LE201 Version 5.[ADDRESS_559355] occurred at the administration site (e.g., 
injection -site reactions) of study  treatment are allowed.  These may  include topi[INVESTIGATOR_441087], acetaminophen, NSAIDs, or low -potenc y topi[INVESTIGATOR_11930].  An y 
medications used should be recorded in the eCRF.  
Treatment for severe SLE flares leading to the use of rescue medication per SoC will be 
considered as a protocol deviation for the anal ysis.  Subjects are allowed to stay  inthe study  and 
remain on the investigational product.  An y medications used should be recorded in the eCRF.
See Section [IP_ADDRESS] for medications permitted during the Treatment Period.
See Section [IP_ADDRESS].2 for detailed guidance on oral corticosteroid use.
See Section [IP_ADDRESS] for detailed guidance on the use of oral corticosteroid as rescue medication 
for SL E disease activity  (Part A only ).
[IP_ADDRESS]. Rescue Medication Usage Guidelines During the Safety Follow -Up Period
Subjects will be treated according to local So C during the Follow- up Period.  The initiation of 
immunosuppressants, immunomodulators, and/or biologics should be avoided during the 
Follow -up Period (approximately  5 half -lives of study  treatment) at the discretion of the 
Investigator.  An y medications u sed should be recorded in the eCRF.
11.4.2. Concomitant Procedures
A concomitant procedure is any  therapeutic intervention (e.g., surgery /biopsy , phy sical therap y) 
or diagnostic assessment (e.g., blood gas measurement, bacterial cultures) performed between 
the tim e the subject is enrolled in the study  and the last Follow -up Visit.  
The following nondrug therapy is not permitted during the stud y (from the initial Screening Visit 
until the last Follow -up Visit, unless the subject has been previously  stabilized on th e therapy):
Allergen desensitization
The following nondrug procedures are not permitted during the study  (from initial Screening 
Visit until the last Follow -up Visit):
Major medical procedures (e.g., invasive diagnostic procedures, such as arthroscopy )
Surgical procedures and acupuncture
The use of concomitant treatment or procedures defined above must be recorded on the subjects’ 
eCRF according to the instructions for eCRF completion. AEs related to the administration of 
these therapi[INVESTIGATOR_71293]. 
11.5. Continuation of Treatment 
No further provisions are made for access to the study  treatment.  If BIIB059 is proven to be 
beneficial, all regulatory  requirements regarding post -study  access will be met.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6712. STUDY TREAT MENT MANAGEMENT
Study  site staff should follow the Directions for Handling and Administration (DHA) for specific 
instructions on the handling, preparation, administration, and disposal of the study  treatment.  
The DHA supersedes all other references (e.g., protocol).
Study  treatment must be dispensed only  by a pharmacist or appropriatel y qualified staff.  Stud y 
treatment is to be dispensed only  to subjects enrolled in this study .  Once study  treatment is 
prepared for a subject, it can be administered onl y to that subject.  Following administration of 
study  treatment, subjects should remain at the study  center for 1 hour to observe for the 
development of potential allergic or anaph ylactic reactions.  Study  treatment is for one -time use 
only; do not use an y study treatment remaining in the vial for another subject.
12.1. BIIB059
BIIB059 is a full y humanized antibody  consisting of [ADDRESS_559356] containing 150 mg/mL BIIB059, 20 mM 
histidine, 100 mM L -arginine hy drochloride, 3% sucrose, 0.05% pol ysorbate 80 and at a pH of 
5.5.  I t is provided in 3- mL vials containing 255 mg of BIIB059 per vial.
The BIIB059 l abel includes conditions for storage, batch/lot number, and other pertinent 
information such as Sponsor, caution statement, and, when required, manufacturer.  The 
expi[INVESTIGATOR_441088] y if one is not provided on the kit.  BIIB059 shoul d not 
be used after the expi[INVESTIGATOR_320].
The contents of the BIIB059 label will be in accordance with all applicable regulatory  
requirements
12.1.1. BIIB059 Preparation
The individual preparing BIIB059 should carefully review the instructions provided in the DHA.
If the packaging is damaged or if there is an ything unusual about the appearance or attributes of 
the vials, the study  treatment should not be used.  The vial in question should be saved at the 
study  site, and the problem should be immediately reported to Biogen.
12.1.2. BIIB059 Storage
BIIB059 must be stored at 2°C to8°C (36°F to 46°F) in a secure location, preferabl y a locked 
refrigerator with limited access.  BIIB059 vials are to be protected from light and are not to be 
frozen.  If BIIB059 is frozen, Biogen sh ould be notified immediately , and the drug should not be 
used.  For the most up- to-date storage requirements, follow the instructions provided in the 
DHA.
Protocol 230LE201 Version 5.[ADDRESS_559357] be notified, 
in writing, of the details of the study  treatment destroy ed (e.g., lot numbers, quantities), the date 
of destruction, and proof of destruction.
12.1.4. BIIB059 Accountabili ty
Accountability  for study  treatment is the responsibility  of the Investigator.  The study  site must 
maintain accurate records demonstrating dates and amount of study  treatment received, to whom 
dispensed (subject -by-subject accounting), and accounts of a ny study  treatment accidentall y or 
deliberatel y destro yed or lost.  
Unless otherwise notified, all vials both used and unused, must be saved for study  treatment 
accountability .  At the end of the study , reconciliation must be made between the amount of 
BIIB059 supplied, dispensed, and subsequently destroyed or returned to Biogen.  A written 
explanation must be provided for an y discrepancies.
12.2. Placebo 
The placebo (control agent) to be used in this study  will be sterile normal saline (0.9% sodium 
chloride for SC administration).  Sterile normal saline will be supplied by  [CONTACT_441124] (based on local regulations).  The manufacturer’s directions for material storage and 
handling are to be followed, as are standard clinical practices for ensuring sterility  of the 
material.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
6913. EFFICACY ASSESSMENTS
See Section 4for the timing of all assessments.
13.1. Clinical Efficacy Assessments
The following clinical assessments will be performed to evaluate the efficacy  of BIIB059.
CLASI-A and 

BILAG -2004 (Part A only ) 
Joint counts (tender joint count and swollen joint count based on a 28 -Joint 
Assessment) [Part A only]
PGA of SLE (in Part B, only  for subjects with SLE at Screening) 
  


  

Descriptions of the efficacy  instruments are pr ovided in Appendix A.
13.2. Pharmacok inetic Assessments
Sparse PK serum samples to measure levels of BIIB059 over time will be obtained from all 
subjects at timepoints specified in the Schedule of Assessments (Table 3).  

  

  
  
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
70 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7114. SAFETY ASSESSMENTS
Refer to Section 4for the timing of all safet y assessments.
14.1. Clinical Safety Assessments
The fo llowing clinical assessments will be performed to evaluate the safety  profile of BIIB059: 
AE and SAE recording
Physical examinations, including weight and height measurements (height will be 
measured onl y on Day  1/baseline)
Vital signs (e.g., seated arter ial blood pressure, heart rate, and oral bod y temperature)
12-lead ECG
Concomitant therap y and procedure recording
14.2. Laboratory Safety Assessments
The following laboratory assessments will be performed to evaluate the safety profile of 
BIIB059:
Hematology :  Complete blood count with differential and platelet count, and absolute 
neutrophil count
Blood chemistry :  total protein, albumin, creatinine, blood urea nitrogen, uric acid, 
bilirubin (total and direct), alkaline phosphatase, alanine aminotransferase, asp artate 
aminotransferase, gamma
-glutamy l transferase, glucose, calcium, phosphorus, 
bicarbonate, chloride, sodium and potassium. Creatine phosphokinase (CPK) will also 
be assessed in subjects in Part A.
Coagulation
Direct Coombs Test
Immunoglobulins IgG, Ig M, and IgA
Immunoglobulins and vaccine -related immunoglobulin titers
Urinaly sis:  dipstick for blood, protein, and glucose (microscopic examination, if 
abnormal) 
Urine protein:  creatinine ratio (spot urine)  
14.3. BIIB059 Specific Safety Assessments
The following assessment will be performed to determine the safet y of BIIB059
Immunogenicit y (anti -BIIB059 antibodies)
Protocol 230LE201 Version 5.[ADDRESS_559358] a causal relationship 
with this treatment.  An AE can therefore be an y unfavorable and unintended sign (e.g., an 
abnormal laboratory  finding), s ymptom, or disease temporall y associated with the use of a 
medicinal (investigational) product, whether or not related to the med icinal (investigational) 
product.
Determination of whether an abnormal laboratory  value meets the definition of an AE will be 
made b y the Investigator.  Although abnormal laboratory values are t ypi[INVESTIGATOR_204883], the following considerations may  result in an abnormal laboratory  value being considered 
an AE:
A laboratory  test result that meets the criteria for an SAE
A laboratory  test result that requires the subject to receive specific corrective 
therap y
A laboratory
 abnormality that the I nvestiga tor considers to be clinicall y 
significant
15.1.2. Serious Adverse Event
An SAE is any  untoward medical occurrence that at any  dose:
Results in death
In the view of the Investigator, places the subject at immediate risk of death (a 
life-threatening event); however , this does not include an event that, had it occurred 
in a more severe form, might have caused death
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Results in a con genital anomaly /birth defect
An SAE may  also be any other medicall y important event that, in the opi[INVESTIGATOR_689], 
may jeopardize the subject or may  require intervention to prevent one of the other outcomes 
listed in the definition above.  (Examples of such medical events include allergic bronchospasm 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
73requiring intensive treatment in an emergency  room or convulsions occurring at home that do not 
require an inpatient hospi[INVESTIGATOR_059].)
15.1.3. Prescheduled or Elective Procedures or Routinely Scheduled Trea tments
A prescheduled or elective procedure or a routinely  scheduled treatment will not be considered 
an SAE, even if the subject is hospi[INVESTIGATOR_057].  The study site must document all of the following:
The prescheduled or elective procedure or routinely sched uled treatment was 
scheduled (or was on a waiting list to be scheduled) prior to obtaining the subject’s 
consent to participate in the study .
The condition requiring the prescheduled or elective procedure or routinel y scheduled 
treatment was present before and did not worsen or progress in the opi[INVESTIGATOR_204884]’s consent to participate in the study  and the time of 
the procedure or treatment.
The prescheduled or elective procedure or routinely scheduled treatment is the sole 
reason for the intervention or hospi[INVESTIGATOR_063].
oIf a subject is hospi[INVESTIGATOR_204885], the hospi[INVESTIGATOR_204886] 15.1.[ADDRESS_559359] be assessed to determine the following:
If the event meets the criteria for an SAE as defined in Section 15.1.2.
The relationship of the event to study  treatment as defined in Section 15.2.2 .
The severit y of the event as defined in Section 15.2.3 .
15.2.2.
Relationship of Events to Study Treatment
The following definitions should be considered when evaluating the relationship of AEs and 
SAEs to the study  treatment.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
74Relationship of Event to Study Treatment
Not related An AE will be considered “not related” to the use of the investigational drug if there is 
not a reasonable possibility that the event has been caused by [CONTACT_56695].  Factors pointing toward this assessment inclu de but are not limited to:  the 
lack of reasonable temporal relationship between administration of the drug and the 
event, the presence of a biologically implausible relationship between the product and the 
AE, or the presence of a more likely alternative explanation for the AE.
Related An AE will be considered “related” to the use of the investigational drug if there is a 
reasonable possibility that the event may have been caused by [CONTACT_56695].  Factors that point toward this assessment include but are not limited to:  a 
positive rechallenge, a reasonable temporal sequence between administration of the drug 
and the event, a known response pattern of the suspected drug, improvement following 
discontinuation or dose reduction, a biologically plausible relationship between the drug 
and the AE, or a lack of an alternative explanation for the AE.
15.2.3. Severity of Events
The following definitions should be considered when evaluating the severity  of AEs and SAEs:
Severity of Event
Mild Symptoms barely noticeable to subject or does not make subject uncomfortable; does not 
influence performance or functioning; prescription drug not ordinarily needed for relief of 
symptoms but may be given because of personality of subject.
Moderate Symptoms of a sufficient severity to make subject uncomfortable; performance of daily 
activity is influenced; subject is able to continue in study; treatment for symptoms may be 
needed.
Severe Symptoms cause severe discomfort; symptoms cause incapacitation or sig nificant impact 
on subject’s daily life; severity may cause cessation of treatment with study treatment; 
treatment for symptoms may be given and/or subject hospi[INVESTIGATOR_057].
15.2.4. Expectedness of Events
Expectedness of all AEs will be determined b y Biogen according to the Investigator’s Brochure.  
15.3. Monitoring and Recording Events
15.3.1. Adverse Events
Any AE experienced by  [CONTACT_441125] y treatment and final 
follow -up visit is to be recorded on the eCRF, regardless of the severit y of the event or its 
relationship to study  treatment.
15.3.2. Serious Adverse Events
Any SAE experienced by [CONTACT_441126] -
up visit is to be recorded on an SAE form, regardless of the severity  of the event or its 
relationship to study  treatment.  SAEs must be reported to the safet y vendor listed in the Study  
Protocol 230LE201 Version 5.[ADDRESS_559360] as described in the Study  Reference Guide within 24 hours of 
the study  site staff becoming aware of the SAE.  It is the I nvestigator’s responsibility  to ensure 
that the SAE reporting information and procedures are used and follow ed appropriatel y.
Reporting Information for SAEs
Any SAE that occurs between the time that the subject has signed the ICF andfinal follow -up 
visit must be reported as described in the Study  Reference Guide within [ADDRESS_559361] be submitted as described in the Study  Reference Guide regardless of the 
following:
Whether or not the subject has undergone study -related procedures
Whether or not the subject has received stud y treatment
The severit y of the event
The re lationship of the event to study  treatment
To report initial or follow -up information on an SAE, fax, or email a completed SAE form as 
described in the Stud y Reference Guide.
[IP_ADDRESS]. Deaths
Death is an outcome of an event.  The event that resulted in death should be recorded on the 
appropriate eCRF.  All causes of death must be reported as SAEs within 24 hours of the site 
becoming aware of the event.  The Investigator should make every  effort to obtain and send 
death certificates and autopsy  reports as descr ibed in the Study  Reference Guide.  The term death 
should be reported as an SAE only  if the cause of death is not known and cannot be determined.
15.3.4. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) are SAE s that are unexpected and 
judged b y the Investigator or Biogen to be related to the study  treatment administered.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
76Appropriate personnel at Biogen will unblind S[LOCATION_003]Rs for the purpose of regulatory  reporting.  
Biogen or designee will submit S[LOCATION_003]Rs (in blinde d or unblinded fashion) to regulatory  agencies 
according to local law.  Biogen or designee will submit S[LOCATION_003]Rs to I nvestigators in a blinded 
fashion.
15.4. Procedures for Handling Special Situations
15.4.1. Pregnancy
Subjects should not become pregnant or impregnate thei r partners during the study and 
for [ADDRESS_559362] according to the protocol.  Overdoses are not considered 
AEs and should not be recorded as an AE on the eCRF; however, all overdoses must be recorded 
on an Overdose form and faxed to Biogen or d esignee within [ADDRESS_559363] be recorded on the 
dosing eCRF.  Refer to the Study  Reference Guide for additional details.
15.4.3. Medical Emergency
In a medical emergency  requiring immediate attention, study site staff will apply  appropriate 
medical intervention, according to current SoC.  The Investigator (or designee) should contact 
[CONTACT_1758] ’s Medical Director.  Refer to the Study  Reference Guide’s Offi cial Study  Contact [CONTACT_102109].
[IP_ADDRESS]. Unblinding for Medical Emergency
In a medical emergency  when knowledge of the subject’s treatment assignment may  influence 
the subject’s clinical care, the I nvestigator and, if applicable, designate d personnel at Biogen 
may access the subject’s treatment assignment by  [CONTACT_12067].  The Investigator must document the 
reasons for unblinding in the subject’s source documents.  The Investigator is strongl y advised 
not to divulge the subject’s treatment assignmen t to any  individual not directly  involved in 
managing the medical emergency , nor to personnel involved with the analy sis and conduct of the 
study .  The Investigator can contact [CONTACT_204907].
Protocol 230LE201 Version 5.[ADDRESS_559364] dose of study  treatment.
For the purposes of this study , women who do not meet one of the following criteria listed below 
are considered to be ph ysiologicall y capable of becoming pregnant and are, therefore, defined as 
women of childbearing potential:
Postmenopausal
o12 months of natural (spontaneous) amenorrhea without an alternative medical 
cause and a serum follicle-stimulating hormone level >40 mIU/mL 
o6weeks after surgical bilateral oophorectom y with or without hy sterectomy
Posthy sterectomy
Female surgical sterilization (e.g., bilateral tubal ligation)
For the purposes of the study , highl y effective contraception is defined as the use of one of the 
following:
For females:
Established use of oral (birth control pi[INVESTIGATOR_3353]), injected, or implanted hormonal methods of 
contraception
Placement of an intrauterine device or intrauterine sy stem.
Vasectom y of male sexual partner (with the appropriate postvasectom y documentation of 
the absence of sperm in the ejaculate).
For males:
Effective male contraception includes a vasectomy with negative semen analysis at 
follow -
up, or the use of condoms with spermicide.
Complete abstinence, when this is consistent with the preferred and usual lifesty le of the subject, 
can be considered an ac ceptable method of contraception based on the evaluation of the 
Investigator who should also take into consideration the duration of the clinical trial.  Periodic 
abstinence (e.g., calendar, ovulation, sy mptothermal, postovulation methods) and withdrawal a re 
not considered acceptable methods of contraception.
Pregnancy  reporting is described in Section 15.4.1 .
15.6. Safety Responsibilities
15.6.1. The Investigator
The Investigator’s responsibilities include the following:
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
78Monitor and record all AEs, including SAEs, regar dless of the severity  or relationship 
to study  treatment.
Determine the seriousness, relationship, and severity  of each event.
Determine the onset and resolution dates of each event.
Monitor and record all pregnancies and follow up on the outcome per Secti on 15.4.1
Complete an SAE form for each SAE and send it to Biogen or designee within 24 
hours of the study  site staff becoming aware of the event.
Pursue SAE follow- up information activel y and persistently.  Follow -up information 
must be reported to Biogen or designee within 24 hours of the study  site staff 
becoming aware of new information.
Ensure all AE and SAE reports are supported b y documentation in the subjects’ 
medical records.
Pursue AE follow -up information, if possible, until the event has resolve d or become 
stable.
Report SAEs to local ethics committees, as required by  [CONTACT_1769].
15.6.2. Biogen 
Biogen’s responsibilities include the following:
Before stud y site activation and subject enrollment, the Clinical Monitor is 
responsible for reviewing with study site staff the definitions of AE and SAE, as well 
as the instructions for monitoring, recording, and reporting AEs and SAEs.
Biogen is to notify  all appropriate regulatory  authorities, central ethics committees, 
and Investigators of SAEs, as required b y local law, within required time frames.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
7916. STATISTICAL METHODS AND DETERMINATION OF
SAMPLE SIZE
The objectives of the study  and the endpoints to be anal yzed are listed in Table 4.
This is a 2
-part study  consisting of Part A and Part B.  
For Part A, subjects will be randomized in a 1:1 ratio (50 subjects each to 450 mg and placebo), 
and the randomization will be stratified by  [CONTACT_441127] ( ≤10 mg/day  vs. 
>10mg/day ) and by  [CONTACT_1617] ([LOCATION_002] vs. Asia vs. Latin America and Europ e).  
This randomization scheme will apply  to the approximately  100 subjects randomized under 
protocol version 2 or subsequent versions. 
For Part B, subjects will be randomized in a 1:1:1:1 ratio (25 subjects each to 50 mg, 150 mg, 
and 450 mg and placebo), and the randomization will be stratified by  [CONTACT_441118] -A score ( ≤10 vs. 
>10) and DLE (presence, absence).  This randomization scheme will apply  to the approximately  
[ADDRESS_559365] nonmissing measurement prior to 
randomization to study  treatment (Screening or Day  1), change from baseline is defined as post -
baseline value minus baseline value, and percent change is defined as 100 × (change/baseline).   
For each part, all primary, secondary  and exploratory  endpoints will be summarized by  [CONTACT_441128], where applicable, by  [CONTACT_6982], unless otherwise specified in the SAP.
Additional information is provided in the subsections below , anal ysis details will be provided in 
the SAP.  
16.1. Efficacy
16.1.1. Analysis Population
For Part A and Part B, analy sis of efficacy  endpoints will be based on the intent -to-treat (ITT) 
population and the per -protocol (PP) population.
The ITT population is defined a s all randomized subjects who received at least 1 dose of study  
treatment (whether or not the subjects adhered to the protocol).  Subjects will be analyzed 
according to the stud y treatment to which they were randomized.  Anal ysis of other non-safet y 
endpoi nts (e.g., demographics) will also be based on the ITT population, unless otherwise 
specified in the SAP.
The PP population is defined as all subjects in the ITT population who do not meet the criteria 
for exclusion from analysis.  The exclusion criteria w ill be defined prior to database lock for the 
final anal ysis.
16.1.2. Methods of Analysis
Continuous endpoints will be summarized using descriptive statistics (number of subjects [n], 
mean, standard deviation, median, minimum, and maximum), and categorical endpoin ts using 
frequency  and percentage of subjects.  
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
8016.1.2.1. Analysis of the Primary Endpoint
Part A:
A Mixed Effect Model Repeat Measurement (MMRM) model will be used as the primary 
method to analy ze change from baseline in the active joint count using treatment group, study  
visit, prior oral corticosteroid usage, region, and study  visit -by-treatment inte raction as fixed 
effect factors and baseline active joint count as covariate.  The primary  treatment comparison 
will be the difference between the 450 mg dose and placebo at the end of the Week 24 on the 
change from baseline in active joint count. 
In add ition, sensitivity  analy sis based on the MMRM model, with missing values imputed, will 
also be performed (imputation methods are defined in the SAP).
Due to the impact of corticosteroid and rescue medication use on active joint count, if a subject 
has an i ncrease from baseline in corticosteroid use after Week 4 (excluding allowed 
corticosteroid use as described in Section [IP_ADDRESS].2) or uses an y SLE rescue medication (as 
described in Section [IP_ADDRESS].1 ) during the [ADDRESS_559366]’s joint count after the increased corticosteroid use or 
after SLE rescue medication will not be included in the primary  analy sis. For subjects who are 
treatment failures prior to the Week [ADDRESS_559367] (WOCF) method will be applied using the patient’s last post -baseline joint count prior to 
treatment failure.  In addition, if a subject deviates from the planned tapering schedule ( Table 7), 
they might be con sidered as a treatment failure depending on the severit y and timing of 
deviation.  Additional details will be provided in the SAP.
Part B:
An MMRM model will be used to anal yze the percent change from baseline in CL ASI-A score 
using treatment group, study visit, study  visit -by-treatment interaction, DLE (presence or 
absence), and SLE (presence or absence) as fixed effect factors, and baseline CL ASI-A scores as 
a covariate.
The primary  anal ysis of the primary endpoint is a test of dose -response, using the Multiple 
Comparison Procedure –Modelling (MCP -Mod) methodology  [Bretz 2005 ].
Five dose -response trends will be tested using the appropriate contrasts, as determined b y the 
MCP -Mod methodology , on the treatment effects obtained from the MMRM model.  Additional 
infor mation will be provided in the SAP.
 
 
 
 
 
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
81  
The following anal yses of the primary  endpoint will also be performed:
Pairwise comparison of each BIIB059 treatment group versus placebo, based on the 
MMRM model.
Sensitivity  analy sis based on the MMRM model, with missing values imputed 
(imputation methods defined in the SAP).
Due to the impact of corticosteroid use on CLASI -A score s, if a subject has an increase from 
Screening in corticosteroid use, the subject’s CLASI -A scores after the increased corticosteroid 
use will not be included in the primary  analy sis. The missing data handling methodology  will 
follow the methods described for Part A.  For subjects in Part B with a diagnosis of SLE in 
addition to CL E, see Section [IP_ADDRESS].1. Additional details will be provided in the SAP. 
[IP_ADDRESS]. Analysis of the Secondary Endpoints
Part A:
The secondary  efficacy  endpoints are defined in Table 4.  A ll continuous endpoints, such as 
change from baseline over time in CL ASI-A score and active joint count, will be summarized 
using standard descriptive statistics.  All categorical endpoints, such as CLASI -[ADDRESS_559368] stratified by  [CONTACT_1617] ([LOCATION_002] vs. Asia vs. Latin America and Europe) and 
prior oral corticosteroid usage ( ≤10 mg/day  at baseline vs. >10 mg/day  at baseline) comparing 
the BIIB059 treatment gro up versus placebo.
Part B:
The secondary  efficacy  endpoints are defined in Table 4.  All continuous and categorical 
endpoints will be summarized descriptively , as indicated for Part A.  
In addition, hy pothesis testing will be performed for all secondary  endpoints, defined below, 
unless otherwise specified in the SAP. 
For the continuous endpoints, p
-values and confidence intervals will be based on the MMRM 
model specified above for the pr imary  anal ysis for Part B, with the model performed b y visit.  
For the categorical endpoints, p- values will be based on the Cochran -Mantel -Haenszel test 
stratified by  [CONTACT_441118] -A score ( ≤10 vs. >10), and DLE (presence or absence)comparing each 
BIIB059 treatmen t group versus placebo.
For both Parts A and B, a WOCF method will be applied as outlined in Section [IP_ADDRESS] for 
subjects who are treatment failures. Additional details will be provided in the SAP.

Protocol 230LE201 Version 5.[ADDRESS_559369] variability , and estimate random residual variability  
associated with the estimation of PK model parameters. Population PK analy sis may  also be used 
to identify  sources of variability  (continuous and categorical covariates) that may  influence the 
PK of BIIB059.  In addition, exposure- response (efficacy ) analy sis will be performed to evaluate 
the relationship between exposure of BIIB059 and clinical endpoints, which will be used to 
justify  doses for Phase [ADDRESS_559370] 1 dose of study treatment (whether randomized or 
not, or randomized in error).  S ubjects will be analy zed according to the study  treatment actually  
received.
16.5.2. Methods of Analysis
For Part A and Part B, all continuous endpoints will be summarized by  [CONTACT_1570] (50 mg, 
150 mg, 450 mg, and placebo) and, where applicable, by  [CONTACT_6982], using 
standard descriptive statistics, and all categorical endpoints using frequency and percentage of 
subjects.  In addition to the by -treatment group summaries, AEs will also be summarized for all 
BIIB059 treatment groups combined versus placebo.  
No statistical hy pothesis testing is planned.
[IP_ADDRESS]. Adverse Events
For Part A and Part B, AEs will be coded using the available, current version of the Medical 
Dictionary  for Regulatory Activities (MedDRA).  A TEAE will be defined as any  AE that star ted 
or worsened in severit y after initial dose of study treatment through the follow -up period; 
hereafter referred to simply  as AE.  AEs will be grouped by  [CONTACT_9313], preferred term, 
and overall, and then summarized.  The incidence, severit y, and relationship to study  treatment 
will be summarized, separatel y for all AEs, treatment -related AEs, and SAEs.  
[IP_ADDRESS]. Clinical Laboratory Evaluations and Vital Signs
For Part A and Part B, the raw values, changes from baseline, and shifts for clinical laboratory  
and vital signs parameters will be summarized, as appropriate.  In addition, clinical relevant 
abnormalities (values outside the normal range for each parameter) will be summarized.  Clinical 
abnormalities will be defined in the SAP.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
84 
16.7. Interim Analyses
16.7.1. Interim Analysis 1:  Futility
Parts A and B:
An IA for futility  of Part B and possible expansion of Part A will be performed.  The IA will be 
performed after approximately  45% of Part B subjects under protocol version [ADDRESS_559371] completed their Week 12 Treatment Visit.  At the time of the IA, it is estimated 
that over 50% of subjects in Part A will have completed their Week [ADDRESS_559372] baseline characteristics (e.g., Join t Count, SL EDAI -
2K) will be assessed.  The randomization stratification factors will be re -evaluated in the 
expanded enrollment to achieve balance between treatment groups.  The 3 objectives for adding 
additional subjects to Part A after the IA are to: 1) potentially  include an expanded SLE patient 
population based on more inclusive criteria,  2) potentially  adjust the dose of BIIB059 and, 3) to 
provide greater precision for the Week 24 endpoints, including the SRI -4.  Unblinded tables, 
listings, or graphs (TLGs) will be generated by  [CONTACT_441129] (internal or external) not 
involved in the conduct of the study .  The IA will be performed by  [CONTACT_441129] 
(internal and/or external) not involved in the conduct of the study . At the discretion of Biogen, 
unblinded TL Gs and/or data may  be shared with Sponsor personnel who are not directl y 
involved in the conduct of the study . Additional information will be provided in an unblinding 
plan.  
Details of the data to be used for the IA and the anal yses planned for futility  and possible 
expansion will be provided in the SAP.
16.7.2. Interim Analysis 2 :  End of Treatment Periods
After the last subjects complete the Double-Blind Treatment Periods for Part A (at Week 24) and 
Part B (at Week 16), an interim database lock will occur and an IA of efficacy  and safet ydata 
will be conducted.   All Investigators, study  site personnel, and subjects will remain blinded to 
treatment assignments until after the end of the study . Members of the Biogen study  team not in 
direct co
ntact with the study  sites will have access to the study  data after all subjects complete all
Week [ADDRESS_559373] with study  
sites until after the final database lock. 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
85Unblinding details will be provided in an unblinding plan.  Details of the data to be used for the 
IA and the specific anal yses to be performed will be provided in the SAP.
A complete fin al CSR will be written for the entire study  after the final database lock (i.e., after 
the completion of the Safety  Follow -up periods for Part A and Part B of the study ).
16.8. Sample Size Considerations
Part A:
The sample size for Part A is 100 subjects, random ized in a 1:1 ratio, with 50 subjects allocated 
to each treatment group. This sample size will provide approximately  71% power to detect a 
statistically  significant difference in the Week [ADDRESS_559374] deviation of 6, a maximal difference of BIIB059 over placebo of 2.5, 
a 20% dropout rate, and a 2 -sided testing at the 0.2 level significance.  Additional information 
will be provided in the Statistical Analy sis Plan (SAP). If the study  is not stopped for futility  at 
the IA (details in Section 16.7), then up to 70 additional subjects may  be added to Part A.  If an 
additional 70 subjects are added, the power will increase to approximately  87% at Week 24.
Part B:
The planned sample size for Part B is 100 subjects, randomized in a 1:1:1:1 ratio, with 25 
subjects per dosage arm of BIIB059 (50 mg, 150 mg, and 450 mg) and placebo. This sample size 
will provide approximately  90% power to detect a dose -response relationship in the Week [ADDRESS_559375] deviation of 30, a 
maximal difference of BIIB059 over placebo of 27.5%, and a 20% dropout rate.  Five different 
dose-response relationships will be tested at the 2 -sided 10% significance level with the MCP -
Mod method being used to control for multiplicity  [Bretz 2005] .  
 
 
 
 
 
 
 
 
 
 
 
 
 

Protocol 230LE201 Version 5.[ADDRESS_559376] comply  with all 
instructions, regulations, and agreements in this protocol and applicable International Council for 
Harmonisation (ICH) and Good Clinical Practice (GCP) guidelines and conduct the study  
according to local regulations.
The Investigator may  delegate responsibilities for study -related tasks where appropriate to 
individuals sufficiently  qualified by  [CONTACT_8640], training, and experience, in accordance with 
applicable ICH and GCP guidelines.  The Investigator should maintain a list of the appropriately  
qualified persons to whom signifi cant stud y-related duties have been delegated.
17.1. Declaration of Helsink i
This study  will be performed in alignment with the ethical principles outlined in the Declaration 
of Helsinki.
17.2. Ethics Committee
The Investigator must obtain ethics committee approval of the protocol, ICF, and other required 
study  documents prior to starting the stud y.  Biogen will submit documents on behalf of the 
investigational sites in countries other than the [LOCATION_002].  
If the Investigator makes any  changes to the I CF, Biogen m ust approve the changes before the 
ICF is submitted to the ethics committee.  A cop y of the approved ICF must be provided to 
Biogen.  After approval, the I CF must not be altered without the agreement of the relevant ethics 
committee and Biogen.
It is the r esponsibility  of the I nvestigators to ensure that all aspects of institutional review are 
conducted in accordance with current applicable regulations.
Biogen must receive a letter documenting ethics committee approval, which specificall y 
identifies the pro tocol, protocol number, and ICF, prior to the initiation of the study .  Protocol 
amendments will be subject to the same requirements as the original protocol.
A progress report must be submitted to the ethics committee at required intervals and not less 
than annuall y.
At the completion or termination of the study , the investigational site must submit a close -out 
letter to the ethics committee and Biogen.
17.3. Subject Information and Consent
Prior to performing an y study-related activities under this protocol, including screening tests and 
assessments, written informed consent with the approved ICF must be obtained from the subject 
or subject’s legall y authorized representative (e.g., parent o r legal guardian), as applicable, in 
accordance with local practice and regulations.  
The background of the proposed study , the procedures, the benefits and risks of the study , and 
that study  participation is voluntary  for the subject must be explained to the subject (or the 
Protocol 230LE201 Version 5.[ADDRESS_559377]’s legall y authorized representative).  The subject must be given sufficient time to 
consider whether to participate in the study .
Subjects will be informed that their race and ethnicity will be collected and will be used during
analysis of study  results.
A cop y of the signed and dated ICF must be given to the subject.  The original signed and dated 
ICF will be retained with the study  records.  Local regulations must be complied with in respect 
to the final disposition of the ori ginal (wet signature) and copi[INVESTIGATOR_71323].
Confirmation of informed consent must also be documented in the subject’s medical record.
17.4. Subject Data Protection
Prior to any  testing under this protocol, including screening tests and assessments, candidates 
must also provide all authorizations required b y local law (e.g., Protected Health Information 
authorization in North America).
Ethnicity  data will be used during subgroup anal ysis of the safet y, efficacy , and PK profile of the 
study treatment. Ethnic differences in drug absorption, distribution, metabolism and excretion 
have been described as well as differences in drug safet y and efficacy in distinct ethnic 
groups. Multiple factors may  contribute to observed variation in drug resp onse during a clinical 
study .These observed differences may  be due to intrinsic factors such as genetics and/or 
extrinsic factors such as diet, environmental exposure, and sociocultural issues that differ 
between ethnic groups. Subjects will be informed that their ethnicity  will be collected and used 
during anal ysis of study  results.
Study  reports will be used for research purposes only .  The subject will not be identified by  [CONTACT_441130], study -related forms, study  reports, or any  related publications. Biogen, its partners 
and designees, ethics committees, and various government health agencies may  inspect the 
records of this study .  Every  effort will be made to keep the subject’s personal medical data 
confidential.
17.5. Compensation for Injury
Biogen mainta ins appropriate insurance coverage for clinical studies and will follow applicable 
local compensation laws.
17.6. Conflict of Interest
The Investigators should address an y potential conflicts of interest (e.g., financial interest in 
Biogen or its partners) with the subject before the subject makes a decision to participate in the 
study .
17.7. Registration of Study and Disclosure of Study Results
Biogen will register the study  and post study  results regardless of outcome on a publicly  
accessible website in accordance wi th the applicable laws and regulations.
Protocol 230LE201 Version 5.[ADDRESS_559378] not screen an y subjects prior to completion of a study initiation visit, 
conducted b y Biogen or designee.  This initiation visit will include a de tailed review of the 
protocol and study  procedures.
18.2. Quality Assurance
During and/or after completion of the study , quality  assurance officers named by  [CONTACT_204915].  The Investigator will be 
expected to cooperate with any  audit or inspection and to provide assistance and documentation 
(e.g., source data) as requested.
18.3. Monitoring of the Study
The Investigator must permit study -related monitoring b y providing direct access to source data
and to the subjects’ medical histories.
The Clinical Monitor will visit the I nvestigator at regular intervals during the study and after the 
study  has completed, as appropriate.
During these visits, eCRFs and supporting documentation related to the study  will be reviewed 
and an y discrepancies or omissions will be resolved.  
Monitoring visits must be conducted according to the applicable ICH and GCP guidelines to 
ensure protocol adherence, quality  of data, study  treatment accountability , compliance with 
regulatory  requirements, and continued adequacy  of the investigational site and its facilities.
18.4. Study Funding
Biogen is the Sponsor of the study  and is funding the study .  All financial details are provided in 
the separate contracts between the institution, Investigator, and Biogen.  
18.5. Publications
Details are included in the clinical trial agreement for this study .
Protocol 230LE201 Version 5.[ADDRESS_559379] -reported 
outcomes will be captured in an electronic diary .  
19.1.4. Central Laboratories for Laboratory Assessments
A central laboratory  has been selected by  [CONTACT_441131] , blood chemi stry, 
and urine samples collected for this study
19.1.5. Central Facility for Other Assessments
A central facility  will be selected by  [CONTACT_441132].  A central reader will be used to adjudicate t he skin photography  
assessments.
19.2. Study Committees 
19.2.1. Independent Data Monitoring Committee 
An independent data monitoring committee (IDMC) will be formed to review interim safet y and 
efficacy  data for this study .  A charter will be written for the IDMC.
19.2.2. CLASI Assessment and Adjudication 
For Part B of the stud y, an independent CLASI Assessment Adjudicator will confirm CL ASI 
scoring at Screening for the purpose of stud y eligibility .  The Adjudicator will review the 
photographs to determine if they  meet CLA SI criteria. 
Protocol 230LE201 Version 5.[ADDRESS_559380].  In th is case, the appropriate regulatory  authorities will be notified 
subsequent to the modification.
In the event of a protocol modification, the I CF may  require similar modifications (see 
Section 17).
19.4. Ethics Committee Notification of Study Completion or Termi nation
Where required, the regulatory  authorities and ethics committees must be notified of completion 
or termination of this study , and sent a cop y of the study s ynopsis in accordance with necessary  
timelines.
19.5. Retention of Study Data
The minimum retention time for study  records will meet the strictest standard applicable to that 
site, as dictated b y any institutional requirements or local laws or regulations.  Prior to 
proceeding with destruction of records, the Investigator must notify  Biogen in writing a nd 
receive written authorization from Biogen to destroy  study  records.  In addition, the I nvestigator 
must notify  Biogen of any  changes in the archival arrangements including but not limited to 
archival at an offsite facility  or transfer of ownership if th
e Investigator leaves the site.
19.6. Study Report Signatory
Biogen will designate one or more of the participating Study  Investigators as a signatory  for the 
study  report.  This determination will be made by [CONTACT_71411], including but not limited to, 
the Investigator's experience and reputation in the studied indication; the I nvestigator's 
contribution to the study  in terms of design, management, and/or subje ct enrollment; or by  [CONTACT_441133] b y Bioge n.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
9120. REFERENCES
Achtman JC, Werth VP. Pathophy siology  of cutaneous lupus ery thematosus. Arthritis Res Ther. 
2015;17:182.
Baechler EC, Batliwalla FM, Kary pis G, et al. Interferon -inducible gene expression signature [CONTACT_441160]. Proc Natl Acad Sci U S A. 
2003;100(5):[ADDRESS_559381] a clinically  useful classification? Rheumatology  
(Oxford). 2012;51(5):771-9.
Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus ery thematosus: first multice nter 
database anal ysis of 1002 patients from the European Societ y of Cutaneous L upus 
Erythematosus (EUSCLE). Autoimmun Rev. 2013;12(3):444 -54.
Bonilla -Martinez ZL, Albrecht J, Troxel AB, et al. The cutaneous lupus ery thematosus disease 
area and severity  index: a responsive instrument to measure activity  and damage in patients with 
cutaneous lupus ery thematosus. Arch Dermatol. 2008;144(2):173 -80.
Braunstein I, Klein R, Okawa J, et al. The interferon -regulated gene signature [CONTACT_441161] y index score. Br J Dermatol. 2012;166(5):971 -5.
Bretz F, Pi[INVESTIGATOR_144676], Branson M. Combining multiple comparisons and modeling techniques in 
dose-response studies. Biometrics. 2005;61(3):738 -48.
Cao W, Zhang L, Rosen DB, et al. BDCA2/Fc epsilon RI  gamma complex signals through a 
novel BCR -like pathway  in human plasmacy toid dendritic cells. PL oS Biol. 2007;5(10):e248.
Chang AY, Pi[INVESTIGATOR_441089], Foering KP, et al. Response to antimalarial agents in cutaneous lupus 
erythematosus: a prospective anal ysis. Arch Dermatol. 2011;147(11):1261-7.
 
 
Dall'era MC, Cardarelli PM, Preston BT, et al. Type I interferon correlates with serological and 
clinical manifestations of SL E. Ann Rheum Dis. 2005; 64(12):1692-7.
Doria A, Gatto M, Zen M, et al. Optimizing outcome in SL E: treating -to-target and definition of 
treatment goals. Autoimmun Rev. 2014;13(7):770-7.
Dzionek A, Sohma Y, Nagafune J, et al. BDCA -2, a novel plasmacy toid dendritic cell -specific 
type II C -type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta 
induction. J Exp Med. 2001;194(12):1823
-34.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
92Fanning SL, George TC, Feng D, et al. Receptor cross- linking on human plasmacy toid dendritic 
cells leads to the regu lation of IFN- alpha production. J I mmunol. 2006;177(9):5829-39.
Farkas L, Beiske K, Lund- Johansen F, et al. Plasmacy toid dendritic cells (natural interferon-
alpha/beta -producing cells) accumulate in cutaneous lupus ery thematosus lesions. Am J Pathol. 
2001;159(1):237-43.
Fauci A, Longo D. Sy stemic L upus Ery thematosus. Harrison's Principles of Internal Medicine. 
17 ed.: McGraw -Hill; 2008.
Ference JD, Last AR. Choosing topi[INVESTIGATOR_11930]. Am Fam Phy sician. 2009;79(2):135 -
40.
Francès C, Cosnes A, Duhaut P , et al. L ow blood concentration of hy droxychloroquine in 
patients with refractory  cutaneous lupus ery thematosus: a French multicenter prospective study . 
Arch Dermatol. 2012;148(4):479-84.
Furie R, Merrill J, Werth V, et al., editors. Anifrolumab, an Anti -Interferon Alpha Receptor 
Monoclonal Antibody , in Moderate to Severe S ystemic L upus Ery thematosus (SL E)2015.
Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo -controlled study  of 
belimumab, a monoclonal antibody  that inhibits B ly mphocy testimulator, in patients with 
systemic lupus ery thematosus. Arthritis and rheumatism. 2011;63(12):3918-30.
Furie R, Werth VP, Merola J, et al. BIIB059, a Monoclonal Antibody  Targeting BDCA2, Shows 
Evidence of Biological Activity  and Earl y Clinical Proof of Concept in Subjects with Acute 
Cutaneous SL E (abstract). Arthritis Rheumatol. 2016;68((suppl 10)).
Ghoreishi M, Vera Kellet C, Dutz JP. Ty pe 1 IFN -induced protein MxA and plasmacy toid 
dendritic cells in lesions of morphea. Exp Dermatol. 2012;21(6):[ADDRESS_559382]. Distinctive cutaneous subsets in the spectrum of lupus 
erythematosus. J Am Acad Dermatol. 1981;4(4):471 -5.
Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity  to change of 3 Sy stemic Lupus 
Erythematosus Disease Activity  Indices: international validation. J Rheumatol. 1994;21(8):1468-
71.
Gladman DD, Ibañez D, Urowitz MB. Sy stemic lupus ery thematosus disease activity  index 
2000. J Rheumatol. 2002;29(2):288-91.
Grönhagen CM, Ny berg F. Cutaneous lupus ery thematosus: An update. Indian Dermatol Online 
J. 2014;5(1):[ADDRESS_559383] A, Järvinen TM, Koskenmies S, et al. Evidence for genetic association and interaction 
between the TYK2 and IRF5 genes in s ystemic lupus ery thematosus. J Rheumatol. 
2009;36(8):1631 -8.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
93Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an 
updated version of the British I sles Lupus Assessment Group's disease activity  index for patients 
with sy stemic lupus ery thematosus. Rheumatology  (Oxford). 2005;44(7):902 -6.
Jacob SE, Steele T. Corticosteroid classes: a quick reference guide including patch test 
substances and cross -reactivity . J Am Acad Dermatol. 2006;54(4):723-7.
Järvinen TM, Hellquist A, Koskenmies S, et al. Poly morphisms of the ITGAM gene confer 
higher risk of discoid cutaneous than of s ystemic lupus ery thematosus. PL oS One. 
2010;5(12):e14212.
Jiménez S, Cervera R, Font J, et al. The epi[INVESTIGATOR_441090]. Clin Rev 
Allergy  Immunol. 2003;25(1):3 -12.
Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II stud y of the efficacy and safet y of 
rontalizumab (rhuMAb interferon -α) in patients with sy stemic lupus ery thematosus (ROSE). Ann 
Rheum Dis. 2016;75(1): 196-202.
Khamashta M, Merrill JT, Werth VP, et al. Safet y and efficacy  of Sifalimumab, an anti IFN -
alpha monoclonal antibody , in a phase 2b study  of moderate to sever s ystemic lupus 
erythamatosus (SLE). Arthritis & Rheumatism. 2014.
Klein R, Moghadam -Kia S , Tay lor L, et al. Quality  of life in cutaneous lupus ery thematosus. J 
Am Acad Dermatol. 2011;64(5):849
-58.
Klein RS, Morganroth PA, Werth VP. Cutaneous lupus and the Cutaneous Lupus Erythematosus 
Disease Area and Severity Index instrument. Rheum Dis Clin North Am. 2010;36(1):33- 51, vii.
Koskenmies S, Järvinen TM, Onkamo P, et al. Clinical and laboratory  characteristics of Finnish 
lupus ery thematosus patients with cutaneous manifestations. L upus. 2008;17(4):337 -47.
 
 
Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy  and safe ty of belimumab in patients 
with active sy stemic lupus ery thematosus: a randomised, placebo -controlled, phase 3 trial. 
Lancet. 2011;377(9767):721-31.
Niewold TB, Kelly  JA, Kariuki SN, et al. IRF5 haploty pes demonstrate diverse serological 
associations whic h predict serum interferon alpha activity  and explain the majority  of the genetic 
association with sy stemic lupus ery thematosus. Ann Rheum Dis. 2012;71(3):463 -8.
Okon LG, Werth VP. Cutaneous lupus ery thematosus: diagnosis and treatment. Best Pract Res 
Clin Rheumatol. 2013;27(3):391 -404.

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
94Pellerin A, Otero K, Czerkowicz JM, et al. Anti -BDCA2 monoclonal antibody inhibits 
plasmacy toid dendritic cell activation through Fc -dependent and Fc -independent mechanisms. 
EMBO Mol Med. 2015;7(4):464-76.
Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of ty pe I interferon responsive 
genes in sy stemic lupus erythematosus. L upus. 2009;18(11):980-9.
Petri M, Wallace DJ, Spi[INVESTIGATOR_172360] A, et al. Sifalimumab, a human anti -interferon -α monoclonal 
antibody , in s ystemic lu pus ery thematosus: a phase I randomized, controlled, dose -escalation 
study . Arthritis and rheumatism. 2013;65(4):1011 -21.
Rahman A, Isenberg DA. Sy stemic lupus ery thematosus. The New England journal of medicine. 
2008;358(9):929 -39.
Röck J, Schneider E, Grü n JR, et al. CD303 (BDCA -2) signals in plasmacytoid dendritic cells 
via a BCR -like signalosome involving Sy k, Slp65 and PL Cgamma2. Eur J Immunol. 
2007;37(12):3564 -75.
Ruiz -Arruza I , Ugarte A, Cabezas- Rodriguez I , et al. Glucocorticoids and irreversible damage in 
patients with sy stemic lupus ery thematosus. Rheumatology  (Oxford). 2014;53(8):1470 -6.
Schultz HY, Dutz JP, Furukawa F, et al. From pathogenesis, epi[INVESTIGATOR_623] , and genetics to 
definitions, diagnosis, and treatments of cutaneous lupus ery thematosus and dermatomy ositis: a 
report from the 3rd International Conference on Cutaneous L upus Ery thematosus (I CCLE) 2013. 
J Invest Dermatol. 2015;135(1):7-12.
Stevens L A, Coresh J, Feldman HI, et al. Evaluation of the modification of diet in renal disease 
study  equation in a large diverse population. J Am Soc Nephrol. 2007;18(10):2749 -57. Epub 
2007/09/12.
Vallin H, Perers A, Alm GV, et al. Anti -double -stranded DNA antibodies and 
immunostimulatory  plasmid DNA in combination mimic the endogenous IFN- alpha inducer in 
systemic lupus ery thematosus. J I mmunol. 1999;163(11):6306-13.
van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of sy stemic lupus 
erythematosus: high disease activit y predictors of response. Ann Rheum Dis. 2012;71(8):1343 -9.
Vasque z R, Wang D, Tran QP, et al. A multicentre, cross- sectional study  on quality  of life in 
patients with cutaneous lupus ery thematosus. Br J Dermatol. 2013;168(1):145 -53.
Vermi W, L onardi S, Morassi M, et al. Cutaneous distribution of plasmacy toid dendritic c ells in 
lupus ery thematosus. Selective tropi[INVESTIGATOR_441091]. 
Immunobiology . 2009;214(9- 10):877-86.
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
95Winkelmann RR, Kim GK, Del Rosso JQ. Treatment of Cutaneous Lupus Ery thematosus: 
Review and Assessment of Treatment Benefits Based on Oxford Centre for Evidence -based 
Medicine Criteria. J Clin Aesthet Dermatol. 2013;6(1):2 7-38.
Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG -2004 index. 
Rheumatology  (Oxford). 2010;49(9):[ADDRESS_559384] read the foregoing protocol, “ A 2-Part Phase 2 Randomized, Double -blind, Placebo -
Controlled Study  Evaluating the Efficacy  and Safety  of BIIB059 in Subjects with Sy stemic 
Lupus Ery thematosus and Active Skin Manifestations andinSubjects with Active Cutaneous 
Lupus Ery thematosus with or without Sy stemic Manifestations ” and agree to conduct the study  
according to the protocol and the applicable ICH guidelines and GCP regulations, and to inform 
all who assist me in the conduct of this study  of their responsibilities and obligations.
____________________________________________________
Investigator’s Signature [CONTACT_1782]
____________________________________________________
Investigator’s Name (Print)
____________________________________________________
Study  Site (Print)
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
97APPENDIX A.DESCRIPTIONS OF EFFICACY INSTRUME NTS 
Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)
The CL ASI instrument was developed to specifically  evaluate lupus skin manifestations.  It 
differentiates and separately  scores disease activity  (CLASI -A) and sk in damage (CLASI -D).  
The activity scale includes measurements of ery thema, scale and hy pertrophy , and mucous 
membrane disease, whereas the damage scale measures h yperpi[INVESTIGATOR_371], atroph y, and scarring 
alopecia.  Each part of the body  is listed separately , from the scalp to the feet, in addition to 
sections focusing on mucous membrane involvement and alopecia.  For the activity  score, points 
are given for the presence of erythema, scale, mucous membrane lesions, recent hair loss, and 
inflammatory  alopecia.   For the damage score, points are given for the presence of 
dyspi[INVESTIGATOR_371], scarring, and scarring alopecia.  Total dy spi[INVESTIGATOR_441092] d yspi[INVESTIGATOR_441093] [ADDRESS_559385] y summin g the individual 
component scores.  CLASI -A scores of 0 -9, 10- 20, and 21 - 70 represent disease severit y of mild, 
moderate, and severe, respectivel y [Bonilla -Martinez 2008 ; Klein 2010].
A cop y of the CLASI is provided in the Study Reference Guide.
Systemic Lupus Erythematosus Disease Activity Index -2000 (SLEDAI -2K)
The SL EDAI -2K is a reliabl e, valid, simple, 1- page activity  index that measures disease activity  
and records features of active lupus as present or not [Gladman 2002] .  It is a modification of the  
SLEDAI to reflect persistent, ac tive disease in those descriptors that had previously  only 
considered new or recurrent occurrences.  The SLEDAI -2K has been validated against the 
SLEDAI, which has been shown to be reliable at different levels of disease activity  [Gladman 
1994] .  
The SL EDAI -
2K uses a weighted checklist to assign a numeric score based on the presence or 
absence of 24 s ymptoms at the time of assessment or during the previous 28 day s.  Each 
symptom present is assigned between 1 and up to 8 points based on its usual clinical importance, 
yielding a total score that ranges from 0 points (no sy mptoms) to 105 points (presence of all 
defined s ymptoms).  However, if scored correctl y, it is rare for even the sickest patients to score 
more than [ADDRESS_559386]’s sy mptoms using the 
visual analog scale (VAS) for the Ph ysician’s Global Ass essment (PGA).
SLEDAI -2K assessments should be conducted b y the same trained evaluator at each visit.
A cop y of the SLEDAI -2K and glossary  is provided in the Study  Reference Guide.
 
 
  
A mild/moderate flare is defined as an y of the following:

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
98Change in SLEDAI instrument score of 3 points or more (but not to >12)
New or worse discoid, photosensitive, profundus, cutaneous vasculitis, bullous lupus; 
nasophary ngeal ulcers; pleuritis; pericarditis; arthritis; or fever due to s ystemic lupus 
erythematosus (SLE)
Increase in prednisone requirement, but not to >0.5 mg/kg/day
Addition of NSAID or antimalarial medication for SL E activity
≥1.0 increase in PGA score, but not to >2.5
A severe flare is defined as an y of the following:
Change in SLEDAI instrument score to >12
New or worse central nervous sy stem SLE; vasculitis; nephritis; my ositis; platelets 
<60,000/ml; or hemoly tic anemia with hemoglobin <7 g/dL or decrease in 
hemoglobin >3 g/dL AND requiring: doubling prednisone dose, increase to >0.5 
mg/kg/day  or hospi[INVESTIGATOR_059]
Increase in prednisone dose to >0.5 mg/kg/day
New requirement for cy clophosphamide, azathioprine, methotrexate, or 
mycophenolate for SL E activity
Hospi[INVESTIGATOR_441094] E activity
Increase in PGA score to >2.5
British Isles Lupus Activity Group - 2004 
The BILAG -2004 Disease Activity  Index evaluates SL E activit y in a number of organ s ystems, 
based on the principle of “phy sician’s intention to treat” [ Isenberg 2005 ].  The primary  purpose 
of the BILAG in this study  is to assess possible worsening in specific organ sy stems.  Additional 
analyses of improvements in disease acti vity as assessed by  [CONTACT_310182] -2004 numeric scoring 
will also be performed [Yee 2010 ].
A separate alphabetic score is assigned to each organ sy stem, corresponding in general to the 
following definitions:
BILAG A:  Severe disease activity  requiring s ystemic high -dose oral corticosteroids, 
intravenous pulse corticosteroids, sy stemic immunosuppressants, therapeutic 
high-dose anticoagu lation in the presence of high- dose corticosteroids, or prednisone 
≥20mg/day .  Note that in the context of a clinical trial protocol with medication 
restrictions and blinded study  treatment, the term “requiring” is not taken literally  but 
indicates that i f all else were equal this would be the degree of treatment indicated.  It 
is also understood that some patients respond differently  to levels of medication than 
do others, so that in assessing patients with the BILAG, “intent -to-treat” really  
means that most patients with this degree of s ymptom would require this level of 
treatment, not necessarily  the patient in question.
BILAG B:  Moderate disease activity  requiring treatment with sy stemic low -dose oral 
glucocorticoids, intramuscular or intra -articular or soft tissue corticosteroid injection, 
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
99topi[INVESTIGATOR_441095], or symptomatic therap y such as 
antimalarial medications or NSAIDs
BILAG C:  Mild disease
BILAG D:  Sy stem previously  affected but now inactive
BILAG E:  Sy stem never in volved
The BILAG -[ADDRESS_559387] of signs and sy mptoms as:
1.Improving
2.Same
3.Worse
4.New
0Not present
(ND) Not done
For some items, appropriate responses may  be:  
Y/N  OR numeric values where indicated 
Y/N and confirm this is due to SL E activity
All signs and s ymptoms scored must be due to SLE.  Use of a glossary  provided with the 
BILAG -[ADDRESS_559388]  of 
evaluating the efficacy  of drugs; this judgment has been corroborated by  [CONTACT_441134].
BILAG assessments should be conducted b y a trained evaluator, with documentation of training.
A cop y of the BILAG -2004 and glossary  is provided in the Study  Reference Guide.
Tender and Swollen Joint Counts 
Joint involvement is a frequent manifestation in patients affected by  [CONTACT_441135] 
90% of patients at the onset or during the course of the disease [Ball and Bell 2012 ].  An active 
joint is defined as a joint with pain and signs of inflammation (e.g., tenderness, swelling or 
effusion).  A 28 -joint assessment will be performed. The joints to be assessed bilaterall y include 
the shoulders, elbows, wrists (radiocarpal, carpal, and carpometacarpal bones are considered as a 
single unit), metacarpophalangeal (MCP) joints (MCP 1, 2, 3, 4, and 5), proximal 
interphalangeal (PI P) joints (PI P 1, 2, 3, 4 and 5), and the knees. Artificial and anky losed or 
fused joints will be excluded from tenderness and swelling assessments.
A cop y of the joint count form is provide d in the Study  Reference Guide.
Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
100Physician Global Assessment of SLE (VAS)
The PGA is used to quantify  disease activit y and is measured using an anchored VAS.  The PGA 
asks the Investigator to assess the subject’s current disease activit y from a score of 0 ( none) to 3 
(severe), with the assessment made relative not to the subject’s most severe state but the most 
severe state of SLE that might exist at study  visits.
A cop y of the PGA of SLE is provided in the Study Reference Guide.
 
 
 
 
 
  
 
 
 
 
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
101 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
102 
  
 
 
  
 
  
  
 
 
 
 
 
 

Protocol 230LE201 Version 5.0
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE
CONF IDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MA Inc.
103APPENDIX B.TOPI[INVESTIGATOR_441096] –Non-Exhaustive List 
Potency Generic Name [CONTACT_441162]
(Class 1 [LOCATION_002] classification)Augmented Betamethasone Dipropi[INVESTIGATOR_16847] 0.05% 
Clobetasol Propi[INVESTIGATOR_16847] 0.05% 
Fluocinonide 0.1% 
Halobetasol Propi[INVESTIGATOR_16847] 0.05%
Potent
(Class 2 [LOCATION_002] classification)Amcinonide 0.1% 
Desoximetasone 0.25% Cream
Desoximetasone 0.05% Gel
Naricort 0.025% C
Betamethasone valerate*
Diflorasone Diacetate 0.05% 
Fluocinonide 0.05% 
Halcinonide 0.1%
Mometasone Furoate 0.1%
Triamcinolone Acetonide 0.5%
Upper -mid Strength
(Class 3 [LOCATION_002] classification)Betamethasone Dipropi[INVESTIGATOR_16847] 0.05% 
Betamethasone Valerate 0.1% 
Fluticasone Propi[INVESTIGATOR_16847] 0.005% 
Diflorasone diacetate 0.05%
Clobetasone butyrate*
Mid Strength
(Class 4 [LOCATION_002] classification)Clocortolone Pi[INVESTIGATOR_173812] 0.1% 
Fluocinolone Acetonide*  
Flurandrenolide 0.05% 
Hydrocortisone Valerate 0.2%
Source: [Ference and Last 2009 ; Jacob and Steele 2006]
* See Table 6for allowable strength
Protocol 230LE201 Version 5.[ADDRESS_559389]
Maidenhead Berkshire
SL6 4AY
[LOCATION_008]
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol 230LE201
A 2-Part Phase 2 Randomized, Double -Blind, Placebo -Controlled Study  Evaluating the Efficacy  
and Safet y of BIIB059 in Subjects with Sy stemic Lupus Ery thematosus and Active Skin 
Manifestations and in Subjects with Active Cutaneous L upus Ery thematosus with or without 
Systemic Manifestations
Version 4.0
Date:  [ADDRESS_559390] Number: [ADDRESS_559391] errors that were 
inadvertentl y made in Table 1: Schedule of Activities for Part A
Erroneous footnotes (footnote 10 and footnote 12, Version 3 numbering ) and 
corresponding footnote indicators were deleted from Table 1. The remaining footnotes 
were renumbered accordingl y.
Footnote 
13 (V ersion 3 numbering) was corrected to accuratel y reflect the instructions for 
Part A.  
New text is shown in bold ty pe; deleted text is shown with a strikethrough .
Section 4.2,Schedule of Activities, Table 1:  Schedule of Activities Part A
Now reads: See Table 1 and table footnotes on the following pages.
Rationale:   These changes were made to c orrect errors in the footnotes and footnote indicators of   
Table 1:  Schedule of Activities Part A.
Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
3Table 1: Schedule of Activities Part A
Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D) Tests and 
Assessments2,3
Informed Consent 
Form (s)X
Inclusion/Exclusion 
CriteriaX X
Randomization X
Dem ographic data X
SLE and other 
medical historyX
Documentation of 
SLE by [CONTACT_441136]
12-lead ECG4X X
Chest X -Ray4,5(if 
required by [CONTACT_21482])X
Tuberculosis test6X
Serum virology RNA 
(HIV, hepatitis B and 
C)X
Urine drug screen X
Serum pregnancy 
testX
Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
4Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D) Tests and 
Assessments2,3
Urine pregnancy 
test7 X X X X X X X X X X X
Physical 
examination, weight, 
height8X X X X X X X X X X X
Vital signs9X X X X X X X X X X X X X
BILAG- 2004 X X X X X X X X
CLASI10X X X X X X X X X X
Physicians Global 
Assessment of SLE 
(VAS)11,1210X X X X X X X X X X
Skin photography of 
target lesion1311 X X X1412
Joint Count (28 joint 
assessment)X X X X X X X X X X

Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
5Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D) Tests and 
Assessments2,3
Study treatment 
administration1513 X X X X X X X
Corticosteroid 
diary1614 X X X X X X X X X X X X
Laboratory Assessment
Hem atology X X X X X X X X X X X
Blood chemistry X X X X X X X X X X X
Urinalysis (including 
microscopic 
examination)X X X X X X X X X X X
Urine protein -
creatinine Ratio (spot 
urine)X X X X X X X X X X X
Direct Coombs 
AnalysisX X X X X X X X
Coagulation X X X X X X X X
CD19+ B Cell 
count1715 X
Pharm acokinetics
Serum BIIB0591816X X X X X X X X

Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
6Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D) Tests and 
Assessments2,3

Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
7Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D) Tests and 
Assessments2,3
Safety
Serum for vaccine -
related 
immunoglobulin 
titers2221X X
Antibodies to 
BIIB059X X X X X
Immunoglobulin 
(total, IgG, IgA, 
IgM)X X X
Concomitant 
medication/ 
proceduresMonitor and record from signing of informed consent through the end of the study
Serious adverse 
eventsMonitor and record from signing of informed consent through the end of the study
Adverse events Monitor and record from time of first dose through the end of the study
Abbreviations:   ACR=American College of Rheumatology; BILAG=British Isles Lupus Activity Group; CLASI=Cutaneous Lupus Disease Area and Severi ty 
Index; CLE=cutaneous lupus erythematosus; C=complement; CPK=creatine phosphokinase; CRP=C -reactive protein; D=day; DNA=deoxyri bonucleic acid; 
dsDNA=double -stranded DNA; ECG=electrocardiogram; ESR=erythrocyte sedimentation rate; ET=early termination; FU=follow -up; h=hour(s); HIV=human 
immunodeficiency virus; Ig=immunoglobulin; ; ; 
RNA=ribonucleic acid; ; SLE=systemic lupus erythematosus; SLEDAI -2K=Systemic Lupus 
Erythematosus Disease Activity Index 2000 ;TB=tuberculosis; VAS=visual analog scale.
1Follow -up visit will be conducted 4, [ADDRESS_559392] Treatment Period Visit (Week 24 or ET). 

Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
82Assessments (e.g., CPK, ECG, etc.) may be performed as required to confirm SLEDAI -2K and BILAG findings.  
3Oneach dosing day (Day 1, Day 15, Day 29, Day 57, Day 85, Day 113, and Day 141) all assessments should be performed prior to do sing.
4To be performed locally.
4,5Where mandated by [CONTACT_1295], a chest X -ray will be obtained locally during the screening period, unless a previous chest X -ray or the 
documented results from a chest X- ray obtained within [ADDRESS_559393] X -ray or X -ray results will be reviewed by [CONTACT_3786] (or designee) in order to exclude patien ts with active TB infection from entering the study.
6Testing to be performed locally.  Indeterminate Quantiferon or T -SPOT tests may be repeated once and w ill be considered positive if retest results are positive 
or indeterminate. Subjects with documente d BCG vaccination must perform a TB test at Screening and will be excluded if they exhibit skin induration ≥ 5 mm 
or a positive Quantiferon or positive or borderline T -SPOT (Elispot) test. 
7To be performed locally.
8Height should only be m easured only once; i.e., at the Day 1/baseline visit.
9Vital signs include seated arterial blood pressure, heart rate, and oral body temperature.   
10CLASI will be assessed by [CONTACT_12244] r or a trained designee at all assessments ( Section 19.2.2 ).  CLASI scores at Screening will be verified by [CONTACT_441112].
1110Assessments results should be reported electronically .
12Only applicable for subjects with SLE.
1311For skin lesions with a CLASI -A score greater than 0, photographs of each lesion and of the corresponding region with lesion will be obtained.  Photographs 
will be evaluated by a central adjudicator to verify the CLASI -A score assignment by [CONTACT_737]. One lesion is to be selected at baseline as the target 
lesion (the most severe active CLE lesion is recommended).  The same target lesion must be photographed and the same lesion used for tape harvesting at each 
timepoint and the same lesion over time .  
1412If the ET Visit occurs before Week 16, skin photography should be performed at the ET Visit.
1513Following administration of study treatment, subjects should remain at the study center for [ADDRESS_559394] paper diaries for recording corticosteroid use will be distributed on Day 1, reviewed with site staff at each study v isit, and collected by [CONTACT_441137]. 
1715Only for subjects with prior B cell directed therapi[INVESTIGATOR_014] w ithin 52 weeks of Screening; this test should be performed at a central laboratory.
1816Pharm acokinetic evaluations will be conducted as follows: Study Day 1 (predose –[ADDRESS_559395] -dose 4 h ±1 h), Day 8 (any time during visit), Day 29 
(predose –1 h and postdose 4 h ±1 h), Day 85 (predose –1 h and postdose 4 h±1 h), Day 113 (predose –1 h), and Day 169 (any time during visit). During the 
Follow -up Period, 1 sample will be collected on Days 197 and 253 (any time during the visit) [see Table 3 ].  The time and date o f PK sample collection and 
BIIB059 dose should be recorded in the eCRF.
 
 
 
22Vaccine- related immunoglobulin titers for tetanus, diphtheria, and Pneumococcus will be collected. 

Protocol 230LE201, Version 4
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
9SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following min or changes were made to the protocol, as appropriate:
The version number and protocol date were updated throughout the protocol and 
synopsis.
Minor ty pographical corrections and formatting improvements were made.
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
1Biogen MA Inc.
225Binney Street
Cambridge, MA  [ADDRESS_559396]
Maidenhead Berkshire
SL6 4AY
[LOCATION_008]
______________________________________________________________________
AMENDMENT SUMMARY
Biogen Protocol 230LE201
A 2-Part Phase 2 Randomized, Double -Blind, Placebo -Controlled Study  Evaluating the Efficacy  
and Safet y of BIIB059 in Subjects with Sy stemic Lupus Ery thematosus and Active Skin 
Manifestations and in Subjects with Active Cutaneous L upus Ery thematosus with or without 
Systemic Manifestations
Version 3.0
Date: [ADDRESS_559397] Number: [ADDRESS_559398] 
type of screening biopsy  to be performed . 
New text is shown in bold ty pe; deleted text is shown with a strikethrough .
Section 4.3. 5.1,Skin Biopsy  for Confirming CLE Diagnosis
Now reads:
For subjects without historical biopsy  data, diagnosis will be confirmed during Screening by  [CONTACT_441138] a local laboratory  or the central laboratory , at the discretion of the 
Investi gator. A shave punch biopsy  will be performed for diagnostic purposes . Subjects with an 
available historical biopsy  do not need a screening biopsy  for diagnosis. 
Rationale:   Shave biopsy  was replaced b y punch biopsy  because it is not standard clinical 
practice to perform ashave biopsy  for diagnostic purposes in patients with 
lupus ery thematosus. 
This change also affects Section 4.2, Table 2: Schedule of Activities Part B (footnote s#20 and 
#21).
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
3SUMMARY OF MAJOR CHANGES TO THE PROTOCOL
Changes to the protocol are presented chronologically.  New text is shown in bold type; deleted text is shown with a strikethrough.
Section 1, Sy nopsis
The Sy nopsis was revised to reflect changes made throughout the protocol.
Section 4.2 , Schedule of Activities (Table 1 : Schedule of Activities Part A)
Change :  The phrase “ Where mandated b y local regulation ” was added within body  of Table 1 and footnote #5.
Now reads:
Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,3
Informed Consent 
Form (s)X
Inclusion/Exclusion 
CriteriaX X
Randomization X
Dem ographic data X
SLE and other 
medical historyX
Documentation of 
SLE by [CONTACT_441109]
12-lead ECG4X X
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
4Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,[ADDRESS_559399] X -Ray4,5(if 
required by [CONTACT_21482])X
Tuberculosis test6X
Serum virology 
RNA (HIV,  
hepatitis B and C)X
Urine drug screen X
Serum pregnancy 
testX
Urine pregnancy 
test7 X X X X X X X X X X X
Physical 
examination,  
weight, height8X X X X X X X X X X X
Vital signs9X X X X X X X X X X X X X
BILAG- 2004 X X X X X X X X
CLASI10X X X X X X X X X X

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
5Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,3
Physicians Global 
Assessment of SLE 
(VAS)11,12X X X X X X X X X X
Skin photography of 
target lesion13 X X X14
Joint Count (28 joint 
assessment)X X X X X X X X X X
Study treatment 
administration15 X X X X X X X
Corticosteroid 
diary16 X X X X X X X X X X X X
Laboratory Assessment
Hem atology X X X X X X X X X X X
Blood chemistry X X X X X X X X X X X
Urinalysis 
(including 
microscopic 
examination)X X X X X X X X X X X
Urine protein -
creatinine Ratio 
(spot urine)X X X X X X X X X X X

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
6Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,[ADDRESS_559400] Coombs 
AnalysisX X X X X X X X
Coagulation X X X X X X X X
CD19+ B Cell 
count17 X
Pharm acokinetics
Serum BIIB05918X X X X X X X X

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
7Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,3
Safety
Serum for vaccine -
related 
immunoglobulin 
titers23X X
Antibodies to 
BIIB059X X X X X
Immunoglobulin 
(total, IgG, IgA, 
IgM)X X X

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of Biogen MAInc.
8Screening 
PeriodTreatm ent Period Follow -up Period1
Study Week Within 4 Weeks 
Prior to 
Randomization0 1 2 4 8 12 16 20 24/ET FU4 FU8 FU12
              Study Day 138
(±2D)153
(±2D)293
(±3D)573
(±3D)853
(±3D)1133
(±3D)1413
(±3D)169
(±3D)197
(±5D)225
(±5D)253
(±5D
)Tests and 
Assessments2,3
Concomitant 
medication/ 
proceduresMonitor and record from signing of informed consent through the end of the study
Serious adverse 
eventsMonitor and record from signing of informed consent through the end of the study
Adverse events Monitor and record from time of first dose through the end of the study
5During the s creening period Where mandated by [CONTACT_1295] , a chest X -ray will be obtained locally  during the screening 
period , unless a previous chest X -ray or the documented results from a chest X -ray obtained within [ADDRESS_559401] X -ray or X -ray results will be reviewed b y the Investigator (or designee) in order to exclude patients with active 
TB infection from entering the stud y.
Rationale:   For countries that require a chest X -ray for tuberculosis screening , a provision to obtain a chest X- ray was added to the 
protocol.
This change also affects Section 4.2, Schedule of Activities, Table 2: Schedule of Activities Part B and footnote #5 .
Section 4.2, Schedule of Activities (Table 1 : Schedule of Activities Part A)
Change:   Pharmacokinetic (PK) evaluation tim epoints were corrected for Day  85 and Day  113 in footnote # 18.
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
9Now reads:18Pharmacokinetic evaluations will be conducted as follows: Study  Day  1 (predose –
[ADDRESS_559402] -dose 4 h ±1 h), Day  8 (any  time during visit), Day  29 (predose –1 h and postdose 4 
h ±1 h), Day  85 (predose –1 h and postdose 4 h±1 h ), Day  113 (predose – 1 h and postdose 4 h 
±1 h), and Day  169 (any  time during visit). During the Follow -up Period, 1 sample will be 
collected on Day s 197 and 253 (any  time during the visit).  See Table 3.  The time and date of 
PK sample collection and BIIB059 dose should be recorded in the eCRF.
Rationale:   The PK evaluation timepoints were corrected to align with the PK sampling 
timepoints presented in Table 3 (Pharmacokinetic Assessments). T he description of collection 
timepoints for Week 12 (Day  85) and Week 16 (Day  113) were uninte ntionally  inverted 
according to the site communication letter on PK assessment timepoints. 
Section 4.2, Schedule of Activities (Table 3, Pharmacokinetic Assessments )
Change:   The Follow -Up period was changed to Day 197 and 253 (±5 d) for Part A and Days
141, 169, and 197 (±5 d) for P art B. 
Now reads:
Table 3: Pharm acokinetic Assessments
Study Week 0 1 2 4 8 12 16 20 24Follow -
Up 
Period
Study Day 18
(±2 d)15
(±2 
d)29
(±3 d)57
(±3 
d)85
(±3 d)113
(±3 d)141
(±3 
d)169
(±3 d)Part A
Day 197
, 225 or 
and253 
(±5 d)
Part B
Day 
141, 
169,
orand
197 (±5 
d)
Part A
PK 
Sampling 
Timepoint(s)Predose 
(–1 h)
Postdose 
(4 h ±1 
h)Any 
tim
e 
duri
ng 
visi
tPredose 
(–1 h)
Postdose 
(4 h ±1 
h)Predose 
(–1 h)
Postdose 
(4 h ±1 
h)Predose  
(–1 h)An
y 
tim
e 
duri
ng 
visi
tAny 
time 
during 
visit
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
10Part B
PK 
Sampling 
Timepoint(s)Predose 
(–1 h)
Postdose
(4 h ±1 
h)Any
tim
e 
duri
ng 
visi
tPredose 
(–1 h)
Postdose 
(4 h ±1 
h)Predose 
(–1 h)
Postdose 
(4 h ±1 
h)Any 
time 
during 
visit Any 
time 
during 
visit
Rationale:   In Table 3, Follow -Up Period collection visits had been specified incorrectl y. 
Collection visits were corrected to align with Table 1: Schedule of Activities Part A and Table 2: 
Schedule of Activities Part B.
Section 4.3.3, Joint Count Assess ment (Part A Only )
Change:   The language for joint count assessment was revised to indicate that the same joint 
assessor must perform the joint count assessment for the same subject at every  visit.
Now reads:
Joint counts will be evaluated at all visits by a trained independent joint assessor.  Joint counts 
will be evaluated at all visits by a trained independent joint assessor. The joint counts for 
an individual subject must be performed by [CONTACT_441139].
Rationale:   This change was made to ensure that investigational sites assign same joint assessor 
to the same subject at every  visit . This practice is expected to prevent the occurrence of major 
protocol deviation s.
Section 7.2.3, Follow- Up
Change:   The language pertaini ng to follow -upvisits for subjects who prematurely  discontinue 
study  treatment and/or who prematurel y withdraw from the study was revised.
Now reads:
Subjects are to return to the study  site for follow -up (FU) visits at 4, 8, and [ADDRESS_559403] Treatment P eriod visit (Week 24 or E arly Termination [ET] Visit). Follow -up visits will be 
conducted at Week FU4 (Day 197), Week FU8 (Day  225) and Week FU12 (Day  253) .  The final 
study  visit will be Week FU12.  Subjects who prematurely  discontinue treatment during the 
double -blind treatment period should undergo ET Visit assessments and be encouraged to 
complete the Follow -up Period.
Subjects who prematurely discontinue study treatment during the Double b lind Treatment 
Period should complete all study assessments for the Week 24/ET Visit as soon as possible, 
but within 4 weeks.  Subjects who discont inue study treatment should also complete the 
study assessments for the Safety FU Visits at Week FU4, Week FU 8, and Week FU12 after 
their ET Visit. 
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
11Subjects who are prematurely withdrawn from the study during the Double blind 
Treatment Period should complete all study assessments for the Week 24/ET Visit as soon 
as possible, but within [ADDRESS_559404] is unwilling or unable to attend 
the study FU Visits, or at minimum the ET Visit, an d decides to withdraw consent, the 
reason for withdrawal will be documented and no further assessments will be obtained.    
Rationale:   This new text provides more detailed instructions to the sites regarding stud y 
activities for subjects who discontinue study  treatment and/or who are prematurely  withdrawn 
from the study .
This change also affects Section 4.2, Schedule of Activities
,footnote #1.
Section 7.3.3, Follow- Up
Change:   The language pertaining to follow-up visits for subjects who prematurely  discontinue 
study  treatment and/or who prematurel y withdraw from the study was revised.
Now reads:
Subjects are to return to the study  site for follow up visits on Week FU4 (Day  141), Week FU8 
(Day  169), and Week FU12 (Day  197) after the last Treatment Period visit (Week 16 or ET 
Visit).  The final study  visit will be Week FU12.  Subjects who prematurel y discontinue 
treatment during the double -blind Treatment Period should undergo ET visit assessments and be 
encouraged to complete the Follow up Period. 
Subjects who prematurely discontinue study treatment during the Double blind Treatment 
Period should complete all study assessments for the Week 16/ET Visit as soon as possible, 
but within 4 weeks.  Subjects who discont inue study treatment should also complete the 
study assessments for the Safety FU Visits at Week FU4, Week FU8, and Week FU12 after 
their ET Visit. 
Subjects who are prematurely withdrawn from the study during the Double blind 
Treatment Period should complete all study assessments for the Week 16/ET Visit as soon 
as possible, but within [ADDRESS_559405] is unwilling or unable to attend the study FU Visits, 
or at minimum the ET Visit, and decides to withdraw consent, the reason for withdrawal 
will be documented and no further assessments will be obtained.
Rationale: This new text provides more detailed instructions to sites regarding study  activities 
for subjects who discontinue study  treatment and/or who are prematurel ywithdrawn from the 
study .
This change also affects Section 4.2, Schedule of Activities, footnote #1.
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
12Section 8.2.1, Exclusion Criteria (Parts A and B)
Change:   Exclusion criterion #7 , regarding hepatitis C virus (HCV), was revised.
Now reads:
7. Current active hepatitis C virus (HCV) infection, determined as HCV RNA above the limit of 
detection. Current active hepatitis C virus (HCV) infection, determined as HCV RNA above 
the limit of detection, in subjects with positive HCV antibody titer .
Ratio nale: Thisexclusion criterion was revised to indicate that subject smust have a positive 
HCV antibody  titer in order to confirm the diagnosis of current active HCV infection.
Section 8.2.1, Exclusion Criteria (Parts A and B) , Medical History
Change:   Asentence was added to exclusion criterion #[ADDRESS_559406] ( IP) .
Now reads:
20. History  of any  clinically  significant cardiac, endocrinologic, hematologic, hepatic, 
immunologic, metabolic, urologic, pulmonary , neurologic, dermatologic, psy chiatric and renal, 
or other major disease, as determined b y the Investigator. Specifically, a di agnosis of any other 
systemic autoimmune disease other than secondary Sjögren’s syndrome, such as 
rheumatoid arthritis (RA), psoriatic arthritis (PsA), dermatopolymiositis (DM), systemic 
sclerosis (scleroderma), etc. which may confound the evaluation of th e effect of IP.
Rationale: The added language to this exclusion criterion is intended to prevent study  
Investigator sfrom excluding subjects who were diagnosed with secondary  Sjögren’s s yndrome 
(sicca s yndrome), which is frequent and commonly allowed in clinical trials for SLE
.
Section 8.2.1, Exclusion Criteria (Parts A and B) , Laboratory  abnormalities
Change:   In exclusion criterion 35, t he unit of measure for neutrophils count was changed from 
Lto µL.
Now reads:
35. Hemoglobin <5.5 mmol/L  [9 g/dL ], neutrophils <1.5 x 103/LµL, platelets <75 x 109/L at 
Screening.
Rationale: The operating laboratorie s atinvestigational sites provide results for neutrophils 
count equivalent to 103/µL.The protocol incorrectly  showed the unit for neutrophils as 103/L; 
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
13this change corrects the error. This correction will help investigational sites report clean data for 
neutrophil count s.
Section 10.1, Discontinuation of Study  Treatment
Change:   The language for discontinuation of study  treatment was revised.
Now reads: A subject must permanentl y discontinue study treatment for any of the following 
reasons:
The subject becomes pregnant.  Stud y treatment must be discontinued immediately.  
Report the pregnancy  according to the instructions in Section 15.4.1.
The subject withdraws consent to continue study treatment.  
The subject experiences a medical emergency  that necessitates permanent 
discontinuation of study  treatment.
The subject experiences a medical emergen cy that necessitates unblinding of the 
subject’s treatment assignment.
The subject is unwilling or unable to compl y with the protocol.
At the discretion of the Investigator for medical reasons.
The reason for discontinuation of study  treatment must be recorded in the subject’s electronic 
case report form (eCRF). 
Subjects who prematurely discontinue study treatment during the Double blind Treatment 
Period should complete all study assessments for the ET Visit as soon as possible, but 
within 4 weeks.  Subjects who discontinue study treatment should also complete the study 
assessments for the Safety FU Visits at 4, 8, and 12 weeks after the ET Visit. protocol 
required tests and assessments during the follow -up visits (Week 4, 8, and 12 Follow- Up 
Visits)).  I n the event that a subject withdraws from the study  premature ly, at minimum, an Early  
Termination Visit should be performed as soon as possible, to be followed by  [CONTACT_31051] -up Visits at 
4, 8, and [ADDRESS_559407] visit; all Early  Termination assessments listed in the study  schedule 
should be performed at this Early  Termination visit. 
Rationale: This new text provides more detailed instructions to the sites regarding stud y 
activities for subjects who discontinue study  treatment.
Section 10.2, Withdrawal of Subjects From Study
Change:   A sentence from Section 10.1 ( Discontinuation of Study  Treatment ) was moved to 
Section 10.2.
Now reads:   Subjects must be withdrawn from the study  for any  one of the following reasons:
The subject withdraws consent.
Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
14The subject enrolls into another interventional clinical study  in which an 
investigational treatment or approved therap y for investigational use is administered.
The subject is unwilling or unable to compl y with the protocol.
Subjects who are prematurely withdrawn f rom the study during the Double -blind 
Treatment Period sho
uld complete all study assessments for the ET Visit as soon as 
possible, but within [ADDRESS_559408]’s withdrawal from th e study  must be recorded in the subject’s eCRF. 
The level of consent withdrawal (e.g., whether samples collected but not yet anal yzed can still be 
used/anal yzed, and so on) should also be recorded in the eCRF.
Rationale: The sentence describing visits and assessments to be performed forsubject s who
withdraw from the stud y prematurel y was mistakenly  placed in Section 10.1 (Discontinuation of 
Study  Treatment) ,which applies only to subjects who discontinue the study  treatment. This 
change more appropriately  places the information in Section 10.2.
Appendix A :  Description of Efficacy  Instruments,  
Change:    
Now reads:  
 
 
 
 

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
15Rationale:  
Appendix A :  Description of Efficacy  Instruments,  
 
 
 
  
 
   

Protocol 230LE201 , Version 3.0
CONFIDENTIAL
The information contained herein may not be used, disclosed, or published w ithout the written consent of 
Biogen MAInc.
16SUMMARY OF MINOR CHANGES TO THE PROTOCOL
The following minor changes were made to the protocol, as appropriate :
The version number and date were updated throughout the protocol.
Time periods or timepoints expressed in months were converted to weeks to maintain 
consistency throughout the protocol.
The wording “p rotocol version 2 ”was replaced with “protocol version 2 or 
subsequent versions ” wherever applicable.
Typographical and formatting errors were corrected.
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
[ADDRESS_559409]  
Maidenhead Berkshire  
SL6 4AY  
[LOCATION_008]  
______________________________________________________________________ 
AMENDMENT SUMMARY 
Biogen Protocol 230LE201 
A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Stud y Evaluating the Efficacy 
and Safet y of BIIB059 in Subjects with Systemi c Lupus Erythe matosus and Acti ve Skin 
Manifestatio ns and in Subjects with Acti ve Cutane ous L upus Erythematos us with or without 
Systemi c Manifestations.   
Version 2 
Date:  [ADDRESS_559410] Numbe r:  2015-004359-32 
Version 2 of the protoc ol has been prepared for this amendment, which supersede s Version 1. 

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
2 PRIMARY REASON FOR AMENDMENT 
The primary reason for this amendment to Protocol 230LE201 is to modify the overall design of 
the
 2-part study (Part A in subjects with systemic lupus erythematosus [SLE] with active skin 
manif
estations, and Part B in subjects with cutaneous lupus erythematosus [CLE] with or without 
s
ystemic manifestations). The study design changes take into account Biogen’s initial experience 
to more successfully enroll subjects into Part B and are intended to increase the focus of the 
study on CLE, which is the lead indication for BIIB059. 
Part A was initially designed as a dose-ranging study of the effects of BIIB059 on the skin 
manif
estations of SLE measured by [CONTACT_441140] 
S
everity Index (CLASI). In the amended protocol, Part A has been modified to evaluate the 
e
ffects of a single dosing regimen of BIIB059 on the joint and skin manifestations of SLE. The 
c
hange was made because joint symptoms are a common systemic component of SLE that has 
been shown to improve in th e first 6 months of treatment, based on recent Phase 2 comparator 
da
ta. With this change, Part A of the study now is a pr oof-of-concept study to evaluate whether 
BIIB059 works beyond the skin in SLE. Key changes to Part A are as follows: 
 Of
 the 3 BIIB059 dosing regimens in the original protocol (50, 150, and 450 mg 
subcutaneous ly [SC] every 4 weeks [Q4W]), the 450 mg Q4W regimen will continue to 
be
 evaluated, while the 50 mg Q4W and 150 mg Q4W regimens will be dropped. The 
450 mg
 Q4W regimen, with an additional loading dose at Week 2, was maintained based 
on Phase 1 safety, pharmacokinetic ( PK) , PK-blood dendritic cell antigen-2 (BDC A2) 
internalization relationship, and extrapolated inhibitory potency (concentration resulting 
in 90% inhibition of response [IC 90]) of interferon-alpha (IFN-α) production by 
[CONTACT_441141] ). The T reatment Period remains 24 weeks. 
 S kin-related criteria for study eligibility were made less stringent. Per the original 
protocol, subjects in Part A were required to have a minimum CLASI-Activity (CLASI-
A) score of ≥8.  The CLASI requirement proved challenging for enrollment, so a specific 
C
LASI threshold will no longer be required for Part A (but will still be required for Part 
B). Instead, subjects in Part A will be required to have some sign of active skin disease, 
as defined by [CONTACT_441142] (SLEDAI)-2K 
with no C
LASI restriction. A requirement for skin involvement was maintained because 
da
ta suggest that BIIB059 has its primary effect in the skin. Joint-related criteria for 
study eligibility were also added.  
 T he primary endpoint was modified from the Week 12 percent change from baseline in 
CLASI-A score to the Week 24 change from baseline in active joint count (28-joint 
assessment), in line with the focus of Part A on joint manifestations instead of skin 
manif
estations of SLE. This primary endpoint was selected because joint count is 
c
onsidered a reliable indicator of SLE disease activity, based on the medical literature, 
other
 clinical trials, and discussions with key opi[INVESTIGATOR_46830], indicating that a high 
pr
oportion of SLE patients have joint involvement.  
 The  effect of BIIB059 on skin manifestations in patients with an SLE diagnosis 
(f
ulfilling 4 of 11 American College of Rheumatology [ACR] criteria) will be evaluated 
a
s secondary endpoints. The skin-related secondary endpoints were changed to reflect 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
3 the removal of a minimum CLASI score of ≥8 for eligibility. Since a minimum CLASI 
score is no longer required in Part A, the CLASI-50 and ≥4-point reduction endpoints 
will
 only be evaluable for subjects who have a baseline CLASI score of ≥4.  
Part B was initially designed as a single-dose study of the effects of BIIB059 in CLE. In the 
a
mended protocol, Part B has been modified to be a dose-ranging study of BIIB059 in CLE. A 
large
r number of subjects will be enrolled into Part B (130 instead of 30 subjects). The larger 
sa
mple size and addition of a dose-ranging evaluation will allow for a more thorough evaluation 
of
 the activity of BIIB059 in CLE observed in the Phase 1 study (230LE101) and to identify an  
e
fficacious dose for CLE. Key changes to Part B are as follows: 
 B
IIB059 dosing regimens of 50, 150, and 450 mg SC Q4W, with an additional loading 
dose 
at Week 2, were selected based on the results of the completed Phase 1 study 
(230
LE101) and on a population PK model developed using Phase 1 data. 
 The Treatment Period was extended from [ADDRESS_559411] that the CLASI response does not plateau until after 16 weeks. 
 The
 primary endpoint was modified from the percent change at Week [ADDRESS_559412] the longer treatment period. The skin-related secondary endpoints will be 
e
valuated at both Week 12 and Week 16.  
 The amended protocol specifies a larger planned sample size for Part B. A re vised sample 
size of 100 subjects will provide approximately 90% power to detect a dose-response 
re
lationship in the percent change at Week 16 from baseline in CLASI-A score.     
An interim analysis (IA) was planned in the original protocol to occur approximately 12 weeks 
after 75% of subjects had been randomized into Part A. In the amended protocol, the IA for 
futili
ty of Part B and possible expansion of Part A will be performed.  The IA will be performed 
after approximately 45% of Part B subjects under protocol Version [ADDRESS_559413] completed their Week 
12 Treatment Period visit.  At the time of the IA, it is estimated that over 50% of subjects in 
Part A e nrolled under V ersion [ADDRESS_559414] completed their Week 12 Treatment 
Period visit.  Following the IA, up to an additional 70 subjects may be enrolled in Part A and 
BIIB059 dose may be adjusted.   The additional subjects in Part A may be enrolled based on a 
more
 inclusive criteria to include an expanded SLE population.  Details are provided in 
S
ection 16.7 of the protocol. 
Key sections of the protocol that are affected by [CONTACT_441143]. 
New text is shown in bold type; deleted text is shown with a strikethrough. 
 
Section 5.5, Rationale for Dosing Regimen 
Now reads: 
5.5.1 P art A 
A primary objective of this study is to evaluate the dose-response relationship of BIIB059 at 3 
different dose levels given SC Q4W with an additional loading dose at Week 2.  Dosing 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
4 regimens were selected based on emerging Single IV as well as multiple SC doses of BIIB059 
up to and including 20 mg/kg and [ADDRESS_559415] 
demonstrated acceptable tolerability in the Phase 1 Study (230LE101).  In general,  
BIIB059 serum concentrations were slightly lower in subjects with SLE than in healthy 
volunteers following dosing with BIIB059 50 mg SC (single and multiple dose 
administration).  Additionally, the median percent change from baseline in BDCA2 on 
pDC surfaces was equivalent between SLE and healthy subjects following SC doses of 
50 mg.   
 
Single doses of 450 mg, administered SC every 4 weeks (Q4W) with an additional dose at 
We
ek 2 will be used in Part A.  The dosing regimen was selected based on  Phase 1 safety, 
P
K, PK-BDCA2 internalization relationship and extrapolated inhibitory potency (concentration 
resulting in 90% inhibition of response [IC 90]) of pDC IFN-α production [ Pellerin 2015 ]. The 
B
IIB059 fixed dose of 450 mg SC e very 4 weeks (Q4W) with an additional dose at Week 2 
was selected to achieve C min levels similar to 3-fold of the calculated IC 90 for IFN -α 
inhibition.  Furthermore, this dose regimen with an additional dose of 450 mg at Week 2 and a 
bioava
ilability (F) of 0.45 is expected to result in cumulative exposure comparable to that 
achieved by [CONTACT_441144] 20 mg/kg IV for a 65-kg person, the highest dose tested in 
healthy volunteers.     
Single IV doses of BIIB059 up to and including 20 mg/kg in healthy have demonstrated 
acceptable tolerability to date in Part 1 of the Phase 1 SAD study (230LE101).  BDCA2 target 
engagement, as measured by [CONTACT_441145]2 internalization and reappearance, was observed in a 
dose-dependent manner across the dose range of 0.3 to 20 mg/kg.  EC 90 values for BDCA2 
internalization were derived from population-based PK and PD modeling with the mean value of 
1.5 µg/mL.  IC 90 for IFNα inhibition was estimated from in vitro to in vivo extrapolation of 
BDCA2 internalization and IFNα inhibition[ Pellerin 2015 ].   
BIIB059 fixed doses of 50, 150 and 450 mg SC Q4W with an additional dose at Week 2 were 
chosen and are supported by [CONTACT_716]:   
 The low dose of 50 mg SC Q4W was chosen to maintain BDCA2 internalization for 
the majority of the dosing interval  
 The middle dose of 150 mg SC Q4W was selected to achieve minimum observed 
concentration (C min) levels similar to the calculated IC 90 for IFNα    
 The top dose of 450 mg SC Q4W was selected to achieve C mi n levels similar to 3-fold 
of the calculated IC 90 for IFNα inhibition.  Furthermore, this dose regimen with an 
additional dose of 450 mg at Week 2 and a bioavailability (F) of 0.45 is expected to 
result in cumulative exposure over 3 months comparable to that achieved by [CONTACT_441146] 20 mg/kg IV for a 65-kg person, the highest dose tested in healthy 
volunteers 
To ensure sufficient drug exposure and concentration levels above the target steady-state values 
within 1 month following SC administration, an SC loading dose on Week 2 (Day 15) will be 
included.   
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
5 The emerging PK data from the SAD study using weight-adjusted dosing show that body weight 
is not an influential covariate for BIIB059 exposure.  Further, population PK simulations showed 
that both weight-adjusted dosing and fixed dosing result in comparable BIIB059 exposure.  
Fixed dose regimens, therefore, are proposed for the Phase 2 study.  The proposed doses and/or 
dosing regimen may be modified based on additional PK and PD data emerging from subjects 
with SLE (20 mg/kg IV) and healthy volunteers (multiple doses SC) in the ongoing Phase 1 
study (230LE101). 
 
5.5.[ADDRESS_559416] adequate 
target coverage to suppress pDC function, including the production of type I IFN, over the 12 
weeks preceding the primary endpoint.   
The dosing regimen was selected based on the Phase 1 safety, PK, PK-BDCA2 
internalization relationship, and extrapolated inhibitory potency (concentration resulting 
in 90% inhibition of response [IC 90]) of pDC IFN-α production [ Pellerin 2015 ]. BIIB059 
fixed doses of 50, 150 and 450 mg SC Q4W, with an additional loading dose at Week 2, 
were selected for the Phase 2 study because simulations conducted, based upon the 
p
opulation PK model developed using the Phase 1 data, predicted that: 
 At the low dose of 50 mg SC Q4W is expected to achieve plasma concentrations 
sufficient to maintain 90% BDCA2 internalization for the majority of the dosing 
interval. 
 
 At the middle dose of 150 mg SC Q4W is expected to achieve plasma concentrations 
similar to or in excess of the calculated IC90 for IFNα for the majority of the dosing 
interval. 
 At the top dose of 450 mg SC Q4W is expected to achieve C min levels similar to 3-
f
old of the calculated IC90 for IFN-α inhibition.  
T
he selected doses are considered safe and tolerable, based upon the results of Phase 1 
study.  The dosing regimen of 450 mg SC Q4W, with an additional dose of 450 mg at Week 
2 an
d a bioavailability (F) of 0.45, is expected to result in cumulative exposure over 3 
months comparable to that achieved by [CONTACT_441144] 20 mg/kg IV for a 65-kg person, the 
highest dose tested in healthy volunteers . 
 
Section 6, Study Objectives and Endpoints (Primary) 
Now reads: 
Primary Objective 
To evaluate the efficacy of BIIB059 in skin reducing disease activity in subjects with SLE w ith 
active cutaneous manifestations and joint involvement (Part A), and in subjects with active 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
6 CLE (SCLE or chronic CLE, including DLE) with or without systemic manifestations (Part B) . 
a
nd to investigate the dose-response relationship in subjects with active SLE and skin 
manifestations (Part A only) 
Primary Endpoint  
Week 12 percent change from baseline in CLASI-A score 
Part A:  
Change in active joint count (28-joint assessment) from Baseline to Week  24; the active 
joint c
ount is defined as the sum of tender and swollen joint counts. 
Part B:  
Percent change from baseline in CLASI-A score fr om Baseline to Week 1216 
 
 
Section 6, Study Objectives and Endpoints (Secondary Endpoints, Skin-related, Parts A and B) 
Now read s: 
 CLASI-50 response, defined as a 50% improvement from baseline in CLASI-A score at 
Week 24 (Part A) and Weeks 12 and 16 (Part B ) 
Percent change in CLASI-A score from Baseline to Weeks 16 and 24 (Part A) and Week 12 (Part 
B) 
 A ≥4 -point reduction in CLASI-A score relative to baseline at Week 24 (Part A) and at 
Weeks 12 and 16 (Part B) 
 
Section 6, Study Objectives and Endpoints (Secondary Endpoints, SLE-disease activity related 
(Part A only) 
Now reads: 
 Composite endpoint of SRI-4 at Week 24 compared with baseline, with concomitant oral 
corticosteroid dosage ≤ 10 mg/day and ≤ Day 1, and stable or decreased oral corticosteroid 
dose between Weeks 12 and 24.   
Composite endpoint SRI-4 is defined as:  
 A reduction from baseline of ≥ 4 points  in SLEDAI-2K score AND 
 No new organ system affected as defined by [CONTACT_441108]-2004 A or ≤ 2B 
AND  
 No worsening from baseline in subject’s lupus disease activity defined by ≤ 
0.3 point increase in PGA(VAS) AND 
No protocol-prohibited medication/treatment 
 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
7  P roportion of subjects with a composite response, defined as:  
 SLE Responder Index (SRI) of ≥4 (SRI-4) at Week 24, where SRI-4 is 
defined as: 
o A reduction from baseline of ≥4 points  in Systemic Lupus Erythematosus  
Disease Activity Index 2000 (SLEDAI-2K)  and 
o No new organ system affected, as defined by [CONTACT_441108]-[ADDRESS_559417]’s lupus disease activity defined by 
<0.3 point  increase in PGA (VAS)  
 No protocol-prohibited medication or treatment. 
 Concomitant corticosteroid dosage at Week 24 to be ≤10 mg/day 
 Conco
mitant corticosteroid dosage at Week 24 to be ≤Day 1 corticosteroid 
d
osage 
 No increase in corticosteroid dose between Weeks 17 and 24 
 
 Chan ge from baseline to Week 24 in SLEDAI-2K score 
 P roportion of subjects with no new organ system affected, as defined by [CONTACT_441147]-2004 A and no more than one new BILAG-2004 B from baseline to Week 24 
 Chan ge from baseline to Week 24 in PGA VAS score 
 
Section 7.1, Study Overview 
Now reads: 
This is a 2-part randomized, double-blind, placebo-controlled, multicenter Phase 2 trial designed 
to evaluate the efficacy and safety of BIIB059 in subjects with SLE with skin manifestations 
(Part A) or active CLE, defined as discoid or subacute subtypes, with or without SLE (Part B). 
The study will be conducted at approximately 95 centers in the [LOCATION_002], Europe, 
Latin/South America and Asia.  
In Part A, subjects will be randomly assigned to 1 of 4 treatment groups in a 1:1:1:1 ratio and 
receive either fixed doses of  BIIB059 (50, 150 or 450 mg) or placebo subcutaneously Q4W for 
24 weeks with a loading dose at Week 2, for a total of 7 doses (Figure 1).  Randomization will be 
stratified by [CONTACT_441148]-A score (≤ 10, >10) and prior oral corticosteroid usage (≤ 10 mg/d, 
>10 mg/d).  Approximately 100 subjects are planned to be randomized (25 per treatment group).  
An interim analysis is planned to occur approximately 12 weeks after 75% of subjects are 
randomized.  Following review of the interim analysis data, up to 40 additional subjects in each 
group (up to a total of approximately 260 subjects) may be enrolled based on pre-defined 
decision criteria.  See Section 16.7 for details.   
In Part B, 30 subjects will be randomly assigned to 1 of 2 treatment groups in a 2:1 ratio 
(20 subjects to BIIB059, 10 subjects to placebo) and receive either a fixed dose of BIIB059 
(450 mg) or placebo SC Q4W for 12 weeks with a loading dose at Week 2, for a total of 4 doses.  
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
8 (Figure 2).  Randomization will be stratified by [CONTACT_441118]-A score (≤ 10, >10) and SLE (presence, 
absence). Individual subjects may participate in EITHER Part A or Part B.   
This is a 2-part randomized, double-blind, parallel-group, placebo-controlled, multicenter 
P
hase 2 trial designed to evaluate the efficacy and safety of BIIB059 in subjects with SLE with 
active skin manifestations and joint involvement (Part A) or active CLE, defined as SCLE  or 
c
hronic CLE including DLE , with or without SLE (Part B). The study will be conducted at 
approximately 130 centers in the [LOCATION_002], Europe, Latin/South America, and Asia.  
Study treatment will begin following a 28-day Screening period. 
In Part A, subjects will be randomly assigned to 1 of 2 treatment groups in a 1: 1 ratio and receive 
either BIIB059 (450 mg) or placebo subcutaneously e very 4 weeks ( Q4W) for 24 weeks, with 
an
 additional dose at Week 2, for a total of 7 doses (Figure 1) . The maximum number of 
su
bjects in Part A is approximately 190 subjects.  Of these 190 subjects, approximately 100 
subjects will be enrolled under protocol version 2.  If the study is not stopped for futility at 
the interim analysis, then up to 70 additional subjects may be added (up to a total of 
approximately 170 subjects under protocol version 2).   Subjects enrolled under protocol 
ve
rsion 1 will remain on their original treatment assignment (up to a total of approximately 
20 su
bjects)  and not be re-consented under protocol version 2.  Randomization will be 
str
atified by [CONTACT_441117] (≤10 mg vs >10 mg) and by [CONTACT_1617] 
(
[LOCATION_002] vs. Asia vs. Latin America and Europe).  
In Part B , approximately 130 subjects will be r andomized; of these, approximately [ADDRESS_559418] completed the Week 12/Early Termination Visit. 
Subjects enrolled in protocol version 2 will be randomly assigned to 1 of 4 treatment groups in 
a 1:
1:1:1 ratio with approximately 25 subjects per treatment arm  and receive either a fixed 
dose of BIIB059 ( 50 mg, 150 mg, or 450 mg) or placebo SC e very 4  weeks (Q4W) for 16 
w
eeks with an additional  dose at Week 2, for a total of 5 doses (Figure 5). Randomization will 
be stratified by [CONTACT_441118]-A score (≤10  vs >10) and DLE  (presence, absence) .  
An IA f
or futility of Part B and possible expansion of Part A will be performed.  The IA 
w
ill be performed after approximately 45% of Part B subjects under protocol version [ADDRESS_559419] completed their Week 12 Treatment Visit.  At the time of the IA, it is estimated that 
over 50% of subjects in Part A will have completed their Week 12 treatment visit.  
Following the IA, up to an additional 70 subjects may be enrolled in Part A and BIIB059 
dose
 may by [CONTACT_441119].  The additional subjects in Part A may be enrolled based on a more 
inclusive criteria to include an expanded SLE population.  Details are provided in Section 
16.7.  
 
Section 8.1.2, Inclusion Criteria (Part A Specific) 
Now reads:   
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
9  Dia gnosis of SLE fulfilling at least 4 out of 11 1997 revised ACR classification criteria 
for SLE ( Appendix C ), with a diagnosis made ≥24 weeks prior to signing the informed 
c
onsent form (ICF). 
 P ositive antinuclear antibody test at Screening (central laboratory titer ≥1:80) and/or 
elevated anti-double-stranded DNA (≥30 IU/mL ). 
 At  least one sign of active skin disease, including acute, subacute, and/or chronic 
cutaneous lupus (e.g., discoid lupus erythematosus), with skin activity defined by 
[CONTACT_257441]-2K 
 M ust have at least 4 tender joints based on assessment of 28 joints as described in 
Section 4.3.3.  
 M ust have at least [ADDRESS_559420] joints.  Note:  A 
joint t
hat is both tender and swollen will be included in both categories (counts as 1 
tender and 1 swollen).  
 T o allow for accurate assessment of joint tenderness and swelling, subjects who may 
be taking NSAIDs or other analgesics including narcotics or medical marijuana 
must agree not to take a dose of these medications within 12 hours prior to the joint 
assessment visits. 
 CLASI-A ≥ 8 at Screening and Randomization.   
 SLEDAI-2K ≥ 4 at Screening and Randomization (excluding fever). 
 
Section 8.1.3, Inclusion Criteria (Part B Specific) 
Now reads: 
 Must  have diagnosis of CLE  that has been histologically confirmed (in the past or  at 
S
creening),  with or without systemic LE m anifestations.  The histological diagnosis 
confirmation  should be documented at Screening. For subjects without historical biopsy 
da
ta, a skin biopsy must be performed at Screening to confirm CLE diagnosis prior to 
randomization. All subjects must also  have ac tive skin manifestations that fulfill the 
following:   
­ Subacute CLE with a CLASI-A erythema score of ≥2 
and/or 
­ Chronic CLE, including DLE, with at least 1 active CCLE  lesion with a 
mi
nimum CLASI- A erythema score ≥2  and in addition  CLASI-D scarring ≥1  
 CLAS I-A ≥8 at Screening and randomization 
 Must  have active CLE despi[INVESTIGATOR_441071] (defined as 
either topi[INVESTIGATOR_441072] 12 weeks prior to 
Screening) OR previously documented failure to respond to these agents when used 
Protocol 230LE201, Amendment [ADDRESS_559421] 12 weeks OR the requirement to discontinue these agents due to side 
effects or poor tolerability . 
 
Section 8.2.1,  Exclusion Criteria (Parts A and B), Previous Therapi[INVESTIGATOR_441097]:  
1. Concomitant and Previous Therapi[INVESTIGATOR_014] 
2. 23. Use of IV, intramuscular (IM), or intra-articular (Part A only) corticosteroids 
within 12 we
eks prior to randomization. 
Use of high potency topi[INVESTIGATOR_199]/or intralesional corticosteroid within 1 month prior to Screening 
and during the study. 
3. 24. Use of high-potency topi[INVESTIGATOR_441098]/or topi [INVESTIGATOR_12450] 
(immunosuppressant) for skin lesions within 7 days prior to randomization. 
4. 25. Use of high-potency int ralesional corticosteroid within 4 weeks prior to 
randomization.   
5. 26. Part A subjects who are receiving systemic corticosteroid treatment at a dose 
e
xceeding 20 mg/day prednisone (or its equivalent), or if any dose of prednisone (or 
its equivalent) has not been stable for ≥4 weeks prior to randomization.   
6. 27. Part B subjects who are receiving systemic corticosteroid treatment at a dose 
e
xceeding 15 mg/day of prednisone (or its equivalent), or if any dose of prednisone 
(or
 its equivalent) has not been stable for ≥4 weeks prior to randomization. 
Use of thalidomide or lenalidomide within 2 months of Screening and during the study.   
7. 28. Use of thalidomide or lenalidomide , IV or  SC immunoglobulin, or 
p
lasmapheresis within 12 w eeks of randomization.  
 Use of cyclosporine, tacrolimus, pi[INVESTIGATOR_180781], sirolimus, imiquimod, IV immunoglobulin, IV and 
oral cyclophosphamide and plasmapheresis within 3 months of Screening and during the study. 
 
29. Use of tacrolimus, pi[INVESTIGATOR_031], and sirolimus wi thin 4 weeks prior to randomization . 
 
Use of abatacept, belimumab, tocilizumab or tumor necrosis factor (TNF) inhibitors within 3 
months or 5 half-lives, whichever is longer, before Screening and during the study. 
8. 30.  Use of or al or parenteral rituximab, atacicept, ocrelizumab, or other 
B cell-directed biologic therapi[INVESTIGATOR_6523] 24 weeks prior to randomization .  Subjects 
with prior B cell-directed therapi[INVESTIGATOR_6523] 12 months of Screening will be excluded if 
tot
al CD19 B cell level is <25 cells/µL as measured at Screening at the central 
laboratory .   
31 Use of cyclophosphamide, cyclosporine, mixoribine, atacicept, abatacept, 
belimumab, tocilizumab, or tumor necrosis factor (TNF) inhibitors within 12 weeks or 5 
half-lives (whichever is longer) prior to randomization.  
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
11 9. Initiation of disease-modifying antirheumatic agents or immunosuppressive treatments 
with the exception of those listed in exclusion criteria 31, within 3 months of Screening 
and during the study.   
10. 32. Use of immunosuppressive or disease-modifying treatments for SLE or CLE (via 
an oral, IV, or SC route) that were initiated less than [ADDRESS_559422] 12 weeks a t doses above the prescribed maximum listed here 
(medication list includes, but is not limited to the following):  antimalarial 
medications (hydroxychloroquine up to 400  mg/day, quinacrine 100 mg/day maximum, 
c
hloroquine 250 mg /day), dapsone 150 mg/day, methotrexate 25 mg/week, azathioprine 
200 mg
/day, 6-mercaptopurine 100 mg/day, and mycophenolate mofetil (MMF) 3 g/day 
or mycophenolate sodium (MPS)  2160  mg/day.  
11.
 33. Immunizations with live or live-attenuated vaccines within [ADDRESS_559423] dose of study 
tre
atment. 
12. Allergy shots or completion of desensitization therapy within 1 month prior to Screening.   
13.  
 
Section 9.1, Screening and Registration 
Now reads: 
9.1 Screening and Enrollment Registration 
Subjects (or their legally authorized representative [e.g., parent or legal guardian], where 
applicable) must provide informed consent before any screening tests are performed (see Section 
17.3). When a subject signs the ICF, that subject is considered to be enrolled in the study.  
P
articipating study sites are required to document all screened candidates initially considered for 
inclusion in this study.  If a subject is excluded from the study, the reasons for exclusion will be 
documented in the subject’s source documents and on the screening log. 
A subject with a CLASI-A score of > 4 but < 8 and otherwise not meeting any other exclusion 
criteria may be rescreened on CLASI-A alone within 3 months to determine study eligibility or 
undergo full rescreening if beyond 3 months.   
For subjects entering Part A, screening tender and swollen joint scores counts will be 
evaluatedperformed  by [CONTACT_441149]. 
For subjects entering Part B, screening CLASI scores will be verified by [CONTACT_441150] (Section 19.2.2) prior to study entry.  
S
ubjects will be registered at the Screening Visit; as part of study screening, potential subjects 
will have the study risks and benefits explained to them, the associated ICF reviewed with 
them, and all their questions answered .   
Protocol 230LE201, Amendment [ADDRESS_559424] initially fails any of the screening criteria and is deemed as a screen failure by 
[CONTACT_441151] 28-day screening period, they will be allowed to be rescreened one 
time at the discretion of the Investigator.  Upon rescreening, and in consultation with the 
Medical Monitor, subjects should repeat the Screening assessments and receive a new 
Screening Number. 
 
Section 11.1, Study Treatment Regimen 
Part A 
Subjects will be randomized in a 1:1:1:1 ratio to 1 of the following 4 treatment groups: 
 BIIB059 50 mg  
 BIIB059 150 mg  
 BIIB059 450 mg  
 Placebo  
Dose regimen:  Q4W SC, with a loading dose at Week 2, for a total of 7 doses.   
Subjects will be randomized in a 1:1 ratio to 1 of the following 2 treatment groups: 
 B IIB059 450 mg  
 P lacebo  
Dose regimen :  every 4 weeks ( Q4W ) SC, with a n additional  dose at Week 2, for a total of 
7 d
oses.    
Part B  
Subjects will be randomized in a 1:1 ratio to 1 of the following 2 treatment groups:   
 BIIB059 450 mg  
 Placebo  
Dose regimen:  Q4W SC, with a loading dose at Week 2, for a total of 4 doses. 
 
Subjects will be randomized in a  1:1:1:1 ratio to 1 of the following  4 tr eatment groups:  
 B IIB059 50 mg  
 B IIB059 150 mg   
 BIIB059 450 mg  
 Placebo  
Dose regimen:  every 4 weeks SC (Q4W), with an additional dose at Week 2, for a total of 5  
doses. 
 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
13 Section [IP_ADDRESS], Analysis of the Primary Endpoint 
Now reads: 
Part A: 
The primary analysis of the primary endpoint is a test of dose-response, using the Multiple 
Comparison Procedure – Modelling (MCP-Mod) methodology [Bretz 2005 ]. 
Three monotonic dose-response trends will be tested using the appropriate contrasts as 
determined by [CONTACT_271416]-Mod methodology in an analysis of covariance ( ANCOVAA Mixed 
Effect Model Repeat Measurement (MMRM ) model such that the overall Type 1 error rate for 
these 3 resulting p-values is controlled at 0.10 (2-sided testing).  Additional information will be 
provided inused as  the SAP. 
The ANCOVA model will have Week 12 percent primary method to analyze change from 
baseline score in CLASI-A score as the dependent variable, active joint count using  treatment 
(50 mg, 150 mg, 450 mg, and placebo), group, study visit,  prior oral corticosteroid usage,  
season of enrollment and smoking status as region, and study visit- by-treatment interaction as 
fixed effect  factors and baseline SLEDAI 2K and CLASI-A scores active joint count  as 
covariates.  
In addition, the following analyses of the covariate.  The  primary endpoint will be performed: 
Pairwise treatment comparison of each BIIB059 treatment group versus placebo, based w ill be 
the difference between the 450 mg dose and placebo at the end of the Week 24  on the 
ANCOVA model. c hange from baseline in active joint count.   
Sensitivity In addition, sensitivity  analysis based on the ANCOVA MMRM model, with missing 
values imputed will also be performed (imputation methods are defined in the SAP). 
Due to the impact of corticosteroid and rescue medication use on CLASI-A scores active joint 
count , if a subject has an increase from baseline in corticosteroid use after Week 4 (excluding 
allowed corticosteroid use as described in Section [IP_ADDRESS].2)  or uses any SLE rescue medication 
(a
s described in Section [IP_ADDRESS].1) during  the 24-week treatment period  of the study, the 
subject will be a treatment failure.  The subject’s CLASI-A scores joint count  after the increased 
corticosteroid use or after SLE rescue medication will not be included in the primary analysis. 
For subjects who are treatment failures prior to the Week [ADDRESS_559425] (LOCF WOC F) method will be 
applied using the patient’s last post-baseline CLASI-A score joint count  prior to treatment failure. 
Additional  In addition, if a subject deviates from the planned tapering schedule (Table 7), 
they might be considered as a treatment failure depending on the severity and timing of 
deviation.  Additional details will be provided in the SAP. 
Part B: 
The primary analysis of the primary endpoint is An MMRM model will be used to analyze the 
percent change from baseline  in CLASI-A score using treatment group, study visit, study 
visit- by-treatment interaction, DLE (presence or absence), and SLE (presence or absence) 
as fixed effect factors and baseline CLASI-A scores as a covariate. 
Protocol 230LE201, Amendment [ADDRESS_559426] of dose-response, using the Multiple 
Co
mparison Procedure – Modelling (MCP-Mod) methodology [Bretz 2005]. 
F
ive dose
-response trends will be tested using the appropriate contrasts, as determined by 
[CONTACT_271416]-Mod methodology, on the treatment effects obtained from the MMRM model . 
Additional information will be provided in the SAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The credible interval will be derived from an ANCOVA model with Week 12 percent change 
from baseline score in CLASI-A score as the dependent variable, treatment (BIIB059 450 mg, 
placebo), SLE (presence, absence), season of enrollment and smoking status as factors, and 
baseline CLASI-A score as a covariate.   
In addition, the The following analyses of the primary endpoint will also be performed: 
 Comparison Pairwise comparison  of theeach  BIIB059 treatment group versus 
placebo, based on the ANCOVA model (not using the Bayesian 
methodology).MMRM model.  
 Sensitivity analysis based on the ANCOVA MMRM  model, with missing values 
imputed (imputation methods defined in the SAP). 
Due to the impact of corticosteroid use on CLASI-A scores, if a subject has an increase from 
screening Screening  in corticosteroid use, the subject’s CLASI-A scores after the in creased 
corticosteroid use will not be included in the primary analysis. The missing data handling 
methodology will follow the methods described for Part A.  For subjects in Part B with a 
diagnosis of SLE in addition to CLE, please refer to Section  [IP_ADDRESS].1  Additional details will be 
pr
ovided in the SAP.  
Section [IP_ADDRESS].1.  Additional details will be provided in the SAP. 
 
Section 16.7, Interim Analyses 

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
15 Now reads: 
Part A: 
An interim analysis is planned  and B: 
An IA for futility of Part B and possible expansion of Part A will be performed .  The IA will 
b
e performed  after approximately 12 weeks after 75 45% of Part B subj ects under protocol 
version [ADDRESS_559427] been randomized. c ompleted their Week 12 Treatment Visit.  At the time of 
the IA, it is estimated that over 50% of subjects in Part A will have completed their Week 
[ADDRESS_559428]  baseline characteristics (eg, Joint Count, SLEDAI-2K) will be 
assessed.  The randomization stratification factors will be reevaluated in the expanded 
enrollment to achieve balance between treatment groups.  The objective 3 objectives  for adding 
additional subjects atto Part A after the interim analysis to Part A is ar e to: 1) potentially 
include an expanded SLE patient population based on a more inclusive criteria,  2) 
potentially adjust the dose of BIIB059 and, 3)  to provide greater precision for the Week 24 
e
ndpoints, including the SRI-4.  The details of the interim analysis plan will be specified in the 
SAP. Unblinded tables, listings,  or graphs (TLGs) will be generated by [CONTACT_441129] 
(internal or external) not involved in the conduct of the study.  Unblinded TLGs T he IA will be 
performed by [CONTACT_441129] (internal  and/or data will external)  not be shared with 
subjects, investigators, or the study team members directly involved in the conduct of the study, 
prior to unblinding the study for final analysis or stoppi[INVESTIGATOR_16589]. . At the discretion of 
Biogen, unblinded TLGs and/or data may be shared with sponsor Sponsor  personnel who are not 
directly involved in the conduct of the study. Additional information will be provided in an 
unblinding plan.  Details of the data to be used for the interim analysis and the analyses 
planned for futility and possible expansion will be provided in the SAP.  
Details on data to be used for the interim analysis and the analyses planned will be provided in 
the SAP. 
Part B: 
No interim analysis is planned.   
Section 16.8, Sample Size Considerations 
Now reads (no strikethrough text is provided):    
Part A:  
The sample size for Part A is 100 subjects, randomized in a 1:1 ratio, with 50  subjects allocated 
to e
ach treatment group. This sample size will provide  approximately 71% power to detect a 
stat
istically significant difference i n the Week [ADDRESS_559429] deviation of 6, a maximal difference of BIIB059 over placebo of 2.5, 
a 20% drop out rate , and a 2-sided testing at the 0.2 level significance.   Additional information 
will
 be provided in the Statistical Analysis Plan (S AP). If the study is not stopped for futility at 
the interim analysis (details in Section 16.7), then up to 70 additional subjects may be added to 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
16 Part A.  If an additional 70 subjects are added, the power will increase to ap proximately 87 % at 
Week 24. 
Part B: 
The planned sample size for Part B is 100 subjects, randomized in a 1:1:1:1 ratio , w ith 25  
subjects per dosage arm of BIIB059 (50 mg, 150 mg, a nd 450 mg) and  placebo. This sample 
size
 will provide approximately 90% power to detect a dose-response relationship in the 
Week [ADDRESS_559430] 
deviation of 30, a maximal difference of BIIB059 over placebo of 27.5%, and a 20% drop 
ou
t rate.  Five different dose-response relationships will be tested at the 2-sided 10% 
significance level with the MCP-Mod method being used to control for multiplicity [Bretz 
2005].   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
17 SUMMARY OF MAJOR CHANGES TO THE PROTOCOL 
Changes to the protocol are presented chronologically.  New text is shown in bold type; deleted 
text is shown with a strikethrough. 
 
Section 3, Synopsis 
The Synopsis was revised to reflect changes made throughout the protocol. 
 
Section 4 .2, Schedule of Activities,Table 1 (Part A) and Table 2 (Part B) [Skin Photography] 
Change:   The whole-body skin photography requirement was removed from Part A; instead, a 
photograph of the target lesion only will be taken at the time of tape harvesting (W eeks  0, 4, and 
16)
. No adjudication of the target lesion photography will be necessary in Part A.  Footnote 10 
be
low Table 1 provides additional details and requirements. 
In Part B, whole-body photography was replaced by [CONTACT_441152] a CLASI-A and/or CLASI-D score is present (including but not limited 
to the target lesions, biopsy lesions, head, and so on).  The photographs taken at Screening will 
be
 evaluated by a central adjudicator to verify the CLASI-A score assignment by [CONTACT_441153].  Also, the number of skin photography assessments was reduced from 6 
(a
t Screening, baseline, and Weeks 2, 4, 8, and 12) to 4 (at Screening  and Weeks 0, 4, and 16).  
F
ootnote 12 below Table 2 provides additional details and requirements. 
Now reads:   
(S
ee Table 1, Schedule of Activities Part A, and Table 2, Schedule of Activities Part B, in the 
pr
otocol.) 
Rationale:   Skin photography is a general enrollment barrier in subjects with skin rash. In order 
to fa
cilitate subject enrollment, the necessity of this tool was reassessed across the study. In Part 
A, whole-body photography (and the associated adjudication process) proved unnecessary due to 
the change in outcome measure for the primary endpoint (from CLASI-A to joint count).  
In Part B, the procedure was streamlined to include only affected skin areas based on CLASI- A 
and/or CLASI-D.  The frequency was also reduced to focus on the most significant timepoints. 
This change also affects Section 4.3.4, Additional Information – Skin Photography. 
 
 
Section 4.2, Schedule of Assessments,  (Table 1 (Part A) and Table 2 (Part B) 
Change:  The timing, frequency, and/or associated guidance for several study assessments were 
revised as follows: 
 The  following footnote was added to the “Tests and Assessments” column in Table 1 and 
Ta
ble 2 : “2Assessments (e.g., CPK, ECG, etc.) may be performed as required to 
confirm SLEDAI-2K and BILAG findings ” (“an d BILAG findings” Table 1 only) .  
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
18  The  chest X-ray was removed as a requirement for both Part A and Part B, and a footnote 
on tuberculosis testing was added to Table 1 and Table 2 :  “5T esting to be performed 
locally.  Indeterminate Quantiferon or T-SPOT tests may be repeated once and will 
b
e considered positive if retest results are positive or indeterminate. Subjects with 
documented BCG vaccination must perform a TB test at Screening and will be 
excluded if they exhibit skin induration ≥5 mm or a positive Quantiferon or positive 
or borderline T-SPOT (Elispot) test. ” For further information, see the change to 
e
xclusion criterion 16 (Section 8.2) below. 
 Ur ine Pregnancy Test:  An assessment was added at Week 2. 
 A footnote w as added to the Physical Examination, Weight, and Height assessment in 
Ta
ble 1 and Table 2:   “7Heig ht should be measured only once; i.e., at the Day 
1/baseline visit. ”  
 For the Vital Signs assessment, it was clarified in footnote 8 to Table 1 and Table 2 that 
oral
 body temperature should be measured. 
  
 
 
 
 J oint count assessments were added to Table 1 at Screening and Weeks 2, 4, 8, 16, 20, 
and FU12.  See detailed explanations in this document under  Primary Reason for 
Ame
ndment and Section 8.1.2, Inclusion Criteria (Part A Specific). 
 The  timing of PK assessments was revised in Table 1 and Table 2. In Table 1, 
a
ssessments were removed at Weeks 2, 8, 20, and FU8.  In Table 2, assessments were 
re
moved at Weeks 2 and 8. Also, a separate table on PK assessments (Table 3) was added 
to spec
ify when PK assessments should be done during each visit. The frequency of 
, c
omple
ment, skin RNA 
tape harvesting, , and blood RN A [Paxgene]) was reduced in Table 
1 and Table 2. 
 The  following footnote was added to Table 1 (footnote 15) and Table 2 (footnote 17) to 
provide more guidance on performing the ESR:  
 
 A f ootnote on which vaccine-related immunoglobulin titers will be collected in Part A 
was added to Table 1 : “19Vaccine-related immunoglobulin titers for tetanus, 
diphtheria, and Pneumococcus  will be collected. ” 
 An e lectronic diary review of subject-reported questionnaires was added to Table 1 and 
Ta
ble 2. 
 The  timing of CLASI assessments in Part B was revised (assessments were removed at 
Week 2). Additional guidance on CLASI assessment and adjudication was provided in 
the f
ootnote: “9CLASI will be assessed by [CONTACT_29517] a trained designee at all  

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
19 assessments (Section 19.2.2).  CLASI scores at Screening will be verified by [CONTACT_441112]. ” 
  
 
  
 
 
 
 
 
 The  skin biopsy for confirmation of CLE diagnosis and the optional skin biopsy for 
biom
arkers were separated into 2 different assessments in Table 2. 
 The  vaccine status assessment was removed from Table 2. 
Rationale:  The timing and guidance provided on all study assessments was re-evaluated and, in 
some c
ases, revised in order to align with study design changes, ease patient burden, mitigate 
e
nrollment barriers, and provide clearer guidance on study assessments. 
 
) 
Change:    
Now reads: 
Additional Objectives 
 
Additional Endpoints 
  
  
  
 
 
  
 
  
 
  
 
   
 

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
20  
 
 
 
 
. 
 
Section 8.2.1 , Exclusion Criteria (Tuberculosis) 
Change:   The criterion related to tuberculosis history (now exclusion criterion 16) was revised to 
exclude any subjects who tested positive for tuberculosis, including subjects who are undergoing 
c
urrent treatment.  
Now reads: 
 History of or current diagnosis of active tuberculosis (TB), or untreated latent TB 
infection (LTBI), determined by a TB skin test with purified protein derivative as 
evidenced by [CONTACT_289164] ≥5 mm or a positive Quantiferon, positive or borderline 
T-SPOT (Elispot) test performed locally, either at Screening or documented with 
results within [ADDRESS_559431] received complete LTBI treatment prior to Screening without evidence of 
re-exposure  prior to e ntering the study . 
 Subject with current household contacts with active TB will also be excluded 
unless the subject is being treated and there is evidence that household contacts 
are being treated 
 Indeterminate Quantiferon or T-SPOT tests may be repeated once, and will be 
considered positive if retest results are positive or indeterminate. Subjects with 
documented BCG vaccination must perform a TB test at Screening and will 
be excluded if skin induration ≥5 mm or a positive Quantiferon or positive or 
borderline T-SPOT (Elispot) test.   
 
Rationale:  This change was made to support the removal of the chest X-ray assessment from the 
sc
hedule of activities for both Part A and Part B.  
Investigators have indicated that performing the chest X-ray for all subjects as a screening tool 
for
 tuberculosis is unnecessary since tuberculosis is infrequently seen and subjects considered the 
chest X-ray burdensome. Furthermore, chest X-rays may not be permitted in some regions due to 
local regulations. However, in order to address the risk of enrolling a subject with active 

Protocol 230LE201, Amendment [ADDRESS_559432] X- ray verification, the tuberculosis exclusion criterion was 
revise to exclude any subjects being treated for a latent tuberculosis infection as these subjects 
were previously allowed to participate.    
This change also affects Section 4.2, Schedule of Activities, Table 1 (Part A) and Table 2 (Part 
B
). 
 
Section 8.2.1 , Exclusion Criteria ( IV, IM, intra-articular, and high-potency topi[INVESTIGATOR_441099]) 
Change:   In the original protocol, high-potency topi[INVESTIGATOR_441100] 1 month 
pr
ior to Screening and for the duration of Part B. In the amended protocol, more specific 
pr
erandomization guidance has been added on when IV, IM, intra-articular, and high-potency 
topi[INVESTIGATOR_88900]. 
Now
 reads: 
(New exclusion criterion 23) 
23. Use of IV, intramuscular (IM), or intra-articular corticosteroids within 12 weeks 
prior to randomization. 
(Revised exclusion criterion 24) 
24. Use of high-potency topi[INVESTIGATOR_441073]/or  topi[INVESTIGATOR_12450] 
(im
munosuppressant) for skin lesions within 7 days prior to randomization.  
(Revised exclusion criterion 25) 
25. Use of high-potency intralesional corticosteroid within 4 weeks  prior to r andomization .  
25.
  
Rationale:   The revised criterion will allow greater precision and improve clarity in selecting for 
ster
oid use in Part B; the same rule will apply for target lesions in Part A. The criteria pertaining 
to l
ow- and medium-potency topi[INVESTIGATOR_441101]. 
This cha
nge also affects Section [IP_ADDRESS].2.1, Topic al and Intralesional Corticosteroids. 
 
Section 8 .2.1, Exclusion Criteria (General) 
Change:   Several exclusion criteria were modified, as follows:  
Now
 reads: 
26. 1. Current enrollment or a plan to enroll in any interventional clinical study in which an 
investigational treatment or approved therapy for investigational use is administered.  A 
washout period of at least 3 months or  5 half-lives (whichever is longer) is required pr ior 
to randomization .  Participation in observational registries is allowed. 
 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
22 27. 2. For subjects who previously received an investigational or approved treatment that 
blocks IFN-α, a washout period of 6 months is required prior to randomization. 
3. For subjects who previously received BIIB059 in the phase 1 study, a washout 
p
eriod of 6 months is required prior to randomization in the present study.  Subjects 
who discontinued previous BIIB059 study participation due to AEs are not eligible. 
7. Current active  hepatitis C virus (HCV) infection, determined as HCV RNA above the 
limit of detection . 
8. Positive test result at Screening for hepatitis B virus ( HB V; defined as positive for either  
hepatitis B surface antigen or hepatitis B core antibody). 
12. Sy stemic comorbidities requiring systemic corticosteroid therapy (e.g. asthma or 
inflammatory bowel disease); systemic therapy is defined as treatment given orally, rectally, 
or by [CONTACT_441154].  (Comorbidities that require corticosteroid use 
administered by [CONTACT_298440], including inhaled, ophthalmic, otic, and intranasal, are 
allowed). 
16. Active clinically significant viral, bacterial, or fungal infection, or any major epi[INVESTIGATOR_53794]-infectives within [ADDRESS_559433] been completely excised and considered cured >[ADDRESS_559434] dose of study treatment. 
26. Part A subjects who are receiving systemic corticosteroid treatment at a dose 
exceeding 20 mg/day prednisone (or its equivalent), or if any dose of prednisone (or its 
e
quivalent) has not been stable for ≥4 weeks prior to randomization.   
27. Part B subjects who are receiving systemic corticosteroid treatment at a dose 
exceeding 15 mg/day of prednisone (or its equivalent), or if any dose of prednisone (or 
its e
quivalent) has not been stable for ≥[ADDRESS_559435] result at Screening that is considered clinical ly 
significant and unrelated to the underlying disease (SLE/CLE), as determined by [CONTACT_441155]. Clinical 
laboratory tests may be repeated one time, at the discretion of the Investigator, if there 
are questionable results, or if abnormalities are felt to be due to inherent variability of 
the test procedure. A nonclinically significant out-of-range laboratory value would not be 
considered exclusionary. 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
23 8.2.2 Exclusion Criteria (Part A Specific)  
1. For subjects who have initiated systemic corticosteroids, a dose of prednisone exceeding 
20 mg/day (or its equivalent) or if the dose has not been stable for ≥ 1 month prior to  
Randomization.  (replaced with criterion 26 above) 
8.2.3 Exclusion Criteria (Part B Specific) 
1. For subjects who have initiated systemic corticosteroids, a dose of prednisone exceeding 
15 mg/day (or its equivalent) or if the dose has not been stable for ≥ 1 month prior to  
Randomization. (replaced with criterion 27 above) 
29.  
Rationale:   The study exclusion criteria were generally simplified to increase study enrollment 
a
nd, in some cases, made more stringent to ensure a more controlled analysis population.  
 
Section 9.1, Screening and Registration  
Change:  The title of Section 9.1 was changed from “Screening and Enrollment” to “Screening 
and Registration” to better reflect the content of the section. (Information about randomization 
wa
s placed in a new section, Section 9.2, Randomization of Subjects.)   Text was added to 
de
scribe the role of the independent joint assessor (Part A) and the independent CLASI 
A
djudicator (Part B) at Screening.  A description of rescreening criteria was added.  
Now
 reads: 
Subjects (or their legally authorized representative [e.g., parent or legal guardian], where 
applicable) must provide informed consent before any screening tests are performed (see 
Section 17.3 ).  When a subject signs the ICF, that subject is considered to be enrolled in the 
study.  Participating study sites are required to document all screened candidates initially 
c
onsidered for inclusion in this study.  If a subject is excluded from the study, the reasons for 
exclusion will be documented in the subject’s source documents and on the screening log. 
For subjects entering Part A, screening tender and swollen joint counts will be performed 
by [CONTACT_441149].     
For subjects entering Part B, screening CLASI scores will be verified by [CONTACT_441150] (Section 19.2.2) prior to study entry.   
S
ubjects will be registered at the Screening Visit ; as part of study screening, potential subjects 
will have the study risks and benefits explained to them, the associated ICF reviewed with 
them, and all their questions answered. 
If
 a subject initially fails any of the screening criteria and is deemed as a screen failure by 
[CONTACT_441151] 28-day screening period, they will be allowed to be rescreened one 
tim
e at the discretion of the Investigator. Upon rescreening, and in consultation with the 
Medical Monitor, subjects should repeat the screening assessments and receive a new 
S
creening Number. 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
24 Rationale:   The revision provides information about the roles of independent central review of 
ke
y tests for eligibility.  The revision also provides clarification of the circumstance under which 
a subject can be rescreened for study entry.  
 
Section 9.3, Blinding Procedures 
Change:   Text to clarify study unblinding was added.  
Now reads: 
 
  Efforts will be made to ensure that no members of the team involved in study conduct 
will be unblinded.  Unblinding is permitted only in the case of a medical emergency or 
serious medical condition, when knowledge of the study treatment is essential for the 
immediate clinical management or welfare of the study subject, as judged by [CONTACT_3786].  Details of unblinding will be provided in the Study Reference Manual. 
A team of Biogen personnel, independent of the study team, will be set up to conduct the 
unblinded interim analyses as discussed in Section 16.7.  
Rat
ionale:   The revision provides further information about study unblinding directly in the 
pr
otocol instead of a separate unblinding plan, as indicated in the original protocol.  
 
Section 10.1 , Discontinuation of Study Treatment 
Change:   More detailed guidance on early study termination was added.  
 
Now reads:   
Subjects who di
scontinue treatment are allowed to  remain in the study and will be encouraged 
to continue pr
otocol-required tests and assessments during the follow-up visits  (Week 4, 8, and 
12 F
ollow-Up Visits).  In the event that a subject withdraws from the study prematurely, at 
minimum, an Early Termination visit should be performed as soon as possible, to be 
followed by [CONTACT_6492]- up visits at 4, 8, and [ADDRESS_559436] visit; all Early Termination 
assessm
ents listed in the study schedule should be performed at this Early Termination 
visit.  
Rationale:   The revision provides further information about early termination, including the 
de
sired visit window and guidance on assessments to be performed at study end.  
 
Section 11.2 , Study Treatment Precautions 
Change:  In the original protocol, there was no specific guidance on monitoring subjects 
immediately after study treatment administration. In the amended protocol, subjects will be 
asked to remain at the study center for 1 hour after study treatment administration for 
observation.  A description of the process for handling missed doses of study treatment was also 

Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
25 added to th is section, and the section title was changed from “Modification of Dose and/or 
Tr
eatment” to “Study Treatment Precautions.” 
Now reads: 
Following administration of study treatment, subjects should remain at the study center for 
1 hour to monitor for the development of potential allergic or anaphylactic reactions.   
Epi[INVESTIGATOR_441102], diphenhydramine (or equivalent) for IV injection, and 
any other medications and resuscitation equipment for the emergency management of 
a
naphylactic reactions must be available in the room where the infusion is being performed. 
BIIB059 or placebo should be administered within the stated window of the scheduled visit 
(+/ 2 or 3 days; see Table 2 and Table 3).  If a subject misses a planned dose (i.e., outside of 
the 2 or 3 day window), the missed dose should be administered as soon as possible, and no 
later than [ADDRESS_559437] day of the planned window.  If the Week 2 dose (the second 
dose to be administered in the study) can't be given within the planned window, the missed 
dose should be skipped and the subject should receive the next scheduled dose as per 
protocol.  
Rationale:   This change was made because BIIB059 is a monoclonal antibody and, as with all 
monoclonal antibodies, has the potential to be immunogenic and trigger an allergic reaction. 
The
refore, a period of observation after administration is appropriate. If a severe allergic reaction 
occurs, the study treatment must be discontinued immediately and the subject must 
be
 immediately treated appropriately.  Most severe acute allergic or anaphylactic reactions 
ha
ppen within 60 minutes after administration; therefore, observation for this time period is in 
the inter
est of subject safety. 
This change also affects Sections 4.2, Schedule of Activities (Parts A and B); 7.2.2, Overall 
S
tudy Duration and Follow-up (Part A) – Treatment; 7.3.2, Overall Study Duration and Follow-
up (Par
t B) – Treatment; and 12, Study Treatment Management. 
 
The
 detailed description of the process for handling missed doses of study treatment was added 
to improve clarity on this issue and to help ensure safety; i.e., so subjects do not receive study 
treatment dosing <2 weeks apart. 
 
Section 11. [IP_ADDRESS].2, Part A Specific Instructions –  Oral Corticosteroids 
Change:   In the original version of the protocol, a prescribed corticosteroid tapering regimen 
was recommended for all subjects in Part A after [ADDRESS_559438] at specified periods; i.e., during the first 4 weeks of treatment, between Weeks 5 and 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
26 7 (inclusive), and between Weeks 9 and 11 (inclusive). Subjects are allowed to revert to the 
pr
evious dose level once and for only [ADDRESS_559439] and to complete the study, at the discretion of the Investigator. 
Now
 reads: 
 
Eligible subjects will have active SLE with joint and  skin manifestations at S creening and 
randomization.  Subjects may be treated with SLE background SoC therapi[INVESTIGATOR_441103] #31, and if taking corticosteroids, must have been on stable dosage for 
at
 least [ADDRESS_559440] dose  of study treatment (i.e. until Day 28).  T he tapering schedule should begin 
4 weeks (Week 5; Days 29 to 35) after  the first dose of study treatment.  The tapering regimen 
is intended  to reduce the daily d ose of  prednisone (or equivalent) to 10 mg/day or lower by 
[CONTACT_10585] 12 (Day 85) of the study as outlined in Table 1.  
If
 a subject deviates from the planned tapering schedule (Table 7), they might be 
c
onsidered a treatment failure ( See Section [IP_ADDRESS]).  Subjects are allowed to continue to 
r
eceive the investigational product (IP) and to complete the study, at the discretion of the 
Investigator.   
Subjects achieving the Week 12 dose of 10 mg of  prednisone (or equivalent ) or lower may 
remain on this dose or continue to taper between Week 13 and Week 16 at the discretion of the 
Investigator.  The dose of prednisone (or equivalent) will remain stable (at the Week 16 
dose) between Week 17 and Week 24 . 
 
Screening :  
Subjects who are receiving corticosteroids must receive a stable dose throughout the 
Screening period; no  initiation , increase , o r decrease  of corticosteroid  dose is permitted . 
The maximum daily dose of corticosteroid allowed is 2 0 mg  prednisone (or equivalent). 
Treatment period: 
Oral corticosteroid dose tapering (as described in Table 1 ) is mandatory  within the rules for 
dose changes outlined below.  
Briefly, oral corticosteroids dosing guidelines are as follow:  
 Stable corticosteroid dose from Day 1 to Week 4 (Day 1 to Day 28),  
 De crease in corticosteroid dose from baseline between Week 5 and Week 11 
(D
ays 29 to 78), 
 Stable corticosteroid dose at Week 12 (Days 79 to 85) 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
27  S table Week 12  corticosteroid dose or decrease by 2.5 mg b etween Week 13 and 
Week 16 (Day 86 to 113),  
 Stable corticosteroid dose (at a minimum of Week 12 dose) b e tween Week 17 and 
Week 24 (Days 114 to 169) 
 
Between Day 1 to Week 4 the corticosteroid dose can be increased to a maximum of 
10 mg/day above Day [ADDRESS_559441] return to Day 1 level within 7 days (Rescue 1).  
B
etween Week 5 and Week 7 (Rescue 2), OR  between Week 9 and Week 11 (Rescue 3), the 
corticosteroid dose can be increased to the previous dosage level for up to 1 week before 
resuming the tapering schedule.  Only two rescues out of the three described above are 
all
owed, at the discretion of the Investigator. 
Overall, TWO corticosteroid rescues are allowed:    
 Rescue 1 and Rescue 2; OR  
 Rescue 1 and Rescue 3; OR  
 Rescue 2 and Rescue 3. 
 
Any other  increase in corticosteroid dose may be considered a treatment failure and/or 
protocol deviation (depending on the timing or severity of the deviation) for the  analysis 
(se
e Section 0).  Subjects w ho cannot fulfill the corticosteroid tapering schedule should  still 
c
omplete the study and remain on IP.  Corticosteroid dose should be recorded in the subject 
diary (Section [IP_ADDRESS].2.4 ). 
Day 1 to Week 4: 
Stable dosage at Day 1 dose level, 1 oral corticosteroid rescue (Rescue 1)  for SLE activity  is 
a
llowed up to a dose no higher than 10 mg above the baseline level (maximum of 30 mg/day), 
but the dose  must return to baseline (Day 1) level within 7 days. A dose increase is strongly 
re
commended to be avoided within 1 week of a planned study visit. 
Week 5 to Week 7: 
Decrease  as per the tapering schedule.   One oral corticosteroid rescue (Rescue 2) for SLE 
activity  is a llowed up to a dose no higher than the previous dosage  level, but the dose must be 
returned to the last oral corticosteroid dosage prior to rescue level within 7 days.  A dose 
incr
ease is not permitted within 1 week of a planned study visit. 
Week 8: 
Decrease  as per tapering schedule.  No increases  are allowed. 
Week 9 to Week 11: 
Decrease as per tapering schedule. One or al corticosteroid rescue (Rescue 3)  for SLE activity is 
a
llowed up to a dose no higher than  the p revious dosage  level, but the dose  must be returned 
Protocol 230LE201, Amendment [ADDRESS_559442] oral corticosteroid dosage prior to rescue level  within 7 days.  A dose increase not 
permitted within 1 week of a planned study visit. 
Week 12: 
No increase or decrease allowed. 
Week 13 to Week 16: 
Stable dosage or decrease as per the tapering schedule (no increase is allowed).  T he 
corticosteroid dose must always be ≤Week 12 dose. 
Week 17 to Week 24:  
Stable dosage at Week 16 dosage, no increases or decreases are allowed. 
 
Table 1: Oral Corticosteroid Tapering Schedule 
Table 2: Suggested corticosteroidOral Corticosteroid Tapering Schedule  
Allowable 
OCS Rescue 
Dosing1 Timing  by 
[CONTACT_41585] 
(Days)  Corticosteroid OCS  Starting Dose Prior to Tapering (mg/day ) 
 
 20 mg 17.5 mg 15 mg 12.5 mg 10 mg 7.5 mg 5 mg 2.5 - < to <5 
mg 
 Rescue 1  Week 1 -42   
(Day 1 to 
28) Stable  
1 OCS rescue for SLE activity allowed up to maximum 10mg /day above Day [ADDRESS_559443] return to Day 1 level within 7 days  
 Rescue 2  Week 53 
(Day 29 to 
35) 17.5 15 12.5 10 7.5 7.5 5 or 2. 5 2.5 - < to <5 
Week 63 
(Day 36 to 
43) 17.5 15 12.5 10 7.5 7.5 5 or 2.5  2.5 - < to <5 
Week 73 
(Day 44 to 
50) 15 12.5 1012.5 10 or 
7.5 7.5 7.5 or 5 5 or 2.5  2.5 - < 5 
 Week 8  
(Days 51 to 
57) 12.5 15 12.5 10 10 or 
7.5 7.5 7.5 or 5 5 or 2.5  0 or 2.5 - < 
5 
 Rescue 3  Week 93 
(Days 58 to 
64) 12.5 10 10 or 7.5  7.5 7.5 or 
5 72.5 or 
5* 5 or 2.5 0 orto 2.5< 
5 
Week 103 
(Days 65 to 
71) 12.5 10 10 7.5 5 2.5 2.5 0 to 2.5  
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
29 Allowable 
OCS Rescue 
Dosing1 Timing  by 
[CONTACT_41585] 
(Days)  Corticosteroid OCS  Starting Dose Prior to Tapering (mg/day ) 
 
 20 mg 17.5 mg 15 mg 12.5 mg 10 mg 7.5 mg 5 mg 2.5 - < to <5 
mg 
Week 113 
(Days 72 to 
78) 10 10 or 7.5 7.5 or 5 7.5 or 
5 72.5 or 
to <5 5 or 2.5 2.5 0 orto 2.5 - 
< 5 
 Week 11-12 
(Days 79 to 
85) Stable 
at 
Week 
10 
dose 10 7.5 7.5 5 2.5 to 
<5 2.5 2.5 0 to 2.5  
 Week 13 -16 
(Days 86 to 
113) Stable or Decrease by 2.5 mg as tolerated.   
1 OCS rescue for SLE activity allowed up to Day 1 corticosteroid at Week 12 dose 
(maximum 20 mg/day), however must be returned to week 12 level within 7 days. or 
decrease  
 Week 17 -24 
(Days 114 
to 169)  Stable at Week 16 dose  
Abbreviations:  OCS = oral corticosteroids; SLE = systemic lupus erythematosus. 
1 Two rescues are allowed out of the three described.  
2 Between Week 1 and 4 (Rescue 1 ).  Once a dose is reduced  it can be maintained stable but must  not be re-increased, with 
the exception of the 1 time rescue. 
3Between Week 5 and Week 7 (Rescue 2) and  between Week 1 and 4 9 and 11(Rescue 3), the dose can be increased to the 
previous dose level for up to [ADDRESS_559444] OCS dosage prior to rescue level within 7 days 
  
Rationale:   A lower therapeutic level of corticosteroid (or complete washout) will lower the 
re
sponder rate in the placebo group.  
This change also affects Sections 6, Study Objectives and Endpoints; [IP_ADDRESS].1.1, Background 
Therapy for Lupus - Systemic Lupus Erythematosus; [IP_ADDRESS], Rescue Medication Usage 
Guidelines During the Treatment Period; and [IP_ADDRESS], Rescue Medication Usage Guidelines 
During the Safety Follow-up Period. 
 
Section 19.2.2 , CLASI Assessment and Adjudication 
Change:   Reference to the BILAG Assessment and Adjudication Committee was removed. 
R
eference to the CLASI Assessment Adjudicator was added. 
Now reads:    
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
30 BILAG Assessment and Adjudication Committee 
Variability of BILAG data due to reporting issues will be monitored with  an  ongoing  review of 
the data. 
An independent BILAG Assessment and Adjudication Committee may be convened to confirm 
the individual attribution of BILAG scoring.  The Adjudication Committee will review the 
assessments reported by [CONTACT_441156]. 
Information reviewed may include laboratory, pathology and/or imaging data (e.g., 
photographic), physical descriptions, and any other data deemed relevant. The committee will be 
masked to assigned study treatment to ensure the unbiased assessment of clinical outcome. A 
charter for the establishment and operation of the independent BILAG Assessment and 
Adjudication Committee will be provided. 
For Part B of the study, an independent CLASI Assessment Adjudicator will confirm 
CLASI scoring at Screening for the purpose of study eligibility.  The Adjudicator will 
review the photograph to determine if they meet CLASI criteria.  
A charter for the establishment and operation of the CLASI assessment adjudication 
process will be provided by [CONTACT_204903]. 
Rationale:   No BILAG Assessment and Adjudication Committee is planned for this study.  
 
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
31 SUMMARY OF MINOR CHANGES TO THE PROTOCOL 
 
The
 following minor changes were made to the protocol:    
 The  version number and date were updated throughout the protocol. 
 S ection 2, List of Abbreviations, was updated. 
 Te xt was modified throughout the protocol to further clarify guidance and instructions. 
Typographical errors and formatting were corrected. 
 T he definition of washout periods for allowed medications was changed from number of 
months to “half-lives,” where appropriate. 
 Thr oughout the protocol, the units for maximum dose of allowed medications was 
changed from mg/kg/day to a fixed dose/day.   
 S ection [IP_ADDRESS], Allowed Concomitant Therapy:  A statement was added to define the 
term “stable” as applies to corticosteroid dosing.     
 S ection [IP_ADDRESS].1.1,  Systemic Lupus Erythematosus:  The routes of administration (IV, 
SC, or oral) were specified for the standard of care (SoC) therapy that subjects with SLE 
c
an receive during the trial.  Also, dapsone (up to 150 mg/day) was added to the list of 
a
llowed SoC medications.  
 S ection [IP_ADDRESS].2.3, Part B Specific Instructions – Oral Corticosteroids :  An explicit 
state
ment was added to state that no corticosteroid tapering schedule was required for 
subj
ects in Part B and that no increase beyond 15 mg/day was permitted. 
 S ection [IP_ADDRESS].3.1, Nonsteroidal Anti-Inflammatory Treatments (NSAIDs): Ibuprofen 
and naproxen were added to the list of examples of NSAIDs; the original protocol listed 
only aspi[INVESTIGATOR_441104].  
 Section [IP_ADDRESS].3.2, Acetaminophen:  The maximum allowed dose of acetaminophen or 
pain medications with acetaminophen was specified to be 3 g/day. 
 S ection 11.4.2, Concomitant Procedures: In the original protocol, allergy desensitization 
treatment was not permitted in the study. In the amended protocol, subjects are allowed to 
pa
rticipate in allergy desensitization treatment if they have been previously stabilized on 
the therapy prior to screening. Also, the amended protocol contains additional guidance 
re
garding which details abou t c oncomitant treatment or procedures must be recorded in 
the electronic CRF .  
S
ection 14, Safety Assessments:  Text was added to clarify that oral body temperature should be 
mea
sured for vital signs. Creatine phosphokinase was added as a blood chemistry laboratory 
safety assessment.  
Section 15.5, Contraception Requirements:  The contraception requirements were changed from 
“effective” in the original protocol to “highly effective” in the amended protocol.  
Protocol 230LE201, Amendment 1 Amendment Summary  
Phase 2 Study to Evaluate BIIB059 in CLE with or without SLE 
  
CONFIDENTIAL 
The information contained herein may not be used, disclosed, or published without the written consent of 
Biogen MA Inc. 
32 Section 19.1.3, Electronic Data Capture:  It was specified that all subject-reported outcomes will 
be
 captured in an electronic diary, with the exception of the corticosteroid diary, which will be a 
paper diary. 
Appendix A. 1) Descriptions of Efficacy Instruments –Systemic Lupus Erythematosus Disease 
Ac
tivity Index -2000 (SLEDAI-2K):  The first sentence under this heading was deleted as it was 
not necessary as a description of the measure in this Appendix.  2)  
:  A t ypographical error in the order of items in the self-rating scale was 
cor
rected.   
Appe
ndix B, Topi[INVESTIGATOR_441105]:  This new appendix 
contains a table which provides a list of corticosteroids that are not permitted. 
Appendix C, American College of Rheumatology Revised Criteria for Classification of Systemic 
Lupus Erythematosus:  This new appendix contains a table which provides the 1982 ACR 
revised criteria for classification of SLE. 
 
 
